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Effect of erthyropoietin (EPO) treatment on blood lipid profile in end
stage renal failure (ESRF). C.A. Pollock*, R. Wyndham, P. Colleti, G.
Elder, M.J. Field, C.R.P. George, S. Kalowski, J.R. Lawrence, D.
Waugh, Department of Renal Medicine, Concord Hospital, NSW,
2139, Australia. EPO therapy has been associated with normalisation of
several hormonal responses which are known to be dysfunctional in
ESRF. increased insulin sensitivity is postulated to be responsible for
improved carbohydrate tolerance after EPO treatment. However, stim-
ulation of appetite may counterbalance any observed beneficial Se-
quelae. As insulin resistance is responsible in part for the abnormalities
in lipoprotein metabolism in ESRF, we undertook a prospective study
assessing the lipid profile of 108 (58M, SOF) dialysis dependent patients(75 HD, 33 CAPD) prior to treatment with EPO. 86 were reassessed
3—15 (5.1 0.3, mean SEM) months later. As expected an increase in
haemoglobin occurred after EPO treatment (7.6 1.2 to 9.3 0.2 gldl;
P < 0.001). The observed changes in lipid profile are detailed below:
Pre EPO Post EPO P value
Total cholesterol (mmol/l) 5.7 0.1 5.3 0.2 0.16
Triglycerides (mmolIl) 2.3 0.1 2.1 0.2 0.13
HDL cholesterol (mmolil) 1.1 0.4 1.1 0.1 0.80
LDL cholesterol (mmol/l) 3.4 0.1 3.3 0.2 0.80
Apoprotein A1 (g/l) 1.16 0.4 1.2 0.04 0.70
Apoprotein B (g/dl) 1.19 0.04 1.06 0.06 QØ4*
Lipoprotein (a) (mg/I) 803 75 683 79 0.26
Results were similar in the HD and CAPD populations. The length of
time on dialysis prior to the instigation of EPO therapy, the change in
Hb from baseline levels, age or sex did not correlate with any observed
changes in blood lipids. In summary, patients treated with EPO showed
a trend towards an improvement in the lipid profile with a significant
decrease in Apoprotein B. The reasons for these changes are not
addressed by this study and may be due to a direct and/or a secondary
effect. Previous studies in the general population have shown a signif-
icant reduction in vascular events with similar reductions in blood
lipids. Whether these benefits extend to the dialysis population remains
to be determined.
One year treatment with low dialysate calcium (dCa) may induce a rise
in P'H secretion despite satisfactory Ca and Phos control. A. Argiles*,
P.G. Kerr, B. Canaud, J.L. Flavier, G.M. Mion, AIDER, Montpellier,
France and Dept. of Nephrology, Monash Medical Centre, Clayton,
Vic. Low dCa has been proposed to prevent hypercalcaemia whilst
using CaCO as a phosphate binder. However, the long-term effects of
this modification in dialysis treatment have not been adequately as-
sessed. Seven patients were followed for a 1 year period after changing
from dCa 1.5 to dCa 1.25 mmolIl. A control group (N = 6) was
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maintained with dCa = 1.5 for the same period. Total Ca (tCa),
phosphate (Phos) and alkaline phosphatase (ALP) were assessed
monthly and Phos binders and oral vit D derivatives were adapted to
maintain tCa between 2.4—2.8 mmolIl and Phos <1.7 mmolIl. Intact
PTH was determined quarterly. CaCO oral intake was more than
doubled in the low dCa group. tCa, Phos and ALP were similar in both
groups over the assessed year. However, a significant increase in P'FH
was observed after one year with 1.25 mmol/l dCa (94 40 vs 296 99
pg/mI, P < 0.05) which was not observed in the control group (92 24
vs 113 24 pg/mI, P NS). Six of the patients maintained with dCa =
1.25 for one year went on to receive iv high dose 1 a-vit D3. A control
group of 6 patients dialysed with dCa = 1.5 and with comparable PTH
levels was submitted to identical treatment and followup. High dose iv
I a-vit D3 resulted in a similar reduction in iP'l'H (72 and 75%, P < 0.03)
in both groups within four months of treatment. In our experience the
increase in oral CaCO intake while using dCa 1.25 mmol!l was not
sufficient to prevent stimulation of PTH. Complementary treatment
with high doses of vit D derivatives reverses the PTH increase both in
1.25 and 1.5 mmoL/l dCa treated patients.
Neutrophil F-actin and dialysis neutropenia. B. Tabor,' R. Odell,' B.
Geissler,2 M. Blumenstein,2 K. Schindhelm,' 'Centre for Biomedical
Engineering, Univ. NSW, Sydney, 2Nephrology Dept., Klinkum
Grosshadern, Univ. of Munich, FRG. Dialysis neutropenia was first
described 30 years ago. Transient pulmonary sequestration of neutro-
phils (PMNs) is dependent on complement, probably via C5a, but the
mechanism of sequestration is unknown. A hypothesis is that activated
cells are stiff and that transit across the lung capillaries is therefore
retarded. Cell stiffness is derived from the cytoskeleton which com-
prises mainly filamentous actin (F-actin). It is known that F-actin is
polymerised after stimulation by chemoattracts such as fMLP. A
method using fiow-cytometry and the stain NBD-Phallacidin was de-
veloped for measuring the F-actin content of WBCs in whole blood
within 30 seconds of sampling. Cell counts and PMN F-actin were
measured in venous and arterial blood sampled during haemodialysis
with cuprophan (CP, N = II patients), hemophan (HP, N = 6) and
polysulfone (PS, N = 6) membranes. Minimum cell counts and peak
PMN F-actin levels, expressed as C/Cpre, mean (SD), and the times of
occurrence were:
PMN
t count t F-actin (V) t F-actin (A)
CP 20 0.16 (0.23) 180 2.60 (0.38) 30 1.91 (0.33)
HP 20 0.51 (0.19) 180 2.45 (0.31) 15 1.47 (0.09)
PS 15 0.78 (0.06) 30 1.73 (0.25) 10 1.24 (0.19)
PMN counts fell (CP < HP < PS, P < 0.01), then returned to baseline
by 60 mi F-actin levels in arterial PMNs peaked in the first 30 mm (CP
<HP < PS, P <0.01), then fell, but did not return to baseline. Venous
PMN F-actin was increased over arterial throughout dialysis. With CP
and HP it rose quickly to a plateau at 2.5 times baseline. With PS there
was a small, early peak. Other studies showed that normal PMNs were
activated by arterial and venous plasma (CF dialysis, t = 15 mm) and
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that activation was suppressed by prior incubation with an anti-C5a
monoclonal antibody. Conclusions: PMN F-actin content is increased
during dialysis. The inverse relation between peak arterial PMN F-actin
and minimum PMN counts lends support to the cell stiffness hypothe-
sis. That C5a plays a role is supported by the results. However, the
reversal of neutropenia despite the apparent continued activation of
cells by the dialyser means that the phenomenon is not fully explained.
Simultaneous transplantation of the heart and kidney. E. Savdie*,
A.M. Keogh, P.S. Macdonald, P.M. Spratt, A.M. Graham, D.
Golovsky, P.D. Stricker, Departments of Cardiac Transplantation,
Nephrology, Vascular Surgery and Urology, St. Vincent's Hospital,
Darlinghurst, NSW 2010. End-stage cardiac and end-stage renal failure
may occasionally coexist, either as related or discrete conditions. Since
May, 1990, we have accepted seven such patients for cadavenc
combined heart-and-one kidney allografts. This procedure has been
performed simultaneously in three males [1) MCGN type I and idio-
pathic dilated cardiomyopathy, 2) previous failed renal allograft for
chronic GN and ischaemic cardiomyopathy, 3) refiux nephropathy and
post-viral cardiomyopathy], of mean age 35 years. Each recipient
received his organs from a single cadaveric donor with ABO blood
group compatibility and a negative T-lymphocyte cross-match, without
prospective HLA-antigen matching. Cardiac ischaeniic times averaged
3 hrs 18 mins and renal cold and second warm ischaemic times 4 hrs 30
mins and 50 mins respectively. The heart was grafted first and the
kidney second in a procedure which averaged seven hours. Immuno-
suppression was achieved with antithymocyte globulin induction, ste-
roids, azathioprine and cyclosporin A. Excellent early renal graft
function was obtained in all three recipients and no post-operative
dialysis was required. Surgical complications were heparin-related
rebleeding from the left atrial anastomosis in patient 1; a spontaneously-
resolving upper pole renal lymphocoele, also in patient 1; and a urinary
leak from the bladder cystotomy, requiring resuture, in patient 2.
Moderate cardiac rejection on biopsy (lSl-IT grade 3a) was seen on
three occasions in two patients and responded to steroids. Renal
rejection was minimal, but one patient was thought to have mild
cyclosporin nephropathy. All three recipients were alive, well and
rehabilitated II, 20 and 25 months after grafting. Mean creatinine
clearance was 1.35 0.13 mllsec (81 8 mllmin) at last follow-up. No
serious infections had been observed. One patient died a sudden death
whilst waiting, another had a significant improvement in cardiac func-
tion after the commencement of regular dialysis, and was withdrawn
from the list, and two others remain on the active waiting list. Early
listing is now favoured due to the difficulty of treating the combined
syndrome. Simultaneous heart and kidney transplantation provides an
excellent functional solution in the treatment of coexistent advanced
cardiac and renal failure.
T lymphocyte receptor (TCR) Valpha gene expression in rejecting renal
allografts. M.C. Falk (l,2)* V. Zhang (I), G. Ng (1), J.R. Chapman (2),
L.P. Roy (1), J.F. Knight (I), Renal Research Laboratories, The
Children's Hospital, Camperdown (1) and Renal Unit, Wesimead
Hospital, Wesimead (2), NSW, Australia. In renal allografts, infiltrating
T lymphocytes have been demonstrated to play a major role during graft
rejection. Moreover recent studies in murine and human immune
mediated diseases have demonstrated that T cells may employ a
restricted gene expression of the alpha chain variable region (Va) on the
TCR, implying specific local antigen recognition and offering potential
therapeutic targets for monoclonal antibody therapy. We postulated
that similar mechanisms might also occur during allograft rejection. The
biopsies of 14 transplant patients with clinically and histologically
proven acute rejection were studied. Closed biopsy tissue was snap
frozen, the RNA removed by the method of Chomczynski and Sacehi
and then converted to cDNA using reverse transcriptase. A semiquan-
titative PCR analysis for Beta-actin was used to standardise the cDNA
obtained. Polymerase chain reaction (PCR) was individually performed
using 18 Va subfamily primers with a constant Ca primer, the product
dot blotted and probed with a labelled oligonucleotide specific for the
amplified region. This was compared to controls of peripheral blood
mononuclear cells and normal kidney (the unaffected pole of a nephrec-
tomy for Wilm's tumour). 8/14 archival biopsies yielded sufficient RNA
for analysis. In five biopsies the T cell infiltrate expressed alpha chain
variable regions indistinguishable from that found in peripheral blood.
In three biopsies a restricted pattern of predominately Va I, 6, 12 was
detected in the T cells infiltrating rejecting renal allografts. We conclude
that in some rejecting renal allografts, subfamilies of T cells classified
according to the alpha chain of the TCR may perform a major antigen
recognition role, allowing specific therapeutic antibody intervention.
Renal graft vascular thrombosis (RGVT): ANZDATA 1980—1992. Mi.
Penny*, B.J. Nankivell, JR. Chapman, Dept. Renal Medicine, West-
mead Hospital, Westmead, NSW 2145, APS Disney and ANZDATA
Registry Group, Queen Elizabeth Hospital, Woodville SA 5011. Loss of
renal transplants (RTx) from RGVT has remained unchanged since 1980
despite overall improved graft survival. 134 index cases of graft loss
from RGVT, reported to ANZDATA between 1980 and 1992, were
analysed. Two control groups were selected. I) the previous RTx in the
same institution as each index case: Institutional Controls (IC, N =
127). 2) RTx using the contralateral donor kidney of each index case:
Graft Controls (GC, N = 107). RGVT index cases also occurring in
control groups was deleted (6/133 IC, 2/109 GC), the increased occur-
rence in IC was not significant (x2 = 1.342, P = 0.247). RGVT within 30
days after RTx occurred in 1.89% of all RTx and showed no change
over time (slope = 0.036%/year; 95% CI = —0.98, 0.170; P = 0.601). In
contrast, there was an increase in the proportion of all grafts lost within
30 days of RTx due to RGVT over the study period (slope = 1.98%!
year; 95% CI = 0.99, 3.04; P = 0.003). The cumulative occurrence of
RGVT was 83.7%, 90.2% and 93.5% at 7, 14, and 30 days after RTx
respectively. The total ischaemic time of the RGVT group, compared to
IC, was longer (mean SD; 18.4 8.6 hrs, N = 32 vs 14.1 9.1 hrs,N = 30 respectively: P = 0.004). There was a significant increase in
RGVT, compared to IC, with donor grafts 9 years of age (x2 = 7.056,
P =< 0.001). Cyclosporin was not associated with an increase in
RGVT, nor were primary renal disease; pre-transplant haemodialysis or
erythropoietin therapy; perfusion solution or technique; degree of HLA
mismatch; panel reactive antibody levels; recipient age or sex. There
were no significant differences in subgroup analysis of arterial and
venous RGVT, in the parameters examined. The data suggest that
RGVT may be related to prolonged ischaemia times and paediatric
donor grafts but not cyclosporin and other factors investigated.
Effect of sodium intake on active remn content in juxtaglomerular
apparatus of the dog kidney. J. Zhuo*, W. Anderson, K. Song and
F.A.O. Mendelsohn, Department of Medicine, University of Mel-
bourne, Austin Hospital, Heidelberg 3084; and Baker Medical Re-
search Institute, Prahran 3181, Victoria, Australia. We have studied
the effect of sodium intake on active renin content in the juxtaglomer-
ular apparatus (JGA) of dog kidney using a radiolabelled renin inhibitor,
'251-H77, which has high affinity and specificity for dog renin. 3 male
mongrel dogs were given either a normal sodium diet (40 mEq/day),
sodium depletion (5 mEq/day), or sodium loading (200 mEq/kg) for one
week. The dogs were killed by overdose of pentobarbital, the kidneys
perfused with ice cold saline followed by paraformaldehyde to immo-
bilize tissue renin. Frozen kidney sections (20 sm) were incubated in
sodium phosphate buffer containing 25I-H77 without (total binding), or
in the presence of I sM unlabelled 1177 (non-specific binding). The
sections were exposed to X-ray film, and the autoradiographs quanti-
tated. Changes in sodium intake resulted in marked alteration of active
renin in the JGAs as expected: In the sodium-depleted dog, the highest
density of '251-H77 binding was detected (265.4 11.4 dpm/mm2),
compared with that in the control dog (158.5 24.6 dpm/mm2, P <
0.01), and that in the sodium-loaded dog (56.8 13.3 dpm/mm2, P <
0.01). Preincubation of sections with trypsin (0.5 mg/mI) to activate
prorenin had little effect on renin binding in the sodium depleted dog
(+5.5%, ns), but increased active renin by 35% (P < 0.01) in the
control, and by 67.9% (P < 0.01) in the sodium-loaded dog kidneys. In
addition, in sodium depleted dog kidney, more JGAs (35.9 4.5/mm3)
were labelled by '25I-H77 compared with the control (21.1 1.9/mm3,
P < 0.01) and the sodium-loaded kidneys (9.5 1.2/mm3, P < 0.01).
These data demonstrate that radioinhibitor binding with in vitro auto-
radiography can offer high sensitivity and specificity to detect and
quantitate active renin in the kidney.
Intracellular calcium mediates hypertonicity-stimulated urea transport
in rat terminal inner medullary collecting ducts. A.G. Gillin*, R.A. Star,
and J.M. Sands, Dept. of Renal Medicine, Royal Prince Alfred Hospi-
tal NSW, and Renal Divisions of Emory Univ., Atlanta, GA; and Univ.
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of Texas Southwestern, Dallas, TX, USA. Our previous studies sug-
gested that hypertonicity stimulates urea permeability (Parea) in rat
terminal IMCD's independently of AVP, by a post cyclic-AMP mech-
anism. Therefore, to elucidate the mechanism of stimulation more
precisely we used to NaC1 to vary osmolality and measured the
response of two potential second messengers: cAMP and intracellular
calcium (Cai). We measured cAMP production (fmol/mmlmin) by RIA
in non-perfused tubules and Ca using Fura-2 in tubules perfused in
vitro.
mOsm N 290 490 690 890 290 + AVP
cAMP 6 1±0 1±0 1±0 3±0 38± 5*
Ca 5 38±6 69±11*
Data: Mean SE, AVP: 10 nM, * = P < 0.01 vs 290.
To examine if Ca mediates hypertonicity-stimulated 2 strategies
were used: (1) Thapsigargin (1 M) plus 2 mM EGTA and a 0 Ca2 bath
were used to increase the release of Cai, and (2) BAPTA-AM (50 M)
was added to chelate Cai. Firstly, treatment with Thapsigargin
(+EGTAIO Ca2) but without changing osmolality significantly stimu-
lated Ca (from 116 10 to 125 9 nM, N = 5, P < 0.05) and
increased from 16 3 to 31 5 (N = 5, P < 0.02). In control
experiments, the EGTAIO Ca2 bath alone had no effect on ,,rea (N =
3). Next, following incubation with BAPTA-AM, increasing perfusate
and bath osmolality from 290 to 490 mOsm resulted in no change in
Purea; however addition of AVP (100 pM) significantly (P < 0.01)
increased flrea (290: 54 8, 490: 56 9, 490 + AVP: 83 14, N = 6).
In conclusion, in rat terminal IMCDs (1) Hypertonicity had no effect on
cAMP production, and (2) there are two signalling pathways which
stimulate Purea: hypertonicity via Ca and AVP via cAMP. Interestingly
in this subsegment of the collecting duct, these second messengers
work synergistically.
Nitric oxide (NO) synthesis inhibition selectively potentiates the renal
vasoconstrictor response to angiotensin II (All). Chris Baylis*, Jeff
Harvey, and Kevin Engels, Dept. Physiology, West Virginia University,
Morgantown, WV 26506, USA. In the normal, conscious chronically
catheterizedrat, endogenous All levels are low and do not control renal
vascular resistance (RVR). In earlier studies we showed that acute
inhibition of NO (10 mg/kg N-nitro L-arginine methylester, NAME) in
this preparation produces a rise in RVR that is not blunted by acute
inhibition of endogenous All. In the present experiments, we investi-
gated the effect of acute NO inhibition (10 mg/kg NAME, iv) on BP and,
renal function in rats in whom All levels were acutely increased by All
infusion (All, 5 ng!kg/min iv).
BP
mm Hg
GFR
mi/mm!
100gBW
UNaV
eq/min
RVR
mm Hg!
(mI/mm)
Control 119 3 0.92 0.06 1.9 0.4 5.6 0.3
+ All 130 5* 0.92 0.05 2.8 0.8 7.3 0.6*
Control 113 4 0.81 0.07 1.6 0.6 5.4 0.6
+ All + NAME 153 5't 0.44 0.03*t 3.9 1.8 24.3 2.9*t
Control 118 4 0.78 0.02 0.9 0.2 6.9 0.5
+ NAME 156 7*t 0.70 0.02 4.8 1.2* 14.1 1.4*
* significantly different vs control; t significant difference in the vs
+All alone; P < 0.05.
Infusion of All alone caused a mild increase in mean arterial blood
pressure, BP and RVR and no change in GFR. When the same dose of
All was combined with acute NAME, a larger rise in BP occurred that
was similar to the response to NAME alone. However, a profound
increase in RVR occurred (+346 41%) which was greater than the
individual responses to All or NAME alone (+32 10% and + 104
12%;P < 0.01) and the sum of the individual responses (135 9%;P <
0.05). As a result, in All + Name rats, GFR fell markedly. Thus, when
All is controlling RVR and BP, acute NO inhibition greatly potentiates
the renal (but not peripheral) vasoconstrictor effects of All such that a
synergistic increase in RVR occurs with combined All + NOblockade.
Cellular potassium uptake after potassium loading: A role for mito-
chondrial sequestration of potassium? W.R. Adam, B.Z. Wang, R.M.
Wellard, B.P. Shehan and D.J. Craik, Renal Unit, Heidelberg Repa-
triation Hospital, West Heidelberg 3081 and Monash University,
Parkville 3052, Victorian College of Pharmacy. To minimise changes in
the cell membrane potential, the response to an acute K+ load includes
cellular uptake of K+. This study looks at the impact of concurrent
food intake on K+ uptake into liver and muscle and at the intracellular
localisation of K+ using NMR of a K+ congener 'Cs +, because of its
favourable NMR characteristics. Plasma, muscle and hepatic K+
content were measured in control rats and 2 hours after gavage of a 1200
smoles KCI/lOO g, in either water or liquid diet. For the Cs NMR
studies rats were fed a Cs+ loaded synthetic diet leading to tissue levels
of Cs+—lOO mmol/kg. Table 1 shows the increase in liver and muscle
K+ (mmol/l intracellular water) following gavage with K+ in liquid diet
compared to K+ in water or controls. Concentrations of K+ of 220
mmol!l suggest a need for osmotic sequestration to avoid cell swelling.
Compared to other tissues, '31Cs+ NMR spectra of liver show a
broader line width, consistent with physicochemical compartmentalisa-
tion of Cs+ within hepatic cells. Isolated hepatic mitochondria demon-
strate 2-spectral peaks which fall within the chemical shift range of
intact liver. The relative quantities of Cs+ in the two peaks suggest a
component of Cs+, within the matrix space, in slow exchange with the
rest of the Cs+ within the matrix space. As there is no anatomical
delineation of such a compartment within the matrix space, these
findings are consistent with bound Cs+, which might provide a mech-
anism to reduce the high intracellular osmolality following acute K+
loading.
K+, mmole/1 Control K+ , H2O K+, Liquid Diet
Liver
Muscle
175 16
148 3.7
173
153
12
4.0
222 5.1
180 4.3
Dietary protein manipulation alters tubular iron accumulation in
remnant kidney (RK). B,J. Nankivell*, Y.C. Tay, R.A. Boadle, D.C.H.
Harris, Dept. of Renal Medicine & EM Unit, Westmead Hospital,
Sydney. Reactive oxygen species (ROS) have been implicated in the
pathophysiology of rat RK model of chronic renal failure, and its
modification by dietary protein. Iron, which accumulates in substantial
amounts in proximal tubular cells of RK may cause damage by the
generation of ROS via the Haber-Weiss reaction. The effect of high
(40% casein) and low (12%) dietary protein feeding on ROS, tubular
damage and tubular iron accumulation assessed by energy dispersive
X-ray analysis was determined in RK (N = 12)and sham-operated (SO)
rats (N = 10). Renal ablation statistically increased tubular lysosomal
iron, urinary protein and iron excretion and morphological damage, and
impaired GFR. Protein restriction reduced lysosomal iron concentra-
tion and the number of iron-containing lysosomes (both P < 0.05), and
limited renal hypertrophy (P < 0.01), tubular damage (P < 0.05) and
reactive oxygen species assessed by plasma and tissue malondialde-
hyde (MDA) (both P < 0.05). By multiple linear regression, tissue MDA
related to tubular iron accumulation (P = 0.006) and urinary iron
excretion (P = 0.02). Plasma MDA correlated with the number of
iron-containing lysosomes (r = 0.60, P = 0.05). In conclusion, the
variation in tubular iron accumulation and ROS generation with dietary
protein manipulation is consistent with a role for iron as a determinant
of tubular injury in rats with partial nephrectomy.
Acute effect of endogenous calcitonin on rat renal function. S.L,
Carney*, Discipline of Medicine, University of Newcastle, NSW, 2310.
To evaluate the physiological role of calcitonin (CT) in renal calcium
(Ca) transport, increasing concentrations of intravenous Ca (0, 5 and 7.5
mM/L) were administered to rats to provoke parathyroid hormone
(PTH) suppression and CT secretion. These groups of rats were
compared to acutely thyroparathyroidectomized (TPTX) rats also in-
fusedwith differing concentrations ofCa to produce comparable plasma
and ultrafilterable (UF) Ca concentrations. A parathyroidectomized
(PTX) group was also studied. Increasing Ca administration produced a
significant increase in mean serum CT (104 8 to 543 65 pg/mL;P <
0.01) and suppressed PTH secretion. The presence of a high CT level
was associated with a reduced fractional Ca excretion when compared
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to a TPTX group with a similar UF Ca (5.3 0.4 compared to 10.6
0.4%;P < 0.01). Fractional magnesium excretion was similarly reduced
by endogenous CT (26.8 0.9 compared with 37.3 2.1%; P < 0.01).
Glomerular filtration rate (GFR) was increased by CT from 0.87 0.03
to 0.97 0.03 mL/minllOO g body weight; P < 0.05 although the
filtration fraction was unchanged. Because of changes in filtered load
due to an elevated GFR, comparison of TPTX and INTACT groups
with comparable filtered loads again demonstrated greater absolute Ca
and magnesium reabsorption in the presence of CT. This study supports
recent studies and suggests that CT is a renal Ca conserving hormone
like PTH.
I3 integrin independent glomerular neutrophil accumulation and in-jury in anti-GBM glomerulonephritis. P.G. Tipping*, L.J. Cornthwaite,
and S.R. Holdsworth, Monash University Department of Medicine,
Monash Medical Centre, Clayton VJC 3168, Australia. The role of the
132 integrin cell adhesion molecules in directing neutrophil accumulation
and injury in acute anti-GBM antibody induced glomerulonephritis
(anti-GBM GN) was assessed in rabbits by "in vivo" inhibition of CD18
dependent neutrophil/endothelial cell interactions using a monoclonal
antibody. Rabbits given heterologous anti-GBM antibody developed
glomerular neutrophil influx (3,8 0.1 cells per glomeriilar cross-
section [c/gcs]; normal 0.1 0.1 c/gcs) and proteinuria (1389 257
mg/16 h; normal 13 5 mg/16 h). Neutrophil accumulation and injury
were significantly attenuated by neutrophil depletion with mustine
hydrochloride (glomerular neutrophils 0.1 0.1 c/cgs; proteinuria 231
64 mg/16 h) and complement depletion with cobra venom factor
(glomerular neutrophils 0.2 0.1 c/cgs, proteinuria 343 62 mg/l6 h),
demonstrating a major role for complement induced neutrophil recruit-
ment in glomerular injury in this model. Rabbits were treated with
anti-CD18 antibody (60.3) 30 minutes prior to administration of anti-
GBM antibody. This dose of antibody saturated neutrophil binding sites
and prevented neutrophil accumulation in response to intradermal
injection of chemotaxins—IMLP and zymozan activated serum. How-
ever, glomerular neutrophil accumulation (3.5 0.4 c/gcs) and protein-
uria (1205 429 mg/16 h) were unaffected compared to rabbits treated
with isotype matched control monoclonal antibody, (glomerular neu-
trophils (3.8 0.1 c/gcs, proteinuria 1363 403 mg/16 h). These studies
demonstrate that /32 integrin molecules are not essential for neutrophil
recruitment in this model of antibody initiated, complement and neu-
trophil mediated glomerular injury.
Glomerular basement membrane abnormalities in minimal change
disease. Mark Coleman, John W. Stirling and Lindsay J. Barratt,
Departments of Pathology and Medicine, Repatriation General Hospi-
tal, Daw Park, and Flinders Medical Centre, Bedford Park, South
Australia. Abnormalities of the glomerular basement membrane (GBM)
are not usually recognised in minimal change disease (MCD). However,
morphometnc analysis of renal biopsies from 8 patients with uncom-
plicated MCD has revealed significant membrane abnormalities in each
case, with a high prevalence of GBM thinning. In this study, random
measurements of GBM thickness were made from electron micrographs
taken from 3 glomeruli per case. Mean GBM thicknesses were calcu-
lated for each micrograph, each glomerulus and for each case as a
whole. Using one-way analysis of variance, the data were studied in a
step-wise fashion yielding analyses of intergiomerular variation, overall
mean and intraglomerular variation. Step-wise analysis maximises the
detection of irregularly distributed abnormality. Results were compared
with normal control material. Each case contained at least one signifi-
cantly abnormal glomerulus, the majority containing 2 or 3. Six of the 8
cases included glomeruli with significant GBM thinning. GBM thinning
is usually associated with familial nephropathies such as Alport's
syndrome and so-called benign familial haematuria. None of the pa-
tients studied had histories of familial disease. Ultrastructural immuno-
labelling studies by us and others indicate that the major portion of the
GBM (including subepithelial membrane) consists of type IV collagen
subtypes a3(IV), a4(IV) and possibly a5(IV), while subtypes a1(IV) and
a2(IV) are confined to subendothelial membrane. We suggest the
hypothesis that GBM abnormalities may be acquired in MCD possibly
as a consequence of abnormalities of synthesis of 03, 04 and 05 subtypes
of type IV collagen by the visceral epithelial cell. Our findings suggest
that GBM abnormalities are common in minimal change disease.
Detection of epidermal growth factor in glomerulosclerosis. A .M.
Walker*, N.M. Thomson, Department of Paediatric Nephrology, Mo-
nash Medical Centre, Clayton, 3168. Epidermal growth factor (EGF)
has been implicated in the early compensatory growth following renal
ablation, however its role in the subsequent development of glomeru-
losclerosis is unknown. This study was undertaken to detect the
presence of EGF in an animal model of chronic renal injury. Glomer-
ulosclerosis was induced in 16 young inbred Sprague Dawley rats by 5/6
nephrectomy. Renal function (serum creatinine, creatinine clearance)
and urinary protein excretion were monitored for up to 12 weeks.
Animals were killed at 3, 6, 9, 12 weeks and the residual kidney
removed for assessment of histological change and presence of EGF
mRNA and protein product. EGF protein was detected by immuno-
peroxidase staining with rabbit anti-EGF polyclonal antibody. EGF
mRNA production was localized by in situ hybridization utilizing P32
labelled cDNA probe. Changes were correlated with time and histolog-
ical changes. Renal function (s. cr. 38 10 at Day 0) deteriorated in the
first 2 postoperative weeks, thereafter stability then further deteriora-
tion over the study period (s. cr. 166 10 at week 12). Proteinuria was
detected by 2 weeks and increased with time (18 12 mg/day at Day 0,
67 23 mg/day at 8 weeks). Prominent histological features were
glomerular hypertrophy, tubular dilation, interstitial scarring and focal
segmental glomerulosclerosis. A diffuse distribution of EGF was noted
throughout all segments of the kidney, at all time points examined. This
contrasted with normal tissue where discrete staining was localized to
the distal convuluted tubules and ascending Loop of Henle. In situ
hybridization of the disease model demonstrated binding limited to
distal tubules of normal calibre and morphology with little binding over
dilated tubules or in the L of H. The data suggests that EGF may play
a role in the development of focal & segmental glomerulosclerosis.
Ultrastructural analysis of the renal lesion in baboons with placental
ischaemia. A. Hennessy, A.F. Phippard, W.F. Harewood, D.M.
Painter, PD. Kirwan, J.S. Horvath, Departments of Renal Medicine
and Anatomical Pathology, Royal Prince Alfred Hospital, Camper-
down Sydney 2050. When placental ischaemia is induced during late
pregnancy in baboons, a syndrome develops which resembles pre-
eclampsia. Elevated blood pressure and increased urinary protein
excretion are seen and in some animals, a fall in platelet counts.
Haemodynamic changes include a fall in cardiac output, an increase in
systemic vascular resistance and pressor sensitivity. The clinical signs
all resolve after delivery. It has been the observation of this unit that
these animals develop a renal lesion that qualitatively resembles pre-
eclampsia. It is the aim of the present study to apply quantitative
•methods of analysis to these biopsies. The renal biopsy specimens of
four subject and one control animal were subject to computer aided
analysis of the light microscopy for glomerular volume and electron
microscopy for basement membrane thickness. The study animals had
angiographically directed selective uterine artery ligation and delivery
by caesanan section or spontaneous vaginal delivery. The control
animal had angiography of the uterine arteries but no ligation. All
animals were chronically instrumented. They had an open renal biopsy
performed at the time of delivery and again at three months post-
partum. Specimens were handled for Electronmicroscopy (EM) and
Lightmicroscopy (LM) and routine stains including PAS, Silver and
H&E. Digitization of the glomeruli allowed analysis of the total area of
the glomeruli and capillary loops. This area was used to calculate the
volume of the Glomeruli V = 1.25 x A312. The number of available
glomeruli were analysed, 25 to 50 per animal. 3—4 glomeruli were
analysed using a grid system and calculating the harmonic mean for BM
Thickness. The results show that there is a 30% increase in glomerular
volume and capillary loop volume at the time of delivery. The EM
studies suggest that this increase is at least in part due to increase in
basement membrane thickness. Uteroplacental ischaemia in the baboon
produces a renal lesion that allows a closer analysis of the exact
morphometric abnormalities which contribute to glomerular enlarge-
ment in this disease.
Effects of urine and glycine betaine on aminoglycoside antibacterial
activity. B.A. Peddie*, S.T. Chambers andR.R. Bailey, Departments of
Nephrology and Infectious Diseases, Christchurch Hospital, Christ-
church. It is known that urine inhibits the activity of the aminoglycoside
antimicrobial agents against urinary tract pathogens. It is also known
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that glycine betaine (GB), which is present in urine, confers resistance
against high osmolarity to Gram-negative organisms. We postulated
that GB might play a role in aminoglycoside resistance found in
hypertonic urine. Minimal inhibitory concentrations (MIC) of genta-
micin for Escherichia coli were measured in six paired dilute and
concentrated urines, and in minimal medium supplemented with I04M
GB with NaCl added to induce hypertonicity. All concentrated urines
showed a marked inhibitory effect on gentamicin sensitivity even when
pH was adjusted to 7. All urines contained GB at concentrations within
one log of lO4M. E. coli resistance to gentamicin was also increased in
hypertonic minimal medium in the presence of GB (40 x MIC in 0.9M
NaCI). Similar effects were observed with tobramycin, netilmicin and
amikacin. In hypertonic glucose concentrations, resistance was in-
creased to a lesser extent (3 x MIC in l.OM glucose). The results
suggest that the observed synergism is mediated by the known osmo-
protectant effects of NaC1 and glucose. The betaines in urine thus
permit the expression of increased resistance to aminoglycosides in
concentrated urine.
Interleukin.l is not an autocrine growth factor for mesangial cells in
vitro. *DJ Nikolic-Paterson, S.R. Rainone, R.C. Atkins, Dept. of
Nephrology, Monash Medical Centre, Clayton, Victoria 3168, Austra-
lia. Cultured rat and human mesangial cells have been shown to
proliferate in response to added interleukin-l (IL-i) and also to synthe-
size IL-l themselves, leading to the suggestion that IL-i is an autocrine
growth factor for mesangial cells. To test this hypothesis, varying doses
of human recombinant IL-i receptor antagonist (huIL-lra)—which is a
competitive antagonist for both IL-i alpha and beta—was added to
cultures of mesangial cells and proliferation measured by a standard
thymidine uptake assay. To establish whether hulL-Ira could inhibit
the action of rat IL-I, supernatants from LPS-stimulated rat peritoneal
macrophages with known IL- 1 bioactivity were assayed in the presence
of huIL-lra in a rat co-mitogen thymocyte proliferation assay. HulL-
ira inhibited the activity of rat IL-l in a dose-dependent fashion. A
cloned rat mesangial cell line (1097) was used to assess huIL-lra action
on mesangial cell proliferation. Cells were seeded at low density
(3000/well) in 96 well plates and cultured in RPMI + 5% FCS for 1, 2,
or 3 days in the presence of different doses of hulL-ira (100 g —
ng/ml). HulL-Ira treatment made no difference to mesangial cell
proliferation, with cells reaching confluency on day 3. This was
repeated 3 times. In addition, we could not detect production of
IL-i-beta mRNA by unstimulated or LPS-stimulated mesangial cells,
although IL-6 mRNA could be easily detected in LPS-stimulated cells.
This study demonstrates that IL-i is not an autocrine growth factor for
cultured rat mesangial cells in vitro.
Deoxyspergualin (DSP) suppresses adhesion molecule expression by
monocytic cell lines. P.G. Kerr*, D.J. Nikolic-Paterson, P. Hutchinson,
R.C. Atkins, Dept. of Nephrology, Monash Medical Centre, Clayton,
Vic. Deoxyspergualin (DSP) is a potent immunosuppressant drug
whose mechanism of action involves binding to a member of the heat
shock protein 70 family. We have recently demonstrated the efficacy of
this drug in suppressing crescentic glomerulonephritis and pulmonary
injury in accelerated anti-GBM disease in the rat. Inhibition of macro-
phage infiltration appeared to be a key mechanism of DSP action. In this
study we have directly assessed the ability of DSP to modulate
monocyte expression of adhesion molecules as a possible mechanism
for this diminished macrophage infiltration. The study used the human
monocytic cell line, U937, which was cultured in RPMI/lO% pooled
human serum. Cell surface antigen expression was quantitated by
indirect immunofluorescence using an EPICS V flow cytometer. U937
cell constitutively express both ICAM-l (CD54) and LFA-l (CD1 lal
CD 18) adhesion molecules. Treatment of U937 cells for 3 days with 50
sg/ml DSP (' pharmacological concentrations) resulted in an 18%
reduction of ICAM-l expression and a 49% reduction in LFA-l
expression (mean of 3 experiments). This was a specific effect since
expression of the leukocyte common antigen and the fibronectin recep-
tor were unaltered and cell viability and size were unaffected. Stimu-
lation of U937 cells for 24 hours with 1000 U/ml gamma-interferon
caused a 232% increase in ICAM-i expression, however this was
reduced to a 112% increase when cells were pretreated for 3 days with
DSP (mean of 3 experiments). A 3 day exposure was necessary to
observe the maximal effects of DSP upon U937 cells. This is consistent
with in-vivo studies of human renal allograft rejection in which the
immunosuppressive effect of DSP appears to be delayed 2—3 days.
Suppression of the upregulation of ICAM-l expression and of LFA-i
expression may be one mechanism by which DSP acts to inhibit
monocyte infiltration and action during glomerulonephritis and trans-
plant rejection.
Deoxyspergualin (DSP) does not inhibit monokine induction in-vitro.
P.G. Kerr*, S. Rainone, P. Hutchinson, D. Nikolic-Paterson, R.C.
Atkins, Dept of Nephrology, Monash Medical Centre, Clayton, Vic.
The new immunosuppressant, DSP, has been proven to be efficacious in
treating and preventing human renal allograft rejection. The mode of
action of this drug is poorly understood although it was recently shown
to bind to an intracellular protein from the heat-shock protein-70 family.
Since the early description of this drug, it has been postulated that it
may inhibit monocyte functions such as hydrolytic enzyme release,
upregulation of MHC Class II expression and production of superoxide
radicals. There has been a single study reporting inhibition of IL-l
production in-vivo in the setting of rat renal allograft recipients. The
study reported here examined the effects of DSP in pharmacological
concentrations on monocyte cytokine induction in response to LPS
stimulation. Both human monocyte cell lines (U937 and RC2A) and
normal human peripheral blood monocytes were studied. The mono-
cytes were stimulated with varying concentrations of LPS (0.5—10
ng/ml) for 24 hours. DSP was used at 50 g/m1 and was administered
either at the time of stimulation with LPS or 3 days prior (based on
previous experimental and clinical experience). Despite adequate stim-
ulation, there was no significant inhibitory effect of DSP on production
of IL-l/3, TNFa or IL-6 protein as measured by sensitive ELISA
assays. There was actually stimulation (mean 230%) of TNFa produc-
tion by DSP SO sg/ml with peripheral blood monocytes. Northern
blotting was also performed using the RC2A cell line and 50 sgIml DSP
at the time of stimulation with LPS and/or PMA. Cells were harvested
for RNA preparation at 6 hours post-stimulation. Once again, there was
good induction of mRNA for IL-lp and TNFa in the untreated,
stimulated cells but DSP had no inhibitory effects. Thus DSP had no
inhibitory effects in-vitro on monokine induction in response to labora-
tory stimuli. It must be added that in other studies we have demon-
strated inhibition of TNFa production by pulmonary macrophages
in-vivo in the setting of anti-GBM disease in rats. Thus it may be that
whilst DSP is immunosuppressive in-vivo it does not inhibit the host
response to invasive bacteria (as represented here by LPS stimulation)
which may be a considerable advantage in clinical immunosuppression.
An ELISA for anti-neutrophil proteinase 3 (PR3) antibodies. J.G.
Jennings, L. Chang and J.A. Savige*, Dept. of Haematology, Heidel-
berg Repatriation Hospital and *Renal Unit and Universiiy Dept. of
Medicine, Austin Hospital, Heidelberg, VIC 3084. Anti-neutrophil
proteinase 3 (PR3) antibodies are a subgroup of anti-neutrophil cyto-
plasmic antibodies, often associated with cytoplasmic fluorescence. An
ELISA has been established using HPLC-punfied PR3 as the basis.
This is a robust reproducible assay with inter- and intra-assay variations
of less than 10%. Anti-PR3 antibodies were present in 22 out of 76 sera
(29%) positive in a crude neutrophil extract ELISA, and were demon-
strated occasionally in sera with pennuclear fluorescence. Anti-PR3
antibodies were associated with a 29 kd band on western blots as well
as a 53 kd band, which is believed to be a complex of PR3 with alpha 1
anti-trypsin, its naturally-occurring inhibitor. Anti-PR3 antibodies were
found most commonly in patients with Wegener's granulomatosis (77%
of patients) but also in those with microscopic polyarteritis and other
vasculitides. Most antibodies were IgG but 1gM antibodies were also
observed. At least 5 out of 7 sera with anti-PR3 activity (71%) had
activity directed against the catalytic site of the target enzyme. There
was no seasonal variation in the occurrence of anti-PR3 antibodies.
Detection of antibodies to minor antigens of neutrophil cytoplasm. L.
Chang*, J.G. Jennings, A. Hendilass, R. Buchanan, and J. Savige,
Haematology Department, Heidelberg Repatriation Hospital and De-
partment of Medicine, Austin Hospital, Heidelberg, Victoria. The
common target antigens associated with pennuclear and cytoplasmic
patterns of antineutrophil cytoplasm antibodies have been identified as
myeloperoxidase and proteinase 3. Other cytoplasmic antigens, al-
though less common, are increasingly recognised as significant in
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assisting diagnosis of autoimmune diseases which are often associated
with vasculitis and renal dysfunction. We have developed ELISAs for
anti-lactoferrin, anti-lysozyme and anti-cathepsin G antibodies. Absor-
bances of binding greater than mean + 3 SD of normals were considered
positive. One hundred and five sera from patients with Wegeners
granulomatosis (N = 25), microscopic polyarteritis (N = 14), vasculitis(N = 20), systemic lupus erythematosus (N 20), rheumatoid arthritis(N = 20) and ulcerative colitis (N = 6)were tested for these antibodies.
Cathepsin
Lactoferrin Lysozyme G
Wegeners (N = 25) 5 2 2
MPA (N= 14) 1 2 1
Vasculitis (N 20) 3 3 7
SLE (N=20) 5 2 12
RA (N=20) 0 1 3
UC (N=6) 0 0 0
The specificities of binding are currently being investigated.
A comparison of three renal biopsy techniques in 562 patients. P.
Snelling*, A. Hennessy, D.M. Painter, J. Johnson, G.G. Duggin, J.S.
Horvath, D.J. Tiller, Dept. of Renal Medicine and Anatomical Pathol-
ogy, Royal Prince Alfred Hospital, Camperdown 2050 NSW. A retro-
spective analysis of the biopsies performed over three years was
conducted. The aim of the study was to compare three renal biopsy
techniques over this time for of complication rate and adequacy of
tissue obtained. METHODS. The techniques involved the use of the
Franklin modification of the Vim Silvermen 14FG needle, the Trucut
14FG needle, and the Biopty Gun with an 18G needle. The biopsies
were performed between Jan 1990 and December 1992. Biopsies
included all native kidney and transplant biopsies. The procedures were
performed as inpatients, under indirect ultrasound control with the
patient sedated only if required. Contraindications included uncorrect-
able bleeding abnormality, a single native kidney, uncontrolled uraemia
or hypertension and small (<9.0 cm) kidneys. RESULTS. 562 biopsies
were performed in 476 patients, 360 native and 202 transplant biopsies.
(No. of biopsies) GUN TRUCUT VIMSILVERMAN
native 164 133 63
transplant 107 52 43
total 271 185 106
Complications (%
total)
Macro haematuria 6 (2.2) 7 (3.7) 9 (8.5) P < 0.025
transfusion 1(0.5) 2 (1.1) 0 NS
non-diagnostic 8 (2.9) 12 (6.4) 6 (5.6) NS
other organ 0 1 (0.5) 1 (1) NS
Yield (mean no. of glomeruli per biopsy SD)
Native 12 7 18 14 17 11
transplant 12 6 9 6 18 9
CONCLUSION. Adequate tissue was obtained using all three tech-
niques. There was a statistically significant difference in the rate of
bleeding between the three techniques (P < 0.025) but no difference
between techniques in the yield of diagnostic tissue, transfusion re-
quirement or sampling other organs.
Coronary angiography prior to renal transplantation. G.B. Pidgeon*,
R.R. Bailey, R.A. Robson, H. lkram, K.L. Lynn, Departments of
Nephrology and Cardiology, Christchurch Hospital, Christchurch.
Since January 1975 coronary angiography has been performed on all
diabetics and all patients >40 years of age, who were established on
regular dialysis treatment, prior to their acceptance onto the cadaveric
renal transplant waiting list. A total of 89 patients (57 male) were
studied. Time on dialysis prior to angiogram was 1—125 months (median
8 months), and average duration of follow-up 8.2 yrs. Thirty patients
(34%) had evidence of significant coronary artery disease (CAD)—18
single vessel, 8 two vessel, 3 three vessel and one four vessel disease.
Significant predictors for the presence of CAD were the history of
cardiac ischaemic symptoms, positive family history, diagnosis of
diabetes mellitus, and ejection fraction <50%. Neither age, sex, hyper-
tension, duration of dialysis, nor left ventricular mass were significant
predictors of CAD. Twelve patients (10 with CAD) were excluded from
the transplant waiting list. In four patients the presence of CAD was the
sole reason for exclusion. Once accepted for transplantation, 60% of the
CAD group were transplanted, compared with 77% without CAD.
Renal transplant survival was no different in the CAD patients. Total
mortality was increased in the CAD group (47% v 36%), with more
cardiovascular deaths (50% v 24%). There was a trend to reduced
survival in the CAD group (NS), however there was no difference in
survival between the two groups of patients accepted onto the waiting
list. Patients receiving a renal transplant had similar survival to those
remaining on the waiting list. Restriction of coronary angiography to
patients who are either symptomatic or diabetic would most effectively
detect patients with significant CAD.
Effect of chronic nitric oxide inhibition on arterial pressure in the
baboon (Papio hamadryas). A. Hennessy, A.F. Phippard, J.S. Horvath,
D.J. Tiller, Dept. of Renal Medicine, RPAH, NSW, 2050. It is estab-
lished that nitric oxide generated by vascular endothelium acts upon
adjacent smooth muscle to produce a c-GMP dependent relaxation.
However the physiological significance of this vasodepressor mecha-
nism in the human, and relevance of nitric oxide synthesis deficiency to
hypertension, remains controversial. Acute inhibition of nitric oxide
synthesis typically produces a rise in arterial pressure but the data from
chronic studies vary with species. The aim of the present study was to
assess the effect of nitric oxide synthesis inhibition using n-nitro-L-
arginine (NOLA) for a week in baboons. METHODS. 17 animals were
studied, 12 (N) on NOLA 5 mg/kg/day in two divided doses and 5 as
controls (C). Examinations were performed prior to the commencement
of treatment, then repeated at 2 and 7 days. This included blood
pressure, by intra-arterial cannulation of the femoral artery, and heart
rate after intramuscular injection of ketamine (5—8 mg/kg). Mean arterial
pressures were calculated from the direct systolic and diastolic values.
The animals were kept with their social groups in an indoor-outdoor
housing complex throughout the procedure. RESULTS. For these
animals there was no significant difference between the MAP recorded
in animals not on NOLA of (89 10 mm Hg mean SD, N = 27)
compared to (92 9 mm Hg N = 24) on treatment. The heart rate of
animals not on NOLA was 121 6 beats per minute (bpm) and on
NOLA was 111 14 bpm. Analysis of variance showed a slight but
significant upward trend in blood pressure with time for all animals with
P < 0.05. However, there was no demonstrable effect of nitric oxide
synthesis inhibition, MAP 2 and 7 days for N being 92 9 and for C, 96
11 mm Hg. CONCLUSION. These data argue against a critical role
for tonic basal release of nitric oxide for determination of arterial
pressure in primates, and against speculation that hypertensive states
result from nitric oxide deficiency.
The influence of native and modified low density lipoproteins on normal
and diabetic rat glomerular core production of prostaglandins. N.
Harley*, M. Dunlop, R. Larkins, G. Becker, Departments of Medicine
and Nephrology, University of Melbourne, The Royal Melbourne
Hospital, VIC 3050. Hyperlipidaemia is associated with a variety of
renal diseases and experimental evidence suggests a role for lipopro-
teins in their progression. Elevated and abnormal plasma lipoproteins
(LP) may lead to glomeruloscierosis via haemodynamic and cellular
mechanisms. Low density lipoproteins (LDL) may be modified by
oxidation (OXLDL) or glycation (GLCLDL) and via interaction with
nonspecific receptors contribute to the development and progression of
glomerulosclerosis. These modifications are particularly relevant to
diabetes and diabetic nephropathy. The influence of unmodified and
modified LDLs on prostaglandins E2 (PGE2) production by mesangial
cell enriched glomerular cores (GC) was investigated. Human LPs were
purified by KBr density gradient ultracentrifugation; OXLDL and
GLCLDLs prepared using established methods. GCs were prepared
from kidney cortices of control and Streptozocin (STZ 60 mg/kg)-
injected Sprague-Dawley rats with diabetes of 3 weeks duration, by
differential sieving, collagenase digestion and resuspension in modified
phenol-red free RPMI-1640. Glomerular cores were incubated with the
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indicated LP for one hour. PGE2 was assayed by specific radioimmu-
noassay and expressed as pg/l00 protein. In the absence of lipopro-
tein, STZ-derived GCs had a significantly greater level of PGE2
production than controls. Addition of unmodified LDL resulted in a
small but significant PGE2 increase in controls, not observed in
STZ-GCs. In control GCs incubated with 50 or 100 g/ml of either
OXLDL or GLCLDL PGE2 levels significantly increased; in STZ-
derived GCs a significant increase was seen with 50 and 100 g/ml of
oxidized and 100 g/ml of glycated LDL.
g/ml LDL OXLDL GLCLDL
control
1.384 50 2.441 0.342* 11.647 l.221** 4.906 0.337**
0.114 100 2.474 0.315** 13.728 1.165** 5.201 0.648**
STZ rats
4.584 50 3.242 0.491 11.734 0.604 4.891 0.380
0.l07** 100 4.115 0.333 35.168 8.377* 8.231 0.839*
PGE2 production (pgIlOO g protein) of glomerular cores (* P <0.05,
**p < 0.01)
These lipoprotein induced changes in PGE2 production may contribute
to the altered glomerular haemodynamics implicated in the progression
of renal disease with particular reference to diabetic nephropathy.
Expression of renal atnal natriuretic factor (ANF) receptors in the
sheep. Margaret B. Fraenkel*, G.P. Aldred, J.G. McDougall, Howard
Florey Institute of Experimental Physiology and Medicine, University
of Melbourne, Parkville, Victoria, 3052. Investigations into the effects
of ANF infusion in humans and sheep have shown that the sodium
status of the subject has a major influence on the magnitude of the
resulting natriuresis and diuresis. To investigate the role of the renal
receptors for ANF in modulation of the renal response to ANF in the
sheep, we have cloned cDNA for the ovine biological (GC-A) ANF
receptor and the clearance (C) ANF receptor. Primers based on regions
of homology between published nucleotide sequences were used in
reverse transcription of ovine kidney RNA and subsequent polymerase
chain reaction (PCR). The resulting 206 bp fragment of C receptor
cDNA and 440 bp fragment of GC-A receptor cDNA were sequenced
and demonstrated a high degree of sequence similarity to other species
(96% to bovine and 92% to human respectively). The distribution of
receptor mRNA in the ovine kidney and the effect of sodium status on
receptor expression was examined by using these cDNA fragments as
probes for northern analysis of mRNA isolated separately from renal
cortex and medulla of 6 Na loaded, 6 Na depleted and 4 control sheep.
Levels of mRNA for the receptors were quantitated using laser densi-
tometry and standardised to /3-actin expression. Levels of mRNA for
the receptors were quantitated using laser densitometry and standard-
ised to 13-actin expression. Levels of mRNA for the GC-A receptor
were not statistically different between renal cortex and medulla (1.20
0.09 vs 1.10 0.10, mean sEM) while C receptor levels were
significantly higher in cortex than medulla (0.68 0.08 vs 0.06 0.01,
P < 0.001). GC-A receptor expression was significantly higher than C
receptor in renal cortex and also in renal medulla (P < 0.001), where it
was the major transcript present. No change in GC-A or C receptor
expression was observed in either region with changes in Na status.
These results confirm a high degree of homology in the genes for the
GC-A and C natriuretic factor receptors in all mammalian species
studied to date, indicate that GC-A receptor expression is greater the C
receptor expression in ovine renal cortex and medulla and suggest that
the variation in renal responsiveness to ANF seen with alteration in
sodium status in the sheep is not occurring at the level of receptor gene
transcription.
CAPD early discharge programme: Royal Perth Hospital 1989—1992.
G.N. Thatcher, K.J. Warr*, J. Wishaw, S. Porter, M.A.B. Thomas,
Department of Nephrology, Royal Perth Hospital, Perth WA 6000. To
assess the benefits of changing a predominantly inpatient CAPD train-
ing to outpatient and home training, prospective data was collected
between 1989 and 1992 on all new CAPD patients. Patients were
discharged from hospital as soon as recovered from surgery and training
commenced seven days later as an outpatient whilst maintained on
hospital haemodialysis. Training was continued at home until patients
were deemed competent to continue unsupervised. This required an
increase in nursing staff numbers from 2.8 to 3.8 full-time equivalent
positions to visit new and existing patients at home. CAPD technique
changed from disconnect (54%), standard spike (30%) and UV (10%) in
1989 to disconnect (77%) and UV (23%) in 1992. CAPD-related admis-
sions were defined as infection (peritonitis, exit site or tube) or tube
malfunction, but not CAPD training.
1989 1992
Total number of patients 55 66
New cases 19 22
Number of days spent in hospital 30 18*
—CAPD related (per patient) 22 7
—Non-CAPD related (per patient) 8 11
Days of inpatient training 199 13*
Days of outpatient training 0 162
Episodes of peritonitis (inpatient) 41 13*
Peritonitis episodes (patient months) 1:8 1:20
* P = 0.0001
The change from inpatient to outpatient training for CAPD resulted in a
significant decrease in total inpatient days spent in training. The cost
saving was offset by additional staff employed with only a small nett
financial gain. During this time the average number of inpatient days per
patient fell significantly. This fall was predominantly in CAPD vs non
CAPD related problems.
IgA nephropathy (IgAN) patients with C4 null phenotype are genotyp-
ically heterogenous. G. Fanning, M.C. Falk, L.P. Roy, J.F. Knight*,
Renal Research Laboratories, The Children's Hospital, Camperdown,
NSW, 2050. Both homozygous and heterozygous C4 null phenotype
have been associated with an increased risk of IgAN. In 112 individuals
with a C4 null protein phenotype, of whom 32 have IgAN, we have used
the polymerase chain reaction (PCR) to amplify a 550 bp fragment of the
C4 genes with primers which span the sequences differentiating C4A
and C4B. Digestion of the PCR product with restriction enzyme NIa IV
produces two bands of 325 and 290 bp. The 290 bp band was absent in
3 of 8 individuals with homozygous C4A null phenotype and reduced to
50% intensity in another 4 of the 8. The 290 bp band was also reduced
in intensity in 43/62 with C4A heterozygous null phenotype. The 325 bp
band was absent in 11/13 individuals with homozygous C4B null
phenotype and reduced in intensity in 13/30 individuals with C4B
heterozyogous null phenotype. The bands were both present at full
intensity in another 130 healthy controls who did not show any C4 null
phenotype at the protein level. These results suggest that the 290 bp
band corresponds to the C4A gene and the 325 bp band corresponds to
the C4B gene. Absence or reduced intensity of a band suggests that the
C4 null phenotype is due to a homozygous or heterozygous gene
deletion respectively. In those individuals with null protein phenotype
but a normal PCR study, failure of gene expression is presumably due
to point mutation. In the IgAN patients, C4 null was due to gene
deletion in 18/39 alleles (9/16 C4A, 9/23 C4B) and to point mutation in
21/39 alleles (7/16 C4A, 14/23 C4B). This heterogeneity at the DNA
level suggests to us that it is the reduced levels of C4 in the plasma
which predispose patients to IgAN rather than linkage between C4
genes and other genes in the MHC.
Immune events in lymphoid tissue during experimental glomerulone-
phritis (GN). *11. Y. Lan, D.J. Nikolic-Paterson, R.C. Atkins, Depart-
ment of Nephrology, Monash Medical Centre, 246 Clayton Road,
Clayton 3168. To investigate immune events within lymphoid tissues
and their role in relation to glomerular disease, systemic lymphoid
tissues from rats with accelerated experimental anti-GBM GN or with
primed serum sickness were studied. Following disease induction,
changes in leukocytic populations within kidney draining lymph nodes,
axillary lymph nodes and spleen were analysed over a 28 day time
course by immunoperoxidase labelling with monoclonal antibodies. In
anti-GBM ON there was a significant increase of T cells, presumably T
helper cells, present within enlarged germinal centres (GC5) of at day 7
(9.1—11.3% vs 1.5—26% of total cells in normal, P < 0.05), peaked at day
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14 (up to 28%) when there was intense deposition of rat lg€i and C3 on
the GBM. Similarly, significant increase of EDI * macrophages were
evident at day 7 in both GCs (1—3.1% vs 0.1—0.5% in normal, P <0.05)
and T cell areas (3.9—5.2% vs 1.8—2.7% in normal, P < 0.05), peaked at
day 14 (up to 15%). Notably, IL-2R expression in GCs and T cell areas
was also apparent from day 7 onwards (P < 0.05), made up to 4.8% in
GCs (vs 0 in normal, P < 0.001) and 18% in T cell areas (vs 0.5% in
normal, P < 0.001) at day 21. This was the time when widespread renal
interstitial infiltration, immune activation and severe functional and
histological injury developed. In addition, antigen deposited in GCs was
found to be associated with CD4, CD5, EDI cells, most probably
antigen presenting dendritic cells. In contrast, in serum sickness there
was no antigen deposited in GCs and only mild renal injury and minor
changes within lymphoid tissues. These results suggest that immune
activation within systemic lymphoid tissues may amplify the immuno-
logical injury within the kidney and thus exacerbate the progression of
glomerulonephritis.
T helper and T suppressor cells are required for early autologous phase
Injury In anti-GBM glomerulonephritis in rats. PG. Tipping*, J. Deme-
us, X.R. Huang, and S.R. Holdsworth, Monash University, Depart-
mentofMedicine, Monash Medical Centre, Clayton VIC 3168, Austra-
lia. The contribution of T helper (CD4) and T suppressor (CD8) cells to
early proteinuria was studied in anti-GBM glomerulonephritis (GN)
induced in presensitized rats by a subnephrotoxic dose of sheep anti-rat
GBM globulin. Both T helper and T suppressor cells have previously
been demonstrated to localize rapidly in glomeruli in this model. Their
functional role was investigated by depletion using specific monoclonal
anti-rat T cell antibodies (W3/25 for CD4 and 0x8 for CD8) and isotype
matched control monoclonal antibody, in a protocol which aimed not to
alter the humoral immune response to the disease initiating antigen.
Rats were preimmunized 5 days prior to administration of heterologus
anti-GBM globulin. Monoclonal antibodies were administered in a
single dose (5 mg ip) 16 hours prior to disease initiation, and proteinuria
was assessed over the first 24 hours of the disease. Rats treated with
isotype matched control antibody developed significant proteinuria (64
19 mg/24 h [mean SEMI, normal 7 I mg/24 h, P < 0.05) associated
with glomerular localization of T helper cells (1.5 0.4cells/glomerular
cross-section [c/gcsD, T suppressor cells (0.8 0.4 c/gcs) and macro-
phages (6.2 2.1 c/gcs). Treatment with either W3/25 or 0x8 prevented
abnormal proteinuria (W3/25 5.3 0.4 mg/24 h; 0x8, 10.4 2.4 mg/24
h, not significantly different from normal). These treatments prevented
glomerular localization of either T helper cells (W3/25) or T suppressor
cells (Ox-8). Both attenuated glomerular macrophage accumulation,
without altering circulating antibody titres of autologous rat anti-sheep
antibody. These results suggest both T helper and T suppressor cells are
required for the induction of early proteinuria in this model. The cellular
mechanisms of these effects remain to be elucidated.
T lymphocyte receptor (TCR) V alpha gene expression in IgA nephrop.
athy (IgAN) biopsies. MC. Falk*. Y. Zhang, G. Ng, L.P. Roy, J.F.
Knight, Rena! Research Laboratories, The Children's Hospital, Camp-
erdown, NSW, Australia. In renal biopsies from patients with IgAN,
interstitial lymphocyte infiltration is frequently observed. Recent stud-
ies in murine and human immune mediated autoimmune diseases have
demonstrated that T cells may employ a restricted gene expression of
the alpha chain variable region (Va) on the TCR. implying local antigen
recognition and offering potential targets for monoclonal antibody
therapy. We studied the renal biopsies of 13 patients with clinical and
histological evidence of IgAN to determine if a limited ICR Va
repertoire was present. Closed biopsy tissue was snap frozen, RNA
removed by the method of Chomczynski and Sacehi and then converted
to cDNA using reverse transcriptase. A semiquantitative polymerase
chain reaction (PCR) analysis for Beta-actin was used to standardise the
eDNA obtained. Abundant Beta-actin expression was detected in 9/13
IgAN biopsies. On these nine, PCR cDNA amplification was individu-
ally performed using 18 Va subfamily primers with a constant Ca
primer, the product was dot blotted and probed with a labelled
oligonucleotide specific for the amplified region. This was compared to
controls of peripheral blood mononuclear cells and normal kidney (the
unaffected pole of a nephrectomy for Wilm's tumour). One biopsy
showed a polyclonal Va infiltrate while two others showed no evidence
of TCR Va expression. The remaining six showed a restricted pattern.
The restricted infiltrates overexpressed Va 1, 2, 8, 12 subfamilies. This
may implies that the T cells found in kidneys with IgAN serve an
antigen recognition role, furthering the hypothesis that the pathogenesis
of IgAN is in part due to local renal factors.
Multlnucleated giant cells in experimental crescentic glomerulonephn-
tis—evidence for a cell mediated granulomatous component. X.R.
Huang*. P.G. Tipping, S.R. Ho!dsworth, Monash University Depart-
ment ofMedicine, Monash Medical Centre, Clayton VIC 3168, Austra-
lia. Multinucleated giant cells (MGC) are a feature of granulomatous
delayed type hypersensitivity reactions and have been described in
crescentic human glomerulonephritis (GN). T cells via their cytokines
have been demonstrated to induce MGC formation from macrophages
in vitro. The phenotypic characteristics of MGC in crescentic GN and
the role of T cells in their formation was studied in a crescentic model
of anti-GBM antibody initiated GN in WKY rats. Presensitized rats
developed a severe crescentic GN, 10 days after administration of a
subnephritogenic dose of heterologous anti-GBM globulin. Crescents
were present in 64 10% (mean and SEM) of glomeruli together with
heavy fibrin deposition (by immunofluorescence). MGC were more
frequent in crescentic glomeruli (0.7 0.2 cells per glomerular cross-
section [c/gcs]) than non-crescentic glomeruli (0.1 0.04 c/gcs). MGC
showed strong immunohistological staining for macrophage phenotypic
markers including ED-I, Ox-I (common leukocyte antigen) Ox-6 (Ia)
and IL-I. CD4 positive T cells (1.9 0.6 c/gcs) and ED-I positive
macrophages (22 10 c/gcs) were also present in glomeruli. T helper
cell depletion, by i.p. administration of anti-CD4 antibody (W3/25) 24
hours after initiation of GN, blocked cutaneous delayed type hypersen-
sitivity responses to the disease inducing antigen without altering the
humoral immune response. This treatment depleted CD4 positive T
cells in glomeruli and significantly reduced MGC formation (0.04 0.01
c/gcs, P < 0.05). These results demonstrate that MGC in crescentic GN
express macrophage phenotypic surface markers, suggesting they are
macrophage derived. Their presence and requirement for local CD4
positive cells for their development suggest processes akin to granu-
loma formation may participate in crescent formation in this model of
GN.
Evidence for a role for delayed type hypersensitivity in the development
of crescentic anti-GBM glomerulonephritls in rats. PG. Tipping5, X.R.
Huang, S.R. Holdsworth, Monash University, Dept. of Medicine,
Monash Medical Centre, Clayton VIC 3168. The local role of T helper
cells in crescent formation was investigated in anti-GBM glomerulone-
phritis (GN) in rats. Crescentic GN occurred in sensitised WKY rats
due to host immune response to a planted glomerular antigen (sub-
nephntogenic dose of sheep anti-rat GBM globulin). Injury was mani-
fest by proteinuria (129 34 mg/24 h), glomerular macrophage accu-
mulation (EDI positive cells 22 10 cells/glom cross-section [c/gcs])
and crescent formation involving 78 11% of glomeruli. The immune
response involved both B and T cell effectors manifest systemically as
circulating rat anti-sheep globulin antibody (serum end-point titre 10.2
1.2 log2 by ELISA) and cutaneous delayed type hypersensitivity
(DTH) response (1.4 0.4mm swelling after subdermal sheep globulin,
0.09 0.01 mm after horse globulin) and locally as linear glomerular
deposition of rat IgG and accumulation of glomersilar T cells (2.0 0.4
0x19 positive c/gcs, normal 0.02 0.01 c/gcs, P < 0.5). The contribu-
tion of 'f helper cells was assessed by depletion with an anti-CD4
monoclonal antibody (W3/25). When administered 6 days after sensiti-
zation to the disease inducing antigen (I day after anti-GBM antibody)
this treatment did not alter the humoral immune response (serum rat
anti-sheep globulin endpoint titre 10.4 1.2 log2). However skin DTH
(swelling, 0.06 0.01 mm, P < 0.05) was prevented and glomerular T
cell accumulation (0.5 0.3 c/gcs, P < 0.05) was reduced. This was
associated with significantly attenuated proteinuria (78 23 mg/24 h, P
< 0.05) macrophage accumulation (5.9 1.1 c/gcs, P < 0.05) and
crescent formation (12.5 3.2%, P < 0.05). Thus while antibody in T
cell depleted animals can induce macrophage influx and proteinuria, T
helper cells appear necessary for crescent formation and augment
macrophage influx and proteinuria, suggesting DTH responses are
associated with the full expression of glomerular injury in this model.
The effect of atrial natriuretic peptide (ANP) on proximal tubular (PT)
intracellular electrolytes. S. Reddy, N. Sa!ipan-Moore, A.Z. Gyory,
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C.A. Pollock*, M. Dyne, M.J. Field, D. Cockayne, Departments of
Medicine and Electron Microscope Unit, University of Sydney, NSW
2006. The majority of evidence suggests that the natriuresis induced by
ANP is due to inhibition of Na reabsorption in the collecting duct.
However, several studies have also demonstrated that ANP reduces Na
transport in the PT, particularly when this is being stimulated by
angiotensin II. In order to further define the action of ANP on PT
transport, combined clearance/electron microprobe (EMP) experiments
were performed on 4 male Wistar rats. Animals were prepared as for
micropuncture experiments and infused with modified Ringers solution
at 1.2 mls/l00 glhr. After equilibration, two 20 minute clearance
collections were done. ANP was then infused via the jugular venous
catheter at a rate of 30 gig/kg/hr, following which 2 further clearance
collections were made. At the conclusion of the clearance studies,
isotonic RbC1 was infused at 0.5 mmoL'kg lvi over 30 secs, as a further
marker of K transport, and the kidney immediately removed. Results
were compared to similarly prepared animals, without ANP infusion.
Clearance data confirmed the expected increase in fractional Na and K
excretion, but no change in GFR during the ANP infusion. EMP
analysis of PT cells revealed a similar [Na]1 in both the control and ANP
treated groups (15.9 0.6 vs 16.5 0.4; P = 0.39). However, the
animals treated with ANP had a significant reduction in dry weight of
the PT cells (21.1 0.3 vs 19.2 0.3; P < 0.0001), indicating significant
cell swelling in the ANP treated group. Thus, despite a normal [Na]1,
there is a net accumulation of [Na]1 following ANP treatment. [Cl]1 was
lower in the ANP treated animals (15.7 0.5 vs 12.3 0.4; P <0.0001)
as was [KJ1 (131.0 2.0 vs 118.2 1.9; P < 0.0001). [Rb]1 was
significantly higher in ANP treated animals (5.1 0.3 vs 11.3 0.4; P
< 0.0001). These results suggest that the natriuresis induced by ANP
may be in part due to inhibition of Na-K ATPase in the proximal tubule.
Because of the resultant accumulation of [Na]1, cell swelling occurs,
which results in a volume regulatory exit of K-Cl. Rb then enters the
cell via open K channels down its electrochemical gradient. These
results are consistent with the postulate that dopamine may mediate
ANP inhibition of PT Na reabsorption via a reduction in basolateral
Na-K ATPase (1).
1. APERIA A ET AL: Am J Physiol 252:F39—45, 1987
Effect of an antagonist of vasoactive intestinal peptide (VIP) in two rat
models of cirrhosis. M.A. Lonergan*, S. Aglibut and M.J. Field,
Department of Medicine, University of Sydney, Concord Hospital,
NSW 2139, Australia. It has been proposed that VIP may contribute to
the disturbance of sodium and water homeostasis that occurs in
cirrhosis. To explore this possibility, we conducted clearance studies in
cirrhotic Sprague-Dawley rats using a putative antagonist of VIP, the
peptide fragment VIPIO—28. Two models of cirrhosis were utilised,
namely carbon tetrachloride-induced cirrhosis (CCI4) and common bile
duct ligation and resection (CBDL). Animals were studied under
mactin anaesthesia after 16 weeks (CCI4) and 5—6 weeks (CBDL). The
response to an acute saline load was assessed in a protocol involving
infusion of Ringer's solution at 4% body weight/h following a baseline
infusion at 1% body weight/h. During the 4% infusion, VIPIO—28 was
included at 2 nmol/l00 g/h. Sham-treated animals for both models also
received the same infusion. The animals receiving VIP1O—28 were
compared to control groups receiving acute volume loading alone.
Tritiated inulin and '4C p-aminohippuric acid were included in the
infused fluids to permit calculation of GFR, fractional electrolyte
excretion rates, renal plasma flow and filtration fraction (FF). In the
CCI4 study, infusion of the VIP antagont resulted in an improved
capacity for excretion of the saline load, fractional excretion of sodium
(FENa) rising above baseline by 1.26 0.2% of filtered load, compared
to no significant rise in CCI4 rats without antagonist. A similar response
occurred in absolute sodium excretion. Urine flow also increased
significantly over baseline by 18.66 4.4 sl/min/100 g, compared to no
significant rise in the CCI4 rats without the antagonist. However, the
diuretic response of the antagonist-treated group remained significantly
less than that of the sham-treated controls (F1ow 56.06 5.7, P <
0.001). FF was not altered by VIP1O—28. In the CBDL study, VIP1O—28
at this dose did not alter the sodium and water retention of cirrhosis. In
both models, VIP1O—28 did not alter the response of the sham-treated
group to saline loading. We conclude that VIP may play a role in the
sodium and water retention in CCI4-induced cirrhosis.
The role of growth factors in stimulating hypertrophy and hyperplasia
in primary culture of rat proximal tubular epithelium. M.S. Nobes, C.A.
Pollock*, Pan T. Heng, M.J. Field, Departments of Medicine, Royal
North Shore and Concord Hospitals, University of Sydney, NSW,
Australia. It is postulated that growth factors, acting in an autocrine or
paracrine fashion, may contribute to the renal hypertrophy of renal
tubular epithelium observed in pathophysiological states such as com-
pensatory renal hypertrophy and diabetes mellitus. The current inves-
tigation aimed to study the direct effects of growth factors on renal
tubular epithelium in primary culture of rat proximal tubular cells
independent of their effects on renal blood flow and glomerular filtration
rate. Primary cultures of rat renal proximal tubular cells were grown to
confluence and quiescence with serum free, hormonally defined media
for 5 days, and then serum free, hormone free media for 1 day. The cells
were then incubated with insulin-like growth factor (IGF 1), epidermal
growth factor (EGF) or platelet derived growth factor (PDGF), with or
without transforming growth factor beta (TGF-/3) for I day. The effects
of these various growth factors on cellular content of protein (hyper-
trophy) and DNA synthesis (hyperplasia) were measured, as assessed
by spectrophotometric assay and [3H]thymidine incorporation respec-
tively. IGF-l increased the cellular content of protein by 25.7% (P <
0.05), whereas EGF or PDGF did not alter protein content per cell
compared to control. TGF/3 alone, or in the presence of the other
growth factors, had no effect on cell hypertrophy. IGF-l and EGF both
stimulated DNA synthesis by 64.7% (P < 0.05) and 46.2% (P < 0.001)
respectively, whereas PDGF had no effect. The addition of TGF/3 to
EGF, IGF-l or PDGF resulted in decreased DNA synthesis by 44% (P
<0.01), 54.1% (P < 0.01) and 49.2% (P < 0.01), respectively, compared
to control. In summary, in rat renal proximal tubular cells studied in
primary culture, IGF-l stimulates cellular hypertrophy. Both IGF-l and
EGF stimulate hyperplasia. TGFI3 inhibits DNA synthesis in normal
cells, and completely reverses the stimulatory effect of growth factors
on hyperplasia. However, in the current experiments, TGF/3 has no
direct or regulatory role in cell hypertrophy.
Characterisation of nonpeptide orally active AVP receptor antagonists.
L.M. Burrell*, P.A. Phillips, J. Risvanis, J. Stephenson, C.!. Johnston,
Department of Medicine, University of Medicine, Austin Hospital,
Heidelberg 3084, Victoria. Arginine vasopressin (AVP) causes vaso-
constriction via the vascular type VI receptor, and antidiuresis via the
renal V2 receptor. Orally active nonpeptide AVP receptor antagonists
have recently been developed. We have characterised the in vitro and in
vivo effects of the orally active Vl receptor antagonist, OPC2 1268, and
V2 antagonist, OPC3 1260, on Sprague-Dawley rat (200—250 g) renal and
hepatic VI and renal V2 receptor binding using selective VI and V2
receptor antagonist radioligands. OPC2 1268 caused a concentration
dependent displacement of the VI receptor radioligand from liver (1C50
= 4 x l08M) and kidney (1C50 = 1.5 X 108M) membranes but had
little effect on V2 receptor radioligand binding in kidney (1C50 >
104M) in vitro. OPC3 1260 similarly caused a concentration dependent
displacement of the V2 receptor radioligand from kidney (IC5O = 2 x
108M) and also the Vl receptor radioligand from liver and kidney
membranes (1C50 = 5 x 107M) in vitro. Scatchard analyses of
saturation binding in liver or kidney membranes showed that each
antagonist increased the apparent dissociation constant with no change
in the maximum number of binding sites indicating competitive inhibi-
tion at the respective receptors. Lastly, orally administered OPC21268
(10 mg/kg) decreased VI radioligand binding to liver at I and 2 hr. At 30
mg/kg oral 0PC21268 decreased Vl radioligand binding to liver and
kidney at I to 4 hr. Thus, these novel, nonpeptide orally active AVP
receptor antagonists are competitive antagonists at the Vi and V2
receptor subtypes in vitro and in vivo. 0PC21268 is relatively more
selective for the V 1 receptor than OPC3 1260 is for the V2 receptor.
LMB is supported by the British Heart Foundation. OPC21268 was
kindly supplied by Otsuka Pharmaceuticals Co Ltd, Japan.
Reduced oropharyngeal inhibition of AVP secretion in the elderly. PA.
Phillips*, J. Risvanis, J. Stephenson, D. Casley, C.!. Johnston and L.
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Gray, Departments of Medicine and Geriatrics, University of Mel-
bourne, Austin Hospital, Heidelberg 3084, Victoria. Acutely on drink-
ing, preabsorptive oropharyngeal factors inhibit thirst and AVP secre-
tion before water absorption occurs and corrects body water/volume
deficits. Since thirst is reduced but AVP secretion maintained in the
elderly, we determined whether preabsorptive inhibition of thirst and
AVP secretion is maintained with age. Following 24 hr water depriva-
tion, ten healthy, informed, volunteer old (64—76 yr) and young (20—32
yr) men received 10 mI/kg oral water loads and their thirst and plasma
[AVP] were determined over the next 120 mins. After 24 hr water
deprivation plasma [Na], osmolality and [AVP} were increased (P <
0.001) and plasma atrial natriuretic peptide (ANP) levels fell (P < 0.05)
similarly in both groups. Although thirst increased in both groups (P <
0.05) this was less in the elderly (P < 0.05). Following the oral water
load thirst was inhibited in both groups throughout the study (P < 0.05).
However, plasma [AVP] fell immediately after drinking (P < 0.05) only
in the young group and rose to predeprivation levels after 15 mins.
There were no concomitant changes in plasma [Na] or osmolality.
Plasma [AVP} were no different to postdeprivation throughout the
study in the old group and after 15 mm in the young group probably
because the water load was insufficient to replace the water deficits.
This was confirmed by the plasma ANP results which, although always
higher in the old group (P < 0.05), remained suppressed at postdepri-
vation levels throughout in both groups indicating lack of plasma
volume replenishment. These results demonstrate reduced oropharyn-
geal inhibition of AVP secretion in healthy elderly men but maintained
inhibition of thirst.
Interaction between epidermal growth factor (EGF) and arginine
vasopressin (AVP). S.L. Grant*, C.B. Gow and P.A. Phillips, Depart-
ment of Medicine, University of Melbourne, Austin Hospital, Heidel-
berg, and Department of Agriculture, LaTrobe Universily, Bundoora.
EGF is a potent mitogen and is produced by renal tubular cells. It also
causes natriuresis, diuresis and inhibition of AVP-induced tubular
water reabsorption. The mechanism of these effects is unclear. The aim
of this study was to determine whether EGF antagonises the action of
AVP at a receptor or post receptor level. Renal medullary membranes
from female Sprague-Dawley rats (250 g approx) were used for all
experiments. To determine any interaction between EGF and the VI
(vascular) and/or V2 (antidiuretic) AVP receptor subtypes, radioligand
binding displacement assays using EGF and the selective VI receptor
antagonist radioligand {'251]-[d(CH2)5, Sarcosine7) AVP and V2 selec-
tive antagonist ligand [3H] [desGlyNH2, d(CH2)5, D-Ileu2, Ileu4]AVP
were determined. Although AVP related peptides displaced both radi-
oligands at low concentrations, EGF displaced neither, suggesting no
interaction between EGF at either receptor subtype. To determine
whether EGF inhibited the V2 receptor second messenger, cAMP, the
inhibitory effect on AVP-stimulated cAMP production was studied.
AVP-stimulated cAMP production was inhibited by EGF (1C50 =
l0-7M) in a dose dependent way suggesting an effect on the V2 receptor
second messenger system. In addition, NaF (a potent G-protein stim-
ulant) induced cAMP production was also inhibited by EGF but only at
much higher concentrations. Therefore the diuretic effect of EGF is not
via direct antagonism of AVP receptors but seems mediated via
inhibition of the V2 second messenger system. The inhibition of
NaF-stimulated cAMP production only at higher doses of EGF suggests
that EGF acts at an alternative to the V2 receptor G-protein.
A non-invasive method of measuring blood volume (BV) of patients
during haemodialysis. S.B. Campbell*, M. McMahon, S.J. Fleming,
Departments of Renal Medicine and Physical Sciences, RoyalBrisbane
Hospital, Qid, 4029. AIMS: Hypotension during dialysis, and fluid
overload between treatments, are major problems for haemodialysis
patients. Clinical means of assessing hydration state can be imprecise.
We describe a non-invasive method of measuring BV during a dialysis
session which aids that assessment. METHOD: As fluid is removed by
ultrafiltration, the haemoglobin concentration [Hb] rises proportion-
ately to the fall in BV. An optical monitor clamped across the
transparent dialysis tubing gives a continuous readout of near infra-red
light transmitted through the blood, and this can be converted to [Hb].
With further analysis a measure of starting BV can be determined. The
accuracy of the method was tested in vitro and in vivo. RESULTS: This
optical method accurately measures change in BV over a range of [Hb]
from 3 to 15 g/dL and pump speeds of 150 to 300 mIs per minute. In a
series of 9 in vitro experiments the mean error in optically measured
starting BV was 5% (±2.9%). Preliminary in vivo experiments show a
good correlation with radioisotope dilution measures of BV. CONCLU-
SIONS: This readily repeatable technique can accurately measure BV
during a haemodialysis session, thus adding to the clinical assessment
of hydration state.
Maintenance of dialyser performance with manual reprocessing using
peracetic acid. P.G. Kerr*, A. Lo, S. Mattingley, R.C. Atkins, Dept. of
Nephrology, Monash Medical Centre, Clayton, Vic. The reuse of
haemodialysers is mostly practised in the setting of automated reuse
with either formalin or peracetic acid as the cleanser/sterilant. For the
home dialysis patient, manual reuse procedures have been developed
predominantly using formalin. However, there is a trend away from
formalin due to its potential toxicity. Peracetic acid, the usual alterna-
tive, presents problems for home patients as it cannot be used in saline
and it cannot be coloured for ease of identification. We have developed
a procedure for use of peracetic acid for home dialysis patients and
report here on the dialyser performance data using this system. Ten
stable HD patients were studied. All used a new Cuprophane or
Cellulose acetate dialyser and then reprocessed it using peracetic acid
after the first and second uses to provide a total of 3 uses. Instantaneous
dialyser clearance was measured 1 hour into dialysis at Q 200 mI/mm
and TMP of 0 for each of the 3 uses studied. In addition, pre and post
dialysis temperature was recorded. Microbiological testing of dialysers
was performed prior to the 2nd and 3rd uses; this included culture of
dialysate and assessment of endotoxin levels. Dialyser clearances were
unaltered by reprocessing, being 169.4 3.1 mI/mm at 1st use, 168.0
4.5 mI/mm at 2nd use and 172.3 3.8 mllmin at 3rd use (P = NS by
Wilcoxon). The mean change in temperature was also similar for all 3
uses (0.63 0.14 vs 0.54 0.13 vs 0.70 0.13 respectively). All
dialysers had dialysate bacterial counts less than 40 cfus/ml prior to the
2nd and 3rd uses (AAMI standard being <2000 cfulml). All dialysers
were negative for endotoxin prior to the 2nd and 3rd uses (assay
sensitivity 5 pg/mI). Thus manual reprocessing of haemodialysers using
peracetic acid is safe and effective and offers large potential cost savings
for home HD patients.
Comparison of parathyroid hormone estimations by mid-molecule and
intact molecule assays in dialysis patients. K.L. Lynn*, N.M. Hay, A.L.
Buttimore, Department of Nephrology, Christchurch Hospital,
Christchurch. The clinical usefulness of the intact (1-84) parathormone
(PTH) immunoradiometric (IRMA) assay (Nicholls Institute) [NR 5—70
ng/I] was compared with the commonly used mid-molecule PTH radio-
immunoassay (RIA) [NR 30—150 ng/l] in patients on dialysis. Fifty (24
men) patients aged 50 (SD 16) years were studied. Forty-two patients had
been on haemodialysis and 8 on CAPD for 12—172 (median 39) months.
Three patients had had sub-total parathyroidectomy. Pre-dialysis PTH
results were: IRMA 7—1280 (median 104) ng/l and RIA 402—19600
(median 2100) ng/l. Twenty (40%) patients had normal range IRMA
PTH and none normal range RIA PTH. IRMA PTH measurements were
correlated with RIA PTH (r2 = 0.89; P < 0.001) but not with duration
of dialysis, ionised or total plasma calcium, phosphorus, aluminium or
alkaline phosphate. One of 8 patients with clinical evidence of hyper-
parathyroidism had normal IRMA PTH compared with 19 of 42 without
hyperparathyroidism (x2 = 1.79; P = NS). Mean IRMA PTH did not
change in 29 patients over 12 months (185 [SD266] and 203 [SDI68I).
IRMA PTH is more clinically relevant than RIA PTH and should
improve the clinical assessment of renal bone disease and its response
to therapy.
Metastatic endophthalmitis in dialysis patients. K.G.C. Smith*I, B.U.
IhIe', W.J. Herioz2 , and G.J. Becker', Departments of Nephrology' and
Ophthalmology2, Royal Melbourne Hospital, Post Office RMH, Vic.
3050. Metastatic bacterial endophthalmitis is a rare but devastating
complication of septicaemia. We present 3 recent cases occurring in
dialysis patients at RMH. Case 1: Despite adequate serum vancomycin
levels for methicillin-resistant staph. epidermidis peritonitis, a diabetic
on CAPD developed left endophthalmitis. Treatment with intravitreal
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and continued systemic antibiotics cured the infection though visual
loss was permanent. Case 2: A 42 year old man on haemodialysis
presented with staphylococcal septicaemia. Despite therapeutic vanco-
mycin levels he later developed bilateral endophthalmitis treated with
left vitrectomy and intravitreal vancomycin. An infected bovine graft
was removed. Partial visual recovery occurred. Case 3: A 75 year old
woman with Wegener's granulomatosis was treated with prednisolone
and cyclophosphamide and required dialysis. She developed MRSA
septicaemia from an infected "permacath," treated with intravenous
vancomycin, permacath removal and cessation of immunosuppression.
Two days later left endophthalmitis was diagnosed. Dialysis patients
with septicaemia seem particularly prone to development of endoph-
thalmitis, due to seeding from infected dialysis access and perhaps also
to general uraemic immunosuppression. Endophthalmitis developed in
the face of therapeutic serum concentrations of appropriate antibiotics
in 2 (possibly 3) cases, demonstrating the efficacy of the blood-retina
barrier and the need for consideration of intravitreal antibiotics. Prompt
treatment is required if vision is to be preserved and therefore early
signs of endophthalmitis should be actively sought, as they are easily
overlooked in the unwell septicaemic patient.
Two centre double blind randomised study of once versus twice weekly
subcutaneous recombinant human erythropoietin in haemodialysis pa-
tients. W.E. James', C. Doecke2, S.f. Goldsworthy', T.H. Mathew',
L.J. Barratt2 and A.P.S. Disney,' Renal Units of Flinders Medical
Centre2, Bedford Park and The Queen Elizabeth Hospital', Woodville,
S.A. At present there is controversy as to the optimum route and dosing
of recombinant human erythropoietin (rHu EPO). This study attempts
to evaluate the efficacy of weekly subcutaneous (SC) rHu EPO com-
pared with twice weekly divided dosing. Twenty five chronic haemo-
dialysis patients at Flinders Medical Centre and The Queen Elizabeth
Hospital who were routinely prescribed twice weekly SC rHu EPO
were entered into a double blind randomised cross over study. Patients
were entered provided their rHu EPO dose was unchanged and their
haemoglobin (Hb) level (9—11.5 g!dl) had been stable for 3 months prior
to the trial (control period). At the commencement of the trial, patients
were randomised to receive either rHu EPO in divided doses twice
weekly or EPO as a single dose with the second weekly injection as a
placebo (trial period A). After four months the treatments were crossed
over for a further four months (trial period B). Thirteen patients were
withdrawn for the following reasons: infection (4), iron deficiency (2),
dialysis problems (3), haemorrhage (1), carcinomatosis (1), myocardial
infarction (1) and social drug abuse (1). Twelve patients completed four
months of the first trial period; of these, 8 patients had been randomised
to receive once weekly rHu EPO. Results—Randomised Trial Period
A—There was no significant change in mean haemoglobin (all trial
patients) over the first four months; mean Hb (start) 10.3 g!dL (range
9.4—11.4 g/dL), mean Hb (4 months) 10.6 g/dL (range 9.6—11.6 g/dL). Of
the 8 patients changed to once weekly dosing, the Hb rose (4), was
unchanged (1) and fell in (3) patients. There was no significant change in
Hb; mean Hb (start) was 10.2 g/dL (range 9.4—11 g/dL), mean Hb (4
months) 10.4 g/dL (9.6—11.3 g/dL). There was no significant change in
rHu EPO dose/weight over this period, mean rHu EPO (start) 89
p1kg!wk, mean rHu EPO (4 months) 90 aJkg/wk. Of the 4 patients
randomised to continue with twice weekly EPO dosing, there was no
significant change in Hb over this period. No patients withdrew because
of side effects of weekly rHu EPO dosing (e.g. local pain at injection
site) (results from trial period B currently being analysed). These results
confirm that changing patients to once a week rHu EPO (I) does not
require a dose increase to maintain haemoglobin, (II) is not associated
with serious local side effects causing non-compliance, (III) offers other
potential benefits such as increased efficiency and reduced costs from
once a week production and administration.
Subcutaneous erythropoietin (EPO) pharmacokinetics and dose re-
quirements. M. Thomas*, K. Warr, K. North, W. Erber, S. Fernando,
G. Thatcher, P. Hurst, B. Saker, Departments of Nephrology and
Haematology, Royal Perth Hospital, Perth WA 6000. Whether varia-
tion in EPO absorption after subcutaneous injection contributes to
interindividual differences in EPO dose requirements is undetermined.
Plasma EPO levels (bioMerieux EIA, normal range 2.6—14 U/L) were
measured at time 0, 4 and 48 hours following 2 consecutive weekly
doses of EPO 4000 units s.c. Ten stable, well-dialysed (KT/V = 1.3
0.3), iron-replete (median ferritin 370, 95% CI 60—1050 tg/l) haemodi-
alysis patients never exposed to aluminium, on EPO therapy for 20 14
months were studied. Plasma EPO levels and area under the curve
(AUC, trapezoidal rule) were correlated agalnst individual patients'
minimum EPO dose required to maintain haemoglobin 90—100 g/l,
determined using a decreasing frequency s.c. EPO regimen (Am J Kid
Dis 199l;18S:115). Results were expressed as mean SD (range), and
correlations performed by simple regression. Plasma EPO levels varied
widely between patients, rising from 15.7 8.1(4—30) to 48 22(27—97)
U/L at 4 hours, returning to 33 17 (11—60) IJ/L at 48 hours, producing
an AUC of 1865 889(900—3398) U/lJhr. Minimum maintenance doses
EPO doses also showed wide variation, being 73 62 (9—200) p1kg!
week. An unexpected and significant positive correlation was found
between maintenance EPO dose and both baseline and 48-hour EPO
level (r = 0.45, P = 0.05) but not peak 4-hour EPO levels or AUC. This
study suggests i) that patients with high baseline EPO levels will have
reduced cost-effectiveness from EPO therapy and ii) that interindividual
variation in maintenance EPO dose requirements is determined by
factors other than pharmacokinetic differences following s.c. injection.
Folate supplementation in maintenance haemodialysis patients: an in
vivo and in vitro study. J. Westhuyzen*, K. Stewart, R. Tracey and S.f.
Fleming, Conjoint Renal Medicine Laboratory and Departments of
Renal Medicine and Haematology, Royal Brisbane Hospital, Herston
4029, Brisbane, Australia. The requirement for folate in haemodialysis
(HD) patients is controversial. We followed a cohort of 41 patients not
receiving erythropoietin for 16 months after the cessation of supple-
mentation with folate (5 mg/day). Erythrocyte folate concentrations
(reflecting body stores) fell linearly from 1931 888 jg/L (mean SD)
to 676 294 g/L after 6 months before levelling off in the 450—500 sg!L
range. No patient developed folate deficiency; mean corpuscular vol-
umes were generally within normal limits. Haemoglobin values in-
creased fractionally during the study. Folate dialysance was examined
in an in vitro dialysis system at 37°C. A unit of donor blood (approx 500
ml) was recirculated through a dialyser at 200 mI/mm against saline
dialysate at =300 mI/mm (single pass). Plasma folate levels decreased
from 4.2 to 2.2 g/L in 10 mm using Cuprophan filters (CUP, N = 4),
and from 3.0 to 2.0 g/L in 8 mm using cellulose acetate (CA, N = 4).
Assuming a constant blood volume (V0), folate dialysance was calcu-
lated to be 32.7 mllmin with CUP and 33.4 mI/mm with CA. The total
dialysis loss of folate per week is therefore projected to be 98.7 g for
CUP and 72.5 sg for CA (3x4 hour sessions), which falls within the
range of urinary folate excretion in normal subjects. These experiments
support the conclusion that HD patients (not receiving erythropoietmn)
do not require folate supplementation, provided dietary intake is
adequate.
The smoking habits of a high cardiovascular risk group: dialysis and
renal transplant. Dr. S.J. Coulshed*, Dr. AM. Davison, Dr. D.S.
Coulshed, Dr. E.f. Will, St. James's University Hospital, Beckett
Street, Leeds, L59 7TF, United Kingdom. Smoking is a recognised risk
factor for cardiovascular (CVS) disease. We surveyed the smoking
habits of all patients on our renal replacement program (RRP). Patients
on the RRP are less likely to smoke than the average population 106/478
smoke. 25% of the males smoke. 17% of the females. Symptomatology
does not stop smoking.
Symptom
Smokers
107
Previous
Smoker 157
Never
Smoked 204 Sig (CHI2)
SOB 43 (40%) 53 (33.8%) 37 (18%) <0.001
Cough 28 (26%) 19 (12%) 21(10.3%) <0.001
Sputum 24 (22.4%) 23 (14.6%) 20 (9.8%) <0.05
Palpitations 48 (44.8%) 67 (42.6%) 74 (36.3%) NS
Chest 25 (23.3%) 29 (18.5%) 27 (13.2%) NS
Pain
Calf Pain 36 (33.3%) 48 (30%) 49 (24%) NS
The common times to smoke were when bored, having an alcoholic
drink or with friends and family. Few patients (16/107) actually want to
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smoke on dialysis. There were few heavy smokers, only 6 smoked
>20/day. 37 of the 159 previous smokers had smoked >20/day. Educa-
tional background was not significant, smokers left school at an av age
of 15.05 compared with of all patients at 15.23. Cost is not a deterrent.
Although 65 of the smokers think of cost only 23 have tried to cut down
because of it. 81/107(52%) recognise that they have been advised not to
smoke. 69 (65%) of the smokers had someone else smoking at home.
Ethnic background does not predict smokers. Of the 403 born in
England 90 smoke, 145 had. There are 11 Scots, 3 smoke, 5 had; 7 West
Indians, I smokes, 3 had; 6 Irish, 3 smoke, I had; 12 Indians, none
smoke, only I had; and 25 Pakistanis, 6 smoke, 3 had. An illness with
a high CVS risk and symptomatology is not sufficient to stop smoking.
Social attitudes remain important.
Prolonged high dose oral calcitriol in dialysis dependent children. P.H.
Henning, W. Wong, R.J. Hogg, S.J. Harris, K.F. Jureidini, Renal
Unit, Adelaide Children's Hospital, North Adelaide, South Australia.
The use of high dose oral calcitriol to suppress secondary hyperpara-
thyroidism in dialysis dependent patients has been reported in short
term trials in children and adults. We report the successful long term
use of this method in 2 boys aged 14 and 15 years. Both patients had
been receiving regular haemodialysis 3 times a week for at least 4
months. Their PTH (n-Tact) levels had been consistently and markedly
elevated for at least 6 months, and at commencement of the study were
55 and 50 pmolllitre respectively. (NR < 10). Both had radiological
evidence of renal osteodystrophy in spite of daily low dose oral
calcitriol and regular phosphate binder use (calcium carbonate). High
dose oral calcitriol, commencing at 2.0 tg, was given 3 times/week (at
each dialysis session) while phosphate levels were controlled with
CaCO3 as before. The dialysate calcium concentration was adjusted to
1.0 mmolJlitre. Each patient experienced a steady decrease in n-Tact
PTH to normal levels by week 15 with only 4 transient episodes of
hypercalcaemia each. (defined as total Ca > 2.8 mmolllitre). The
maximum calcitriol dose used was 4.0 g and 2.5 g respectively, and
both patients have sustained normal PTH levels to the present time
(week 32). Their doses of calcitriol have been reduced to the current
level of 1.25 tg and 0.75 tg. High dose oral calcitriol therapy for
secondary hyperparathyroidism appears to be safe and effective over
prolonged periods.
Triple immunosuppression with subsequent prednisolone (PNL) with-
drawal: six years experience in paediatric renal allograft recipients. Sing
M. Chao, Cohn L. Jones, Harley R. Powell, David M.A. Francis,
Gavin J. Becker, Rowan G. Walker*, Renal Unit, Royal Children's
Hospital, Department of Surgery, University of Melbourne, *Depart
rnent of Nephrology, The Royal Melbourne Hospital. Thirty-four
children (<15 years of age) received 39 renal allografts between 1985
and 1991. All were treated with a triple therapy immunosuppression
regime;' Cyclosporin-A (CyA), Azathioprine and low-dose PNL with
the aim of ceasing the PNL six months after transplantation. Median
(range) duration of follow-up was 2.8 (0.2—6.3) years. There were no
deaths. Graft survival for living-related grafts (N = 9) was 100%. One
and five year actuarial graft survivals for cadaveric grafts (N = 30) were
90% and 79% respectively. At 12 months post-transplant, the median
(range) glomerular filtration rate was 63 (19—109) mllminll .73 m (N =
27) and at 5 years was 48 (17—64) mlIminll.73 m2 (N = 9). Rejection
episodes occurred after discontinuation of PNL, and accordingly 26%
of patients were still taking PNL at 12 months. Hypertension requiring
treatment occurred in >50% of patients. Severe CyA nephrotoxicity
was not seen. Remarkable catch-up growth as determined by the
change () in mean height standard deviation score (Ht-SDS) was noted
at 1 year (ASDS/year = +0.69; P < 0.0001 (N = 14)) and at 2 years(SDS/year +0.29; P 0.002 (N = 13)) in pre-pubertal patients. The
median Ht-SDS at 2 years for pre-pubertal children was —0.61 SD and
growth velocity did not improve thereafter. In pubertal patients, the
mean SDS/year at both 1 year (N = 9) and 2 years (N = 6) did not
show significant catch-up growth and the median Ht-SDS at 2 years was
—2.49 SD. It was concluded that the use of this immunosuppression
regimen was associated with an excellent patient and graft survival.
Catch-up growth is especially encouraging in pre-pubertal patients.
However routine discontinuation of PNL may require review.
1. WALKER RG, DANCE AJF, POWELL HR, FRANCIS DMA, Mc-
CREDIE DA, KINCAID-SMITH P: Paediatric cadaveric renal trans-
plantation. Paed Nephrol 1:611—614, 1987
Ureteric stents reduce urological complications after renal transplan-
tation. David Nicol, Kenny P'ng, David Hardie, Geoffrey Hirsi, Daryl
Wall and Ian Hardie*, Renal Transplant Unit, Princess Alexandra
Hospital, Brisbane, QLD 4102. Technical complications related to the
ureter often cause problems in the early management of renal transplant
recipients. This study examined the impact of ureteric stents on these
problems. An extravesical ureteric implantation with routine use of an
internal stent was performed in 358 transplants (351 cadaveric; 7
live-related) between January 1985 and December 1990. One year
patient and graft survival was 93% and 87%, with a minimum follow up
of 2 years. Ureteric complications developed in 9 patients (2.6%), 3
fistulae—2 of which resolved spontaneously, and 6 stenoses following
stent removal. Nephrostomy drainage and antegrade stenting was used
initially for all stenoses, with success in 4. Three patients (0.9%)
required revision of the ureteric anastomosis [I fistula; 2 stenoses].
Complications related to stent malfunction occurred in 8 patients
(2.2%): 2 obstructions by the stent itself; 2 proximal migration of the
stent; 3 breakages during removal leaving fragments in the upper tract;
and 1 calculus formation on the proximal end of a stent in a patient with
hyper-parathyroidism. Extra-corporeal shock wave lithotripsy was
needed to remove this stent; retained stents and fragments were
removed via percutaneous nephrostomy (PCN). Extrinsic compression
caused ureteric obstruction in 3 cases (2 lymphoceles, I haematoma);
all were cured by drainage of the fluid collection. I-year patient and
graft survival after ureteric or stent-related complications was 100%.
Conclusions: Routine use of ureteric stents will minimise urinary leaks,
early post operative obstruction and the need for reoperation after renal
transplantation. Although infrequent, stent-related problems and ob-
struction may arise. Minimally invasive strategies using PCN and
antegrade stenting are effective in dealing with the majority of compli-
cations that occur following or as a result of ureteric stenting.
Experience with OKT3 in a single transplant unit. J. Petrie, C.
Hawley, R. Rigby, D. Wall and I. Hardie, Transplant Unit, Princess
Alexandra Hospital, Woolloongabba, Queensland. 450 renal trans-
plants were performed in our hospital between 01/11/86 and 01/04/92.
107 of these transplants (23.7%) received 118 courses of OKT3. In 10
grafts (3 CDK1, 4CDK2, 3CDK3) OKT3 was given prophylactically
because the risk of rejection was thought to be high. 9 of these 10 grafts
continue to function. The remaining treatments were for biopsy proven
acute rejection falling to respond promptly to pulse steroid therapy.
Actuarial graft survival in grafts treated with OKT3 for rejection was
80.2% at 6 months, 76.7% at one year, and 75.4% at 2 years. For the 343
grafts in which OKT3 was not used, actuarial graft survival was 93%,
92% and 89% at the above time intervals. Actuarial patient survival
following OKT3 use was 91%, 88% and 88% at 6, 12 and 24 months
respectively. In the 343 graft recipients who did not receive OKT3,
actuarial patient survival was 97%, 96% and 93% at 6, 12, and 24
months. Of the 12 deaths in the OKT3 group, 4 were cardiac or
vascular, two were post EBV lymphoproliferative syndrome, one from
encephalitis (aetiology not established), one from aspergillus, and four
were from CMV (3 of the 4 having pneumocystis carinei in addition). Of
the 19 deaths in the group not treated with OKT3, 9 were cardiac or
vascular, 3 were from pancreatitis, and 1 from cancer. There were 6
infective deaths, four being bacterial and two viral. OKT3 is an effective
agent in treating rejection. Its use, however, is associated with an
increased risk of death from infection (CHI square with Yate's correc-
tion 5.08, P = 0.025)—particularly from viral infection (CHI square
9.09, P = 0.003).
Optimal combination of immunosuppressive agents for renal transplan-
tation: the Australian trial comparing cyclosporin (C) + prednisolone (P)
with C+Azathioprine (A) and C+A+P. I. Hardie*, D. Tiller, J. Ma-
hony, P. Miach, N. Thomson, G. Thatcher, R. Rigby and B. Menzies,
Australian Collaborative Trials Committee, c/Dept. Surgery, Princess
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Alexandra Hospital, Brisbane, 4102. From February 1988 to December
1991, 395 transfused non-diabetic recipients of first cadaver renal
transplants received C+P, C+A or C+A+P. The initial C dose was
12.5 mg/kg/d in the C+P group and 8 mg/kg/d in the other two groups.
Patient details, survivals and complications are shown in the table.
Group
(Number) C+P (133) C+A (127) C+A+P (135)
Males/females 69/64 68/59 78/57
Age: range 15—69 17—68 18—68[mean SD] [47 14] [45 14] [45 14]
no. >50 y 22 (17%) 17 (13%) 19 (14%)
Antibodies 9 (7%) 6 (5%) 6 (4%)
>50%
Patient survival 98 1.5% 91 2.5% 91 2.5% NS
[1 y]
Infection deaths 2 (1.4%) 4 (3.0%) 5 (3.5%) NS
Cardiovasc. 2 (1.4%) 6 (4.6%) 7 (5.0%) NS
deaths
Graft survival 85.6 3% 83.9 3% 85.3 3% NS
[1 y]
Acute rejection 130 = 1/pt 191 = 1.4/pt 139 = 1/pt P < 0.01
[3 m]
Nephrotoxicity 26 22 16 NS
Change trial 40 (28%) 66 (50%) 17 (12%) NS
therapy
The pattern of infections was similar, C+P: 168 in 3 m (71 bacterial, 37
viral, 20 fungal); C+A: 173 (57 bacterial, 45 viral, 14 fungal); C+A+P:
180 (85 bacterial, 44 viral, 10 fungal). However, there were more
infections and deaths from sepsis if OKT3 was used with C+A+P (y2 =
6.8; P < 0.05). Therapy changes included adding A to C+P to control
rejection (22 = 15%); stopping C for nephrotoxicity (18 = 13% on C+P;8 = 6% on C+A); adding P to C+A for rejection (48 = 36%). A was
ceased for marrow depression in 10 (8%) C+A and 10 (7%) C+A+P
recipients. Summary: These three combinations are equally effective as
induction immunosuppression. The increase in early rejection episodes
with C+A did not impair graft survival. Morbidity and mortality were
similar in all three groups. Optimal therapy may involve initial use of
two (C+ 1 other) and later addition of the third.
The potential for elderly donors to increase renal transplantation rates
in Australia. K.G.C. Smith*I, B.N. Martyn', R.G. Walker', S.M.
Davis2, D.M.A. Francis', and G.J. Becker', Departments of Nephrol-
ogy', Neurology2 and Surgery,3 Royal Melbourne Hospital, Post Office
RMH, Vic. 3050. There is accumulating evidence that renal transplan-
tation using elderly donors produces acceptable results, yet such
donors are largely ignored. We aimed to estimate the potential increase
in renal transplantation which could occur if elderly stroke victims were
considered as donors. 198 patients dying from acute brain damage due
to stroke over 3.67 years were identified using the RMH Stroke
Register. Their eligibility for renal donation was determined according
to strict criteria. Most deaths (139 of 198, 70%) due to acute brain injury
after stroke occurred in patients over 60 years of age. Of these 51(37%)
were considered "eligible donors." Of those aged less than 60 years a
higher proportion were eligible for donation (41 of 59, 69%: P <0.0001).
However the absolute number of eligible younger patients was less as
they comprised only 30% of neurological stroke deaths. Overall 92
patients were considered eligible. Of these 7 of 41 (17%) younger
patients became actual donors, but only 1 of 51(2%) patients over 60
became donors (P = 0.015). Annually at least 13 elderly stroke victims
who were potential renal donors were disregarded. Conservative cal-
culations indicate that at least 9 extra kidneys per year could be
obtained if elderly stroke victims at the RMH were actively sought as
donors, increasing the number of kidneys obtained annually in Victoria
by approximately 10%.
Reduced viral mortality in patients treated with OKT3. J. Petrie', M.
Suranyi', R. Rigby', M. Whitby2 and!. Hardie', Transplant Unit' and
Infectious Diseases Unit2, Princess Alexandra Hospital, Woolloong-
abba, Queensland. While OKT3 is an effective anti-rejection agent, its
use is associated with an increase in mortality from infection—partic-
ularily viral infection. During the period 1/11/86 to 30/09/92, 503 renal
transplants were performed at this hospital. In 116 of these transplants,
OKT3 was administered, two courses of treatment being given in II
instances. Eleven of the patients receiving OKT3 died within 6 months
of transplantation. Three deaths were cardiac and 8 were infective (7
viral and 1 fungal). Ten of the deaths (including all 8 of the infective
deaths) occurred in the 73 patients who received OKT3 between 1/1 1/86
and 1/10/90. Actuarial patient survival at 6 months in this group was
86% 4.06%. One death (from cardiac failure) occurred in the 43
patients who received OKT3 between 1/10/90 and 30/09/92. Actuarial
patient survival in this group at 6 months was 97.5% 2.41%. A
prophylactic protocol for CMV and pneumocystis was administered
routinely to all patients receiving OKT3 from 1/10/90. This consisted of
co-trimoxazole and high dose Acyclovir for a three month period.
Anti-CMV immunoglobulin was also used. While CMV mortality was
absent in the second period, CMV infections continued to occur.
Prevention of concommitant pneumocystis infection by co-trimoxazole
may have contributed. An alternative explanation for the reduced
mortality may be the effectiveness of ganciclovir, which was used much
more widely in the second period than in the first.
Evidence for abnormal endothelin.1 gene expression in pre.eclamptic
placental tissue. L.P. McMahon*, C.W.G. Redman and J.D. Firtht,
Nuffield Department of Obs. & Gyn. and Inst. of Molecular Medicinet,
Oxford University, England. Maternal vasoconstriction and foetal
growth retardation (FGR) from placental insufficiency are part of the
syndrome of pre-eclampsia (PET). Preliminary evidence suggests the
powerful vasoactive endothelin (ET) peptides might be involved in the
pathogenesis. Production of ET appears to be regulated by changes in
mRNA levels, measurement of which should therefore reflect ET
activity. We have used 3 RNAase protection assays capable of recog-
nising the 3 different mRNA isoforms (ET-1, 2 & 3) to examine ET gene
expression in RNA extracted from placental villi, amniotic membrane
and myometrium. In each case a specific antisense RNA probe com-
plementary to the coding sequence of the mature peptide was used. The
quantity of mRNA for each isoform was described relative to the
amount within an external standard. Material obtained at Caesarean
Section (CS) from 4 patients with PET was compared with that from 5
normal gestations. Expression of ET-l in placental villi was higher in
the PET group (2.72 0.92 arbitrary units, mean SEM, vs 1.20 0.92,
P < 0.05). By contrast, differences in expression between groups in
amniotic membrane were small and, in myometrium, negligible. Endo-
thelin-2 mRNA was reduced in the PET group in myometrium (28.9
5.9 vs 65.8 8.2, P < 0.05) but comparable with controls in the amnion.
The gene was not expressed in villi. Endothelin-3 was expressed
minimally in all tissues examined. Plasma levels of ET-l from uterine
vein (UV) and peripheral blood were also measured in 4 patients from
each group at CS using a sensitive RIA. Levels from UV tended to be
higher than peripheral, and both UV (8.6 0.9 fmollml vs 6.6 0.1)
and peripheral (7.6 1.4 vs 6.4 0.9) levels were slightly increased in
the PET group. Endothelin-l gene expression is increased in placental
viii of pre-eclamptic gestations, possibly contributing to vasoconstric-
tion and hence FGR. The finding of higher levels of ET-1 in the UV
suggests the placenta might contribute to the increased plasma levels
observed in PET.
Metabolism of uridine in expanded extracellular volume states. Qu-
loobul Hasnain*, Graham Macdonald & Garner T. Haupert, Depart-
ment of Nephrology, School of Medicine, Prince Henry Hospital, Little
Bay, NSW 2036 Australia & Massachusetts General Hospital, Boston,
USA. Uridine and uridine monophosphate are natnuretic and vasopres-
sor in intact rats. In DOCA-salt hypertensive rats metabolic clearance
rate (MCR) of uridine is raised and basal plasma uridine diminished,
suggesting that metabolism of uridine is linked to changes in extracel-
lular space. We studied 18 patients on ultrafiltration (UF) and 55
patients on regular haemodialysis (HD). Plasma uridine concentration
was raised in chronic renal failure patients compared to age and sex
matched healthy controls [8.49 smol 1' (4.37—13.74)-median (inter-
quartile range) and 2.64 mol 1' (2.5 1—2.74) respectively, P < 0.001].
Plasma uridine was significantly diminished after isotonic fluid removal
by UF from 7.25 smol 1_I (3.7—11.08) to 5.07 mol 1' (3.3—8.3)—P <
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0.001, while concentration of marker solutes urea and creatinine
remained unchanged. During HD plasma uridine fell significantly from
its pre-HD level. In an animal model of expanded extracellular space—
the one kidney/one clip rat—plasma uridine was significantly higher
[(mean saM) 20.56 1.19 moI 1', P < 0.01] and MCR diminished
(34.93 3.44 ml kg' min, P < 0.01) compared to sham operated
animals (plasma uridine 12.14 1.07 and MCR 53.59 4.11 ml kg
min1). In two kidney/one clip rats, a model having unchanged or
slightly reduced extracellular volume, plasma uridine and MCR were
not different from sham operated controls or normal intact rats. In a
series of experiments uridine, UMP, UDP and UTP were incubated in
a range of physiological and supraphysiological concentrations with
human red cells with 86Rubidium and purified porcine renal tubular
NaK-ATPase. No nucleotide inhibited Na*K+ATPase in either
system. We conclude that catabolism of uridine is reduced by extracel-
lular expansion and probably increased by volume reduction by UF.
Such a function is strongly suggestive of the hypertensive natriuretic
factor of Dahi and de Wardener but would not be consistent with the
ouabain-like factor postulated by other workers in this situation since it
has no inhibitory effect on NaK-ATPase.
Role of changes in haemorheotogy in IgA nephropathy. B.I. Shand*,
R.R. Bailey, K.L. Lynn, R.A. Robson and P.J. Graham, Departments
of Nephrology & Community Health, Christchurch Hospital, Christ-
church. Changes in blood flow properties (haemorheology) may affect
renal function by contributing to intraglomerular hypertension and
increased ultrafiltration. The aim of this longitudinal study was to
establish whether abnormal haemorheology (increased blood viscosity)
has a role in the pathogenesis of IgA nephropathy (IgAN). Haemorheo-
logical and renal function indices were measured at 6 monthly intervals
for 18 months in 33 patients with biopsy-proven IgAN. The pooled
haemorheology data was compared with similar measurements from
healthy controls (N = 84). Regression and correlation analyses were
used to determine if associations and temporal relationships occurred
between changes in haemorheology and renal function indices. Signif-
icant differences (P < 0.01) in whole blood viscosity at both high and
low shear rate, plasma viscosity and red blood cell (RBC) defonnability
were found in IgAN patients compared to controls. Decreased GFR
correlated significantly (P < 0.01) with abnormalities in RBC rheolog-
ical properties, but not with increased plasma viscosity. No consistent,
significant time relationships were demonstrated between changes in
haemorheology and renal function. These findings indicate that hae-
morheological abnormalities are common in patients with IgAN and
that the changes are greatest in patients with more impaired GFR. It is
most likely that the alterations in blood flow properties are secondary to
the development and progression of the glomerulopathy, but when
present could have a pathogenic role in the glomerular changes.
The value of renal duplex scanning (RDS) in diagnosis of renal artery
stenosis (RAS). R.S. Nanral*, A.E. Bray2, K. Harrison2, W. Lewi,
Nephrology', Radiology and Nuclear Medicine Units, John Hunter
Hospital, and Cardiovascular Centre2, Newcastle, NSW, 2305. To
evaluate the sensitivity (SEN), specificity (SP) and overall accuracy
(OA) of RDS, DTPA isotope scanning (DTPA) and intravenous urog-
raphy (IVU), in the diagnosis of RAS, a retrospective cross-sectional
study was performed in patients who underwent renal angiography
(RA) for investigation of hypertension. RA in 114 patients, mean age 64
(sD 9) years, provided 223 kidneys for evaluation; 12% of kidneys had
multiple arteries. 54 (24%) of kidneys had no RAS, 38 (17%) had RAS
<50%, 73 (33%) had RAS 50—90%, 32 (14%) had RAS >90%, and 26
(12%) had renal artery thrombosis (RAT). The SEN, SP and OA (in
RAS >50% —> RAT) for RDS (N = 216) were 90%, 97% and 93% (95%
CI —5.8 to 8.9), for DTPA (N = 115) were 46%, 84% and 65% (95% CI
8.9 to 29.3), and for IVU (N = 103) were 15%, 93% and 49% (95% CI
35.3 to 50.2), respectively. The 15 'errors' with RDS were related to
multiple renal arteries (N = 9), RAT (N = 3) and ostial RAS (N = 3).
The SEN, SP and OA (in RAS >50% —> RAT) for RDS in detecting
proximal vs distal lesions were 88%, 40% and 84% (95% CI —2.1 to
11.8). The Renal Aortic Ratio (RAR) in RDS was increased in: ERAS>
90% and RAS 50-90%] >> ERAS < 50%] (P < 0.0001)>> [no RAS] (P
= 0.002); RAR was reduced in RAT (P < 0.0001). Prolonged Hilar
Acceleration Time (HAT) gave similar results to RAR, but failed to
differentiate between RAS <50% and no RAS. Renal length was
significantly reduced in: [RAT] << [RAS > 90%] (P = 0.0005) <<
[RAS 50—90%] (P = 0.0172) << [RAS < 50%] (P = 0.0498). Renal
surface area was only reduced in: [RAT] << [RAS > 90%] (P =
0.0267). Conclusion: RDS is a sensitive and specific investigation in the
detection of RAS and RAT, and in defining the location of RAS. CI =
confidence interval
A monoclonal antibody (254 mAb) detects a neoepitope on complement
C9 in C5b-9 (m) complexes. B. Murphy*, J. McRae, M. Polihronis, J.
Saunders, M. O'Bryan, Departments of Nephrology and Clinical
Immunology, St. Vincent's Hospital, Melbourne. The terminal comple-
ment cascade may be activated in two forms; one form (CSb-9(m))
occurs when lytic complement is activated in phospholipid membranes
and involves high grade polymerization of complement component C9(C9) involving up to 16 C9 molecules per complex. The biochemical
basis of this polymerization is currently unknown. The other, non-lytic,
SC5b-9 complex is formed in the absence of cell membranes and does
not elicit polymerization of C9 beyond the dimeric form. The number of
C9 neoantigen reactive monoclonal antibodies (mAbs) have been pro-
duced previously; each of these reacts with C9 in both the C5b-9 (m)
and SC5b-9 forms and is unable to distinguish between these C5b-9 (m)
and SCSb-9 complexes. The 245 mAb was produced following immu-
nization of mice with human glomerular basement membrane extracted
from an autopsy kidney from a patient with membranous glomerulone-
phritis. This mAb identifies C5b-9 complexes in human renal biopsies
and in non-renal tissue. mAb 254 does not react with human serum,
purified C9 or with SC5b-9 complement complexes. It does, however,
react specifically with C9 in C5b-9 (m) complexes extracted from cells
lysed with human complement. The epitope for mAb 254 is therefore
expressed in C9 only in the membrane activated complex. mAb 254 is
the first reagent which is able to distinguish C5b-9 (m) from SC5b-9 in
vivo and in vitro. Identification of the neoepitope on C9 that is reactive
with mAb 254 should contribute significantly to the elucidation of the
currently unknown biochemical mechanisms involved in the activation
and polymerization of C9 in phospholipid membranes.
Effect of angiotensin converting enzyme (ACE) inhibition in renal cystic
disease. C.J. Roe*, L.L. Wit and A. Doyle, Renal Unit, Heidelberg
Repatriation Hospital, Heidelberg West, Victoria 3081. A model of
renal cyst formation has been developed in rabbits. This consists of an
initial uninephrectomy and the addition of 75—150 mmol lithium chloride
to the food for 16 weeks subsequently. The effect of ACE inhibition
using perindopril I mg/kg/day was studied in lithium (LiUNx N = 8)and
lithium and perindopril (PLiUNx N = 8) treated animals. Body weight
and serum Li were measured weekly and after 16 weeks the animals
were killed and the kidneys were weighed and analysed histologically.
Cyst formation was graded semiquantitatively from 0 to 4. Mean serum
Li was greater in PLiUNx compared to LiUNx (mean SEM 1.8 0.2
vs 1.1 0.1 mmol/l, P < 0.01). Despite normal body weight PLiUNx
had higher final kidney weight (mean SEM 0.75 0.08 vs 0.51
0.03% of body weight, P < 0.05), creatinine (170 18 vs 131 19
jmol/l), urea (11.9 0.8 vs 9.0 0.7 mmolIlP < 0.05) and cyst score
(median [mm—max] 4 [1—4] vs 2 [1—4]). Cyst score was positively
correlated with urea (r = 0.71), creatinine (r = 0.62),mean Li (r = 0.67)
and final kidney weight (r = 0.61). Accordingly, ACE inhibition did not
prevent cyst formation and may even be associated with reduced renal
function although the higher Li level may have confounded the results.
Thus, this study does not support the prophylactic use of ACE
inhibition in cystic kidney disease.
Contribution of the nitric oxide (NO) pathway to hypertension in
uraemic and erythropoietin (r-HuEPO) treated rats. S.D. Roger*, G.
Lipkin, A.E.G. Raine, Dept. Nephrology, St. Bartholomew's Hospital,
London, ECJA 7BE, UK. To investigate the role of the NO pathway in
uraemic and erythropoietin-induced hypertension, we studied the hae-
modynamic effects of stimulation and inhibition of NO production with
L-arginine and N°-nitro-L-arginine methyl ester (L-NAME) in both
uraemic and r-HuEPO-treated rats. Wistar rats were divided into two
groups and half made uraemic by subtotal nephrectomy. Each group
was then divided again and received either r-HuEPO, 100 U/kg, 3x/wk,
s.c. or vehicle for 3 weeks. Haemodynamic responses were then
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assessed in conscious animals by means of previously implanted
indwelling catheters. Hb increased in both r-HuEPO treated groups
(normal control (NC): 15.5 0.3, N = 6; control + r-HuEPO (CEPO):
19.4 0.3,N = 7; uraemic control (UC): 13.2 0.2, N = 8; uraemic +
r-HuEPO (UEPO): 19.1 0.3 g/dl, N = 8, P < 0.001). Mean BP was
higher in uraemic and r-HuEPO treated animals (NC: 117 8; CEPO:
133 10; UC: 138 6; UEPO: 155 9 mm Hg, P < 0.05). Following
L-arginine (100 mg/kg, i.v. bolus), there was a larger fall in BP in the
r-HuEPO treated animals in contrast to their respective controls. After
L-NAME (30 mg/kg, i.v. bolus), there was a steady rise in BP in all
groups (NC: +32.5 6.2%; CEPO: +38.7 4.5; UC: +26.9 3.4;
UEPO: +27.5 5.9%, percentage change from baseline, P < 0.01).
However there was no difference in the magnitude of change between
the groups. The fall in BP with sodium nitroprusside (10 sg/kg, i.v.i.
bolus) was similar in all groups, both before and after administration of
L-NAME. The NO pathway plays an important role in vasodilatation in
both uraemic and r-HuEPO-treated animals. No deficiency could be
detected in this pathway in association with uraemic hypertension.
There is no defect in the vascular reactivity to agents donating nitric
oxide in uremic or r-HuEPO-treated rats.
Cyclosporin therapy in steroid dependent nephrotic syndrome—is it
effective in the long term. J.R. Burke*, K. Webb, P. Sargent, Royal
Children's and Mater Children's Hospitals, Brisbane, QId. 4102. Five
children (aged 7—16 years) with multiple relapsing steroid dependent
nephrotic syndrome were treated with continuous cyclosporin (CYA)
for periods ranging from 28 to 48(37 8) months. Renal biopsy showed
mild mesangial proliferation in three and minimal change in two. All
patients had previously been treated with cyclophosphamide (3 mg/kg/
day for 8 weeks) and were showing significant side effects from steroid
therapy. The commencing dosage of CYA was 5 mg/kg/day and was
increased to a trough blood level of 100—200 ng/ml (HPLC) if relapse
occurred below this level. In the initial 12 months of treatment the mean
number of relapses decreased from 6.4 0.54 to 1.6 1.3 compared
with the previous 12 months (P < 0.001).
Patient 1 2 3 4 5
Relapses pre study Yr 7 7 6 6 6
lststudyyr 1 3 0 1 3
2nd study yr 0 3 0 3 4
3rd study yr 0 3 3
Mean dose CYA (mg/kg) 10 7 5 5.5 8.5
Mean level CYA (ng/ml) 105 50 80 125 135
After two years CYA was effective in maintaining remission in two
children. The addition of prednisolone did not alter the frequency of
relapse in two other children. Side effects included hirsuitism (5) and
gum hyperplasia (1). Mean creatinine clearance decreased from 126
16 to 97 22 ml/min/l.73 m2 (P = NS). A repeat renal biopsy between
12—18 months therapy showed no nephrotoxicity. A further biopsy in
one child after 4 years therapy showed severe interstitial fibrosis. CYA
is effective in maintaining short term remission but may not be effective
for long term therapy. Nephrotoxicity may be a major complication and
serial biopsies are recommended every 1—2 years with prolonged
therapy.
Comparative study of lomefloxacin and trimethoprim for the treatment
of women with cystitis. R.R. Bailey*, A.H. Smith, B.A. Peddie, P.R.
Davies,D.J.S. Gray, P. Mackay, L. Hooper, D. W. Kerr, M.R. Robson,
R. Scown, A.J. Bartle, K. Morris and R.E. Aitken, Department of
Nephrology, Christchurch Hospital, Christchurch. The 4-quinolone
group of antimicrobial agents have proven effective for the treatment of
uncomplicated urinary tract infections (UTI5). Lomefloxacin (L) is a
difluorinated addition to this group that has a broad antimicrobial
spectrum, a long half-life allowing for once-a-day administration and a
good safety profile. A prospective, randomised, single-blind study was
undertaken to compare the efficacy and safety of L (400 mg q24h) with
trimethoprim (T) (300 mg q24h) for the treatment of women with
cystitis. All patients were treated for 5 days. The results were assessed
6—8 days after completion of treatment. The results are shown in the
table:
Lomefioxacin Trimethoprim
No. enrolled 37 38
No. patients evaluable for 24 23
efficacy
Patients—clinical response
Cure 19 (79%) 18 (78%)
Improvement 5 (21%) 4 (17%)
Failure 0 1 (4%)**
Pathogens—bacteriological response
E R F E R F
E.coli 17* 1 1 17 1 0
S. saprophyticus 5 0 0 1 0 l**
Others 1 0 0 2 1 0
* 1 patient infected with 2 different strains; E = eradication; R =
eradication of baseline pathogen and reinfection with a new pathogen;
F = failure
Both eradication and reinfection were considered to be a satisfactory
bacteriological response, which was achieved in 23 (96%) and 22 (96%)
of evaluable patients treated with L and T, respectively. All 75 patients
were evaluable for safety. None were withdrawn because of adverse
reactions. Five patients in the L group reported adverse events—
nausea 2, facial erythema 2, dizziness 1. Two treated with T (5%)
reported adverse events—vaginal thrush 1, diarrhoea 1. In summary, L
was highly effective and well tolerated for the treatment of women with
cystitis and proved comparable to T.
Urine levels of glycine betaine and sorbitol in patients with diabetes
mellitus and chronic renal failure. P. Sizeland*, S. Chambers, M. Lever,
L. Bason, R. Robson, Departments of Nephrology, infectious Diseases
and Biochemistry, Christchurch Hospital, New Zealand. Glycine be-
tame (GB) and sorbitol (S) function as osmoprotectants in the human
kidney. Sorbitol (S) has also been implicated in the pathogenesis of
some of the complications of diabetes mellitus, and GB has a putative
role in preventing urea toxicity. Experimental evidence has found an
inverse relationship between medullary cell GB and S in diabetic
animals. We measured urine GB and S and plasma GB in adult patients
with chronic renal failure (CRF) and diabetes mellitus. Results, com-
pared with a normal control population, are shown (median, 95% CI):
.Patient
group N
Plasma
GB
(jsmolll)
.Unne GB .Unne S
(mmol/mol creatinine)
Normal
Diabetes
CRF
72
19
25
34 (18—61)
41 (26—84)
32 (9—55)
8 (3—41)
40 (7_l39)*
28 (l—380)#
3 (1—13)
6 (2—29)#
3 (1—18)
# P < 0.05, * P < 0.01 compared with normal population
In the diabetics, no relationship was evident between diabetic control
(glycated haemoglobin) and urine S or GB levels. In patients with CRF
negative correlations were found between plasma creatinine and GB (r
=
—0.58, P < 0.05) and plasma urea and GB levels (r = —0.65, P <
0.05). We conclude that: (1) the high urine GB in diabetes probably
reflects an elevated medullary cell S content and therefore reduced
requirement for GB by the medullary cells, and (2) GB may be
important in modulating tolerance to the uraemic millieu.
Comparative study of renal biopsy using trucut needle and biopty gun.
M. Tange*, B.A. Pussell, J.A. Charlesworth, J. Greenstein, G. Luxton
& L.C. Yong, Department of Nephrology, Prince Henry Hospital,
Sydney, NSW, 2036 Australia. Percutaneous renal biopsy carries a rate
of significant complications of about 10% for both native and transplant
kidneys. In an attempt to improve efficacy and patient comfort during
the procedure the Biopty gun (Biopty Radioplast AB, Uppsala, Swe-
den) was introduced for native and transplant renal biopsies. 182
biopsies were performed consecutively with the Biopty gun and data
collected prospectively. These were compared to the previous 182
Trucut needle biopsies in which data was also collected prospectively
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as part of a peer review survey. Procedures were performed using
ultrasound localisation of the kidney (lower pole for native kidney or
upper or lower pole for transplant kidney) with an ultrasound scanner
operated by the biopsier. The biopsy was performed in one breath hold
with the Biopty gun which is a spring loaded, automatic firing device
loaded with an 18 gauge needle. Six individuals performed the proce-
dures with two participating in both methods. Results Bleeding com-
plications included macroscopic haematuria, perinephric haematoma
and intra-peritoneal haemorrhage. One patient required nephrectomy.
The other major complication was failure to obtain satisfactory renal
tissue.
Trucut Biopty Gun
Total no. 182 182
Native biopsies 105 (58%) 97 (53%)
Transplant biopsies 77 (42%) 85 (47%)
Bleeding complications 21(11%) 10 (5%)
No renal tissue 14 (8%) 2 (1%)
All complications 35 (19%) 12 (7%)
There was a significant decrease in all complications with the Biopty
gun technique ( = 12.94; P < 0.001) as well as specific bleeding
complications ( = 4.267; P < 0.05). There was also an increase in the
success rate for obtaining useful diagnostic tissue (, = 18.8; P <
0.001). In conclusion, the Biopty gun needle biopsy proved a safer
technique without loss of diagnostic accuracy and achieved a higher
success rate in obtaining renal tissue. Preliminary observations suggest
that patient acceptance of the procedure has also improved markedly,
as assessed by the those (20) who had biopsies performed by both
procedures.
Angiotensin converting enzyme (ACE) in the kidneys of diabetic and
hypertensive rats. S. Panagiotopoulos*, B. Jackson, V. Bogdanoska, R.
Perich, M. Cooper, The University of Melbourne, Departments of
Medicine, Austin and PANCH Hospitals, Bell Street, Preston, Victo-
ria, Australia. Angiotensin converting enzyme (ACE) inhibitor deriva-
tives were used to characterize ACE by radioligand studies, and to
quantitate renal ACE in normotensive, hypertensive and diabetic rats
by analysis of autoradiographs of ligand binding to kidney sections.
Purified somatic ACE was demonstrated to contain two enzymatic
sites, each of which interacted differently with ACE inhibitors. In the
normal rat kidney ACE ligand binding predominated in the cortical
tubules, with a lesser degree of binding present in medullary vascular
bundles. Renal binding density was not different between normotensive
and hypertensive rats. Sprague-Dawley (SD) and Spontaneously Hy-
pertensive Rats (SHR) were studied over 16 weeks after streptozotocin
injection. Variable insulin dosage achieved groups with euglycaemia,
moderate and severe hyperglycaemia. There was no significant differ-
ence in renal ACE concentration between SHR and SD diabetic rats.
Renal cortical ACE was reduced by up to one half in uncontrolled
diabetes and returned towards non diabetic control concentrations with
better glycaemia regulation. Plasma ACE was increased in rats with
hyperglycaemia. Circulating and renal ACE concentration does not
appear linked to hypertension, but renal ACE appears related to
glycaemic control in diabetes.
Trends in incidence of end-stage renal failure: use of cumulative rates.
J.H. Stewart*, M.R.E. McCredie, T.H. Mathew, A.P.S. Disney, West-
ern Clinical School, University of Sydney; Epidemiology Unit, NSW
Cancer Council; and Renal Unit, Queen Elizabeth Hospital, Adelaide.
Cumulative incidence rates are a means whereby the whole range of age
specific rates for two populations can be compared and interpreted so as
to distinguish changing incidence from altering patterns of acceptance
into treatment programmes, and to eliminate the effect of the age
structure of the population. Numbers of patients entering end-stage
renal failure programmes in Australia and New Zealand during the
20-year period 1972—91 were analysed by age (0—4, 5—14 75 and
over), sex, cause of renal failure, and year of entry as recorded by the
Australia and New Zealand Dialysis and Transplant Registry. Cumula-
tive rates were calculated according to Day (1987). In persons under 55
yr, the incidence of end-stage renal failure due to analgesic nephropathy
and hypertension has fallen, while that due to polycystic renal disease
and reflux nephropathy has remained unchanged. However, renal
failure due to glomerulonephritis continues to rise in persons aged 25—55
yr, occurring at a younger age and to a greater extent in females than
males, and is more evident in New Zealand and the less densely
populated Australian states. In polycystic renal disease, end-stage renal
failure occurs about 2 years earlier in men than in women; while in
reflux nephropathy, the rates in males and females are the same until 35
years of age, but thereafter are about 50% higher in women than men.
Lysosomal iron accumulation in human chronic renal failure (CRF).
B.J. Nankivell*, M.J. Penny, R.A. Boadle, D.C.H. Harris, Dept. of
Renal Medicine & EM Unit, Westmead Hospital, Sydney. Iron, which
accumulates in proximal tubular lysosomes in experimental renal dis-
ease, may play a role in the progression of CRF. Renal biopsies from
humans with CRF and/or proteinuria were examined for iron at an
ultrastructural level by energy dispersive analysis and compared with
normal biopsies. Iron accumulated in proximal tubular lysosomes in
renal disease (P < 0.05 vs normals), accompanied by phosphorus and
silicon in some cases. Both the mean concentration of lysosomal iron
(254.5 73.4 mg% vs 81.2 23.8, P < 0.001) and the number of
iron-containing lysosomes per tubular cross-section (1.86 0.41 vs 0.66
0.22, P < 0.05) were increased in patients with (N = 12) compared to
those without nephrotic syndrome (N = 8). The number of iron-
containing lysosomes correlated with protein excretion (r = 0.68, P =
0.003, N = 20),but not with glomerular filtration rate. Damaged tubules
contained greater amounts of iron than tubules with less damage (288.5
68.5 mg% vs 80.4 13.9, P < 0.01). In conclusion, iron accumulates
within human proximal tubular lysosomes and is associated with
proteinuria and tubular damage. Further studies are required to define
the role of iron in causing renal damage and progression of CRF.
Sotalol and end-stage renal failure. G.M. Patrick*, C.A. Pollock, L.S.
Ibels, R.J. Caterson, Department of Renal Medicine, Royal North
Shore Hospital, St. Leonards, NSW, 2065. Sotalol, a class III antiar-
rhythmic p adrenoceptor antagonist, is being increasingly used in the
treatment of supraventricular and ventricular tachycardias. The clinical
implications of its predominant renal excretion appear to be under
recognised. We thus report the adverse cardiac effects of sotalol in
three consecutive haemodialysis patients. Case 1: A male (age 71) with
end-stage renal failure (ESRF) secondary to an unidentified glomerulo-
nephritis and atheroembolic vascular disease developed uncontrolled
atrial fibrillation. He was commenced on sotalol 80 mg bd. He was
admitted one day later with a sinus bradycardia (rate 25 bpm) and
hypotension (100/50 mm Hg). Treatment with atropine, isoprenaline
and haemodialysis improved the bradycardia (rate 50—60 bpm) and
blood pressure (140/80 mm Hg). Ten hours post dialysis he was
resuscitated from a ventricular tachycardia. He required a permanent
pacemaker for a persistent sinus bradycardia despite haemodialysis.
Case 2: A female (age 67) with ESRF secondary to reflux nephropathy
was commenced on sotalol 80 mg tds for uncontrolled atrial fibrillation.
Three days later she became bradycardic (rate 25 bpm) and hypotensive
(BP 90/60). She improved with atropine and isoprenaline (heart rate 60
bpm and BP 150/80) but 12 hours later was resuscitated from a
ventricular tachycardia. Despite haemodialysis she required permanent
pacing for a persistent sinus bradycardia. Case 3: A female (age 71) with
ESRF secondary to calculous disease and hypertension was treated
with sotalol 40 mg bd for paroxysmal atrial fibrillation/flutter. Nine days
later she was resuscitated from a Torsades de Pointes ventricular
tachycardia. Persistent sinus bradycardia, despite haemodialysis, ne-
cessitated a temporary pacemaker for 14 days. In summary, sotalol use
in patients with ESRF may precipitate life threatening complications
and should be used with extreme caution. Although the drug is cleared
by haemodialysis, a rapid rebound phenomenon secondary to redistri-
bution of the drug from the tissue space occurs. If the drug is considered
essential, pharmacokinetic considerations suggest a prolongation in
dosage interval, rather than a reduction in drug dosage, is preferable
and sotalol levels should be monitored.
Erythropoietin (r-HuEPO), blood pressure and intracellular calcium in
experimental hypertension and uraemia. S.D. Roger, R. Fluck, A.
McMahon, A.E.G. Raine, Dept. Nephrology, St. Bartholomew's Hos-
pital, London, ECIA 7BE, UK. The mechanism of erythropoietin-
induced hypertension in dialysis patients is unclear. Intracellular cal-
cium ([Ca]1) may be altered in both hypertension and uraemia, and
Abstracts 1269
the effects of both uraemia and r-HuEPO on [Ca] and blood pressure
in Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR)
were therefore studied. Male WKY and SHR underwent partial ne-
phrectomy or sham operation. Three weeks later a 28 day period of
treatment with either r-HuEPO 100 units/kg, s.c., 3 times/week or
buffer was commenced (N = 10—12 for each subgroup). BP was
measured weekly, by non-invasive Doppler tail-cuff assessment.
[Cat ], was measured following loading with Fura 2 in pooled, primary
aortic vascular smooth muscle cells (VSMC). Serum urea rose 3-fold
after partial nephrectomy. Hemoglobin increased in both non-uraemic
WKY (16.2 to 20.3 g/dl) and SHR (16.4 to 20.5 g/dl) and uraemic animals
(WKY: 13.9 to 20.9; SHR 13.8 to 18.8 gldl; P < 0.01 for all changes)
following 4 weeks of r-HuEPO treatment. BP was unaffected by
r-HuEPO in WKY but increased in non-uremic SHR (210 to 250, P <
0.01) and in uraemic SHR (224 to 251 mm Hg, P < 0.001) at 4 weeks.
VSMC [Ca]1 was higher in SHR than WKY (69 vs 74 nmolll,
MANOVA P < 0.05) but no effect of uraemia or r-HuEPO on [Ca]
was detected. In conclusion, the hypertensive effects of r-HuEPO are
augmented both in a genetic model of hypertension and in uraemia.
Although VSMC [Ca}1 was elevated in SHR, the further increase in
blood pressure induced by r-HuEPO was not associated with alterations
in VSMC cytosolic calcium.
Diagnosis of cystinosis and the heterozygote from polymorphonuclear
Ieukocyte cystine content. L.P. Roy*, G.Y. Zhang, Department of
Nephrology, The Children's Hospital, Camperdown. The diagnosis of
cystinosis has relied on the demonstration of increased uptake of
radiolabelled cystine relative to glutathione by cells from the patient.
The labelling technique has not proved useful for the detection of
heterozygotes. It has been shown that the homozygous state is defi-
nitely diagnosed by measuring the non protein cystine content of
peripheral leukocytes. Obligate heterozygotes tended to have an in-
creased level but there was significant overlap. Smolin et al (Am J Hum
Gen (1987)41:266) have suggested that measuring the cystine content of
peripheral polymorphonuclear leukocytes significantly improves het-
erozygote detection. Polymorphonuclear white cell preparations were
obtained after separation of whole blood by Ficoll-Hypaque discontin-
uous gradient centrifugation. Cystine content was measured on an acid
soluble fraction with an isotope-dilution assay using a specific cystine
binding protein. Blood samples were obtained from 8 children with
cystinosis, 10 parents (being obligate heterozygotes), 2 siblings and 10
apparently healthy adult volunteers. In one family three grandparents,
an aunt and a cousin were tested. 6 of the affected children were taking
cysteamine. Expressed as nmol cystine/mg protein, the levels in
affected patients were (mean SD) cystinotics 8.17 4.53, heterozy-
gotes 0.53 0.25, apparently healthy volunteers 0.1 0.07. Only one
cystinotic taking cysteamine had a level less than 2.0 (1.49). Of siblings
and other family members 6/7 appear to be carriers. These preliminary
observations suggest that this will be a useful method to diagnose
cystinosis and carriers and to monitor cysteamine therapy.
Urinary albumin excretion rates in normal and hypertensive preg-
nancy. M.A. Brown*, M.X. Wang, M.L. Buddle, M.A. Canton, G.M.
Carlo, J.A. Whitworth, Departments of Renal Medicine, Medicine and
Obstetrics, St. George Hospital & University of NSW, Sydney, NSW
2217. Severe pre-eclampsia (PE) may occur in the absence of overt
proteinuria. We hypothesised that if glomerular abnormalities were
present in women with non-proteinuric FE, urinary albumin excretion
rate (AER) would be enhanced. We measured 24 hr. urinary AER by
radioimmunoassay of albumin in 40 normal pregnant women (NP), 58
with "non-proteinuric" FE (20 severe, 38 mild), 17 pregnant women
with essential hypertension (EH) and 26 age-matched normal non-
pregnant women (N). Absence of significant proteinuria was confirmed
in all women by 24 hr. urinary total protein estimation. AER was similar
in NP and N women [8 (4—24) vs 7 (4—17) mg/day; median (range)].
Women with mild PE or EH had similar median AER [7 (1—102) and 6
(2—117) mg/day respectively] but women with severe PE had increased
AER [13 (2—77) mg/day, P < 0.05 compared with all other groups]
despite similar blood pressures to the other two hypertensive groups.
AER was elevated (>20 mg/day) in 40% of severe PE, significantly
more than in either mild PE (11%; P < 0.05) or EH (12%; P < 0.05).
Thus, urinary AER is increased in women with severe FE, and this is
not explained by differences in systemic blood pressure. This probably
reflects subtle or early glomerular endothelial cell changes in women
with severe PE.
Is IgA nephropathy such a terrible disease? L.S. Jbels*, A.Z. Gyory,
Department of Renal Medicine, Royal North Shore Hospital, St.
Leonards, NSW, 2065, Australia. IgA nephropathy currently accounts
for the majority of patients with glomerulonephritis on end stage renal
failure programmes. However, it is clinically apparent that a large
proportion of patients with IgA disease will have a relatively indolent
course and retain excellent renal function. In order to determine the
prognosis of patients with IgA nephropathy and the factors of impor-
tance in progressive renal impairment, 117 patients with biopsy proven
IgA disease were followed for up to 237 (mean 60) months. All patients
were treated in a similar manner with identical advice with regards to
dietary protein restriction, maintenance of adequate fluid intake and
blood pressure control. Renal function, as assessed by creatinine
clearance, showed a moderate decline, to 50—79% of initial renal
function, in 16 patients (14%). In 10 patients (9%), a more accelerated
decline in renal function to less than 50% the initial value occurred.
During the follow up period 6 patients died due to non-renal causes, and
10 patients reached end stage renal failure 4—140 (mean 45) months post
presentation. When patients in whom progressive deterioration in renal
function occurred (creatinine clearance <80% initial estimate) were
compared with those in whom renal function had not deteriorated, the
following features were predictive of a poor prognosis at presentation:
recurrent macroscopic haematuna (P < 0.03); longer duration of
symptoms prior to presentation (P <0.05); a greater number of hyaline
casts in initial urine examination (P < 0.01); severity of proteinuria (P
<0.001); elevated serum creatinine (P < 0.001) and urea (P < 0.001);
and the biopsy findings of: severity of tubular atrophy/interstitial
fibrosis (P < 0.001); interstitial inflammation (P < 0.001); percentage of
sclerosed glomeruli (P < 0.001); segmental sclerosis and adhesions (P <
0.02); and intensity of IgA deposition (P < 0.04). During the course of
follow up, proteinuria (P < 0.001); a creatinine clearance which varied
by greater than 10% (P < 0.001), a fall in serum cholesterol levels (P <
0.05) and a fall in serum IgA levels (P < 0.02) were all associated with
deteriorating renal function. It is proposed that the prognosis of patients
with IgA nephropathy may not be as poor as has been portrayed in
previous studies. The present study demonstrates that a poor prognosis
may be predicted from initial presenting clinical and laboratory fea-
tures, renal biopsy changes and laboratory parameters during the
course of follow up.
Recurrence of mesangial IgA deposits in renal allografts. J. Odum, C.
Peh, A. Clarkson, K. Bannister, A. Thomas, A. Seymour, T. Mathew,
A. Woodroffe*, Renal Units, RAH and TQEH Adelaide, S.A. Recur-
rence of mesangial IgA deposits in renal allografts of patients whose
original disease was primary IgA nephropathy (IgAN) has been studied.
46 patients with primary IgAN, received 51 renal allografts (47 cadav-
eric, 4 LRD) and have been followed 2—183 months. A prospective
study of allograft biopsies of 11 patients (11 biopsies) and a retrospec-
tive analysis of 17 patients (16 biopsies; 2 nephrectomy specimens) has
been combined. Biopsies performed in the early post-transplant period(<3 months) are not considered in this study. When multiple biopsies
were performed the first IgA positive biopsy, or the most recent IgA
negative biopsy is considered. 17 of 29 allografts had mesangial IgA
deposits with corresponding deposits on electron microscopy.
Graft
H P failure CyA
Time on
Dx (m)
Duration
of Tx (m)
Time to
Bx (m)
IgA+ 13 9 8* 6 9.4 2.1 84.6 11.9 45.9 10(N = 17)
IgA— 3 1 8 6 13.2 2.2 40.4 13.6 15.3 4.8(N = 12)
No Bx 2 1 0 14 24.4 5.7 42.9 10.4 —
(N= 18)
(H = microhaematuria; P = proteinuria; No Bx = no biopsy)
* Failing grafts: IgAN (5); IgAN + Tx glomerulopathy (2); IgAN +
rejection (1).
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Length of time post transplantation is the single most important
predictor of recurrence. Of 17 patients with deposits, 8 have recurrent
IgA "disease" and graft failure. In 5 of these patients graft failure is
attributed to IgAN alone, these allografts being 81.8 13.1 months post
transplantation. The 9 patients with recurrent deposits and stable
function are currently 67.6 17.8 months post transplantation. All
patients with recurrent IgAN and graft failure have heavy proteinuria
and microhaematuria. The results do not support (a) time on dialysis
causes disease "burn out" or (b) a protective role for cyclosporin
(CyA). In contrast they suggest that recurrence of IgA deposits is time
dependent and recurrent IgA "disease" may be a much more serious
cause of graft loss than is currently recognised.
Indomethacin potentiates exercise-induced reduction in effective renal
blood flow in athletes. R.J. Walker*, J.P. Fawcett, E.M. Flanne,y, D.F.
Gerrard, Division of Health Sciences, University of Otago, Dunedin,
NZ. Exercise induces a reduction in renal blood flow due to redistri-
bution of blood to skeletal muscles. To maintain renal perfusion, renal
prostaglandin synthesis is increased but this may be compromised by
the use of NSAIDs. We investigated the effects of indomethacin
(INDO) on effective renal blood flow (ERBF mL/min), renal vascular
resistance (RVR dynes/cm3) and glomerular filtration rate (GFRImL/
mm) in eight fit healthy males (aged 21—42) following 30 mins exercise
(treadmill) at 80% V02 max and during 120 mins recovery. Each
volunteer acted as their own control (C).
Time
ERBF
(C) (INDO)
GFR
(C) (INDO)
RVR
(C) (INDO)
Baseline 850 (64) 732 (63) 123 (10) 124 (11) 7681 (817) 8887 (692)
Post-ex 373 (42) 258 (53)** 69 (13) 52 (12) 17577 (2399) 35187 (10040)*
40 mm 593 (53) 551 (58) 98 (14) 77 (11) 9857 (766) 11799 (1859)
80 mm 805 (60) 668 (62)# 121 (9) 108 (11) 7422 (740) 9592 (1296)*
120 mm 872 (59) 762 (55)# 131 (11) 115 (8) 6806 (666) 7998 (775)*
* P < 0.05, ** P < 0.002, # P < 0.01 vs control. Data = mean (saM), N
8.
Indomethacin produced a significant reduction in ERBF compared to
control after exercise plus a significant delay in the rate of recovery.
This was associated with a marked rise in renal vascular resistance
which persisted during the recovery period. With sustained exercise
NSAIDS could compromise renal function and potentiate the risk of
developing acute renal failure.
Urinary endothelin excretion in normal and hypertensive pregnancy.
M.X. Wang, M.A. Brown*, ML. Buddle, M.A. Carlton, G.M. Cario,
J.A. Whitworth, Departments of Renal Medicine, Medicine and Ob-
stetrics, St. George Hospital & University of NSW, Kogarah, Sydney,
NSW2217. Endothelin-1 (ET) is the most potent vasoconstrictor known
in humans. ET also inhibits renin release, alters capillary permeability
and reduces glomerular filtration rate (GFR). These renal abnormalities
occur in pre-eclampsia (PE) and we hypothesised that urinary ET
excretion, derived from both filtered and secreted ET, might be
increased in PE. 24 hr. urinary ET was measured by radioimmunoassay
in 42 normal pregnant women (NP), 69 women with PE (32 severe, 37
mild), 16 women with essential hypertension (EH) in pregnancy and 26
age-matched normal non-pregnant women (N). 24 hr. urinary ET was
increased in NP compared with N [37 (8—73) vs 25(6—69) ng/day; median
(range); P < 0.05]. ET excretion was reduced in all hypertensive groups
compared with NP women (P < 0.01): severe PE 25 (5—66) ng/day; mild
PE 21(5—52) ng/day; EH 23 (6—94) ng/day. The same pattern of results
was observed for ET/creatinine ratios. There was a significant correla-
tion between urinary ET and both creatinine clearance (r = 0.31, P <
0.01) and urinary sodium excretion (r = 0.34, P < 0.01) amongst
hypertensive pregnant women. This study demonstrates that 24 hr.
urinary ET excretion is increased in normal pregnancy and decreased
from these levels in women with hypertensive pregnancy. This finding
is in part explained by reduced filtered ET but impaired renal ET
secretion must also contribute. The finding of reduced urinary ET
excretion in hypertensive pregnancies of varying etiologies indicate that
it is not specific to pre-eclampsia.
Renal involvement in adult spina bifida patients. M. Mclver* and N.
Woolfield, Paediatric Renal Service, Monash Medical Centre, Clayton
Rd, Clayton, Vic., 3168. The records of 117 adult patients (42 women,
39 men, age 18—45 years) with neurogenic bladders were reviewed to
assess incidence of late renal problems. 115 had spina bifida, 1 had
diastematomyelia, 1 sacral agenesis. Most (85%) had ileal conduits in
childhood, 5 had ureterostomies. Continence was achieved in the others
by clean intermittent catheterisation (C.I.C.) or by penile clamp and bag
drainage. 60% have ventriculo peritoneal shunts for hydrocephalus. All
had multiple orthopaedic operations. "Undiversion" by colocysto-
plasty was done in 17%. Major renal complications were related to
infection and calculi. Multiple urinary tract infections (U.T.I.), >6/
year, with coliforms, streptococci, proteus, pseudomonas, corynebac-
terium and candida occurred in 95% of those with conduits, but were
less common with C.I.C. Total cystectomy for pyocystis in childhood
was done in 6%. Abnormal renal radiology, reflux, obstruction, hydro-
nephrosis, ureteric dilation, renal scarring and calculi was present in
90%. Calculi including staghorn were present in 13% and resulted in
nephrectomy in 4. 12% are hypertensive. Chronic Renal Failure
(C.R.F.), S. creatinine >130 mo1/l or clearance <50 mllmin is present
in 10%. 2 have been transplanted and 3 are on dialysis. 4 have had
normal pregnancies without change in renal function. Hyperchloraemic
acidosis occurred in all but one with "undiversion". C1 was 112—121
mmol/l, HCO3 <22 MM/L. 2 had chronic severe acidosis, HCO3 <10
MM/L3. There was no shunt nephritis seen. The oldest, 45, had a
conduit for 32 years. Morbidity was less with low lesions, incidence of
C.R.F. is low, but U.T.I. and calculi are common. Bladder reconstruc-
tion causes metabolic acidosis. C.I.C. is now preferred for children with
spina bifida. Adult patients are a continuing problem.
Effects of different antihypertensive agents in normotensive microalbu-
minuric type I and type II diabetic patients. Melbourne Diabetic Ne-
phropathy Study Group: T. Allen, M.E. Cooper, G. Jerums, M.
DeLuise, F. Alford, A.E. Doyle, J. Hammond, M. Mashford, C.
McMenamin, J. Raffaele, B. Westwood, Austin, Heidelberg Repatria-
tion and St. Vincent's Hospitals, Melbourne. A previous study by our
group has suggested similar efficacy of perindopril and nifedipine in
their effects on albuminuria (AER) in microalbuminuric diabetic pa-
tients (Brit Med J 302, 210—216, 1991). However, the previous study
included hypertensive patients and no placebo group. Therefore, a
prospective study has been commenced to explore the effectiveness of
ACE inhibition, calcium antagonism and no treatment on AER and
renal function in normotensive microalbuminuric diabetic patients. At
present, 51 patients have been recruited from these hospitals. Patients
were eligible for recruitment if they had established microalbuminuria
(2/3 overnight AER of 20—200 g/mmn) and had no evidence of hyper-
tension, urinary tract infection, non-diabetic renal disease or cardiac
failure. Patients were randomised to receive nifedipine SR, perindopril
or placebo. The doses of drugs were titrated to achieve a drop in
diastolic blood pressure (DBP) of at least 5 mm Hg or to the maximum
dose of nifedipine SR 80 mg/day or perindopril 8 mg/day. Serial
measurements of AER, blood pressure, glomerular filtration rate,
glycaemic control, plasma renin activity and ACE were performed.
AER (g/min, geometnc means shown)
Group N 0 6 9 12 months
Placebo 11 59 57 65 77
Perindopril 12 54 39 38 31
Nifedipine SR 7 48 45 50 55
There was no change in glycaemic control, a rise in plasma renin
activity and reduction in plasma ACE in the perindopril treated group.
There was no significant change in blood pressure with any of the
treatments (DBP, months 9—11, placebo, 79 3, perindopril, 75 2,
nifedipine 76 2mm Hg, mean SEM shown). AER rose in the placebo
group, was unchanged in the nifedipine group and decreased in the
perindopril treated group. At 12 months there was a significant differ-
ence in AER between penindopril and nifedipine (P = 0.024), between
perindopril and placebo (P = 0.03) but not between nifedipine and
placebo. These results indicate that longer-term follow-up is required to
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determine if ACE inhibitors have a specific renoprotective effect in
early diabetic nephropathy.
Renal NMR microscopy. Z.H. Endre*, W.E. Huilt, K-P. Fichtnert,
W. Kriz*, U. Wernert, S. Pomert, E. Ritz.t, The University of Queens-
Iand*, Royal Brisbane Hospital, Herston, QId, 4029; the German
Cancer Research Centre1 and the Ruperto Carola University*, Heidel-
berg, Germany. The isolated perfused rat kidney (IPRK) is ideal for the
study of acute renal injury by hypoxia, ischaemia or nephrotoxins.
Imaging of the rat kidney has been limited to low resolution images at
low magnetic field and motion artifacts have often limited the image
quality. We have applied NMR Microscopy to the IPRK at high field
(7.OT) for the first time and reproducibly obtained images with high
resolution and good contrast between Cortex, Inner and Outer stripes
of Outer Medulla and of Inner Medulla. Images were compared with
histology and flow dependence of intensity and contrast was assessed.
Kidneys from Male Sprague-Dawley rats (120—160 g) were perfused at
37°C with Krebs-bicarbonate buffer supplemented with 20 normal
amino acids, glucose 5 mM and albumin 6.7 g%. The kidneys were
perfused within a 20 mm microscopy probe, Bruker AM-300, 7.0 T/l5
cm. Physiological function was monitored throughout. A variety of
pulse sequences were assessed for optimal anatomical resolution and
image contrast. The most suitable was the inversion-recovery gradient-
echo FLASH sequence (IRGE) using gradient strengths of 5—10 G/cm,
repetition and echo times of TRITE = 21/8 ms, a 10° flip angle, and 256
pulse increments during each T1 recovery period (ca. 6 s). Both saggital
and cross-sectional images were collected routinely over 15 or 30 mm
with an in-plane resolution of 80 x 80 m (2562 voxels) and a slice
thickness of 250 m. Images with 1282 voxels could be acquired in 5
mm). Higher resolution cross sectional images (48 x 48 x 150 j.m)
required 30 or 60 mm for adequate signal. With a global spin-inversion
pulse, the images demonstrated good corticomedullary T1 contrast even
in the absence of flow (ischaemia). Intensity and contrast in the cortex
and vascular bundles was enhanced substantially by flow, due to rapid
inflow of relaxed water protons during the inversion-recovery period.
Complete ischemia produced a rapid loss of renal volume within
minutes, but there was good recovery of renal volume upon reflow after
45 mm ischaemia. This microimaging technique appears to be suitable
for the assessment of region-specific changes in models of acute renal
failure.
Proximal tubular iron accumulates in diabetic nephropathy. B.J.
Nankivell*, C.Y. Tay, R.A. Boadle, D.C.H. Harris, Dept. of Renal
Medicine & EM Unit, Westmead Hospital, Sydney. Iron, which may
generate reactive oxygen species and has been shown to accumulate in
experimental renal disease, may play a role in the progression of
proteinuric chronic renal disease. In this study, tubular iron was
examined by energy dispersive X-ray spectrometry in streptozotocin-
induced- (STZ) and spontaneous BB-diabetic rats (which have progres-
sive and non-progressive nephropathy respectively), and in humans
with diabetic nephropathy, and compared to their respective non-
diabetic controls. In STZ diabetic rats, substantial amounts of iron
accumulated in the secondary lysosomes of proximal tubules (3.66
0.06 iron-containing lysosomes/tubule vs 0.73 0.34 in controls, P <
0.001). Proximal tubular iron was related by multiple linear regression
to urinary protein and transferrin excretion which accounted for the
effects of urinary iron excretion. Tubular iron correlated with tubular
damage (r = 0.55, P < 0.001). Minimal tubular iron was observed in BB
diabetic and non-diabetic littermates. In humans with diabetic nephrop-
athy proximal tubular lysosomal iron concentration (35.6 13.0 mg%
Fe vs 9.5 2.7, P < 0.05) and numbers of iron-containing lysosomes
were greater than in non-diabetic controls, and the number of iron-
containing lysosomes correlated with serum creatinine (r = 0.94, P =
0.016). These data suggest that filtered iron enters proximal tubular
lysosomes across the brush-border membrane and are consistent with a
role for iron in the tubular damage of diabetic nephropathy.
Immunohistochemical localisation of extracellular matrix components
in human diabetic nephropathy. Yi-pu Chen*, I.E. Birchall, G.J. Becker,
P. Kincaid-Smith, Pathology Dept., Melbourne University, and Dept.
of Nephrology, The Royal Melbourne Hospital, Victoria, Australia.
The distribution of collagen (Col) types I, III, IV, V, VI fibronectin
(Fn), laminin (Ln) and heparan sulfate proteoglycan (HSPG) was
examined in 34 patients with different grades of diabetic nephropathy.
In normal kidney Col IV, V, VI, Fn and Ln were present in the
mesangium. These extracellular matrix components (EMCs) together
with HSPG were also distributed in the glomerular basement membrane
(GBM), but only Col IV, Ln and HSPG were detected in the membrane
of Bowman's capsule (BC) and the tubular basement membrane (TBM).
Col I, III, V and VI were detected in the interstitium. In diabetic
nephropathy the EMCs present in the expanded mesangium and the
nodules were those present in normal mesangium, but their quantities
and distributions differed between the two lesions. The staining of
HSPG, Ln, and occasionally Fn in the highly thickened GBM and the
staining of Col IV in thickened BC and TBM displayed a double linear
pattern. In most capsular drops and fibrin caps no the EMCs were
detected. Besides the interstitial EMCs, Col IV, Fn and Ln were
detected in peri-glomerular fibrosis. When ruptures in BC occurred, Col
III and I were sometimes seen in a laminated BC, in Bowman's space,
in the space between glomerular capillary lobules, adhesion sites and
within some nodules. The results suggest (1) nodular lesions are not
simply formed by expansion of the mesangial matrix; (2) secondary
incorporation of EMCs into the insudative lesions is possible; (3) when
BC is ruptured the EMCs produced by glomerular cells may be present
in the interstitium and may participate in peri-glomerular fibrosis.
Interstitial collagens may be found in Bowman's space and may be
involved in the progression of glomerular sclerosis.
Effects of deoxyspergualin on rat mesangial cells in vitro. *D.J.
Nikolic-Paterson, PG. Kerr, G.H. Tesch, R.C. Atkins, Dept. of
Nephrology, Monash Medical Centre, Clayton, Victoria 3168, Austra-
lia. Deoxyspergualin (DSP) is a potent immunosuppressant drug which
has been shown to suppress accelerated anti-GBM disease in the rat. A
feature of DSP treatment was the reduction of glomerular hypercellu-
larity. To determine whether this was due to a direct action of DSP on
mesangial cells, we have investigated the effect of DSP treatment on
mesangial cells in vitro. The studies used a cloned rat mesangial cell line
(1097) cultured in RPMI/l0% normal rat serum. DSP (1, 10 and 100
g/m1) was added to cells in subeonfluent growth and proliferation
measured by 3H-thymidmne uptake. No effect on proliferation was
evident on day 1 with any dose of DSP, minor inhibition was seen on
day 2, and significant inhibition of mesangial cell proliferation was
consistently observed on day 3 (. 18%, 26%, and 37% for 1, 10,
and 100 Wml DSP respectively). This inhibition was significant com-
pared to untreated cells at each dose of DSP (P < 0.05) and was seen in
3 separate experiments. In addition, 3 day treatment of mesangial cells
with 50 g/ml DSP did not affect; (i) interferon-gamma induction of
MHC class II antigen expression; (ii) lipopolysaccharide induction of
interleukin-6 mRNA synthesis; or (iii) constitutive levels of transform-
ing growth factor-beta 1 (TGFp1) gene expression. The latter result
suggests that DSP inhibition of mesangial cell proliferation is not due to
upregulation of TGF/31 expression. These results suggest that the
reduction of glomerular hypercellularity apparent with DSP treatment
of anti-GBM disease is due in part to a direct effect upon mesangial cell
proliferation. However, DSP did not affect the potential of mesangial
cells to contribute to immune processes in terms of inducible MHC
class II expression and IL-6 production.
Glomerular morphology in rats co-administered puromycin aminonu-
cleoside and antioxidants. Sharon D. Ricardo*, John F. Bertram and
Graeme B. Ryan, Department of Anatomy and Cell Biology, University
of Melbourne, Victoria 3052, Australia. Marked proteinuria and mor-
phological changes similar to those seen in severe proteinuric condi-
tions such as minimal change disease, are observed when rats are
administered puromycin aminonucleoside (PAN). These changes in-
clude replacement of glomerular epithelial cell (GEC) foot processes by
flattened expanses of cytoplasm. Recent in vivo evidence suggests that
PAN nephrosis may be mediated by reactive oxygen species (ROS). In
the present study, we examined whether a reduction in urinary protein
excretion rate in rats co-administered PAN and antioxidants was
associated with a reduction in GEC cytoplasmic spreading. Daily
urinary protein excretion was measured in female Sprague-Dawley rats
that received a single tail vein injection of saline or PAN (5 mg/lOO g
body weight) with or without co-administration of superoxide dismu-
tase (SOD; a superoxide anion scavenger), dimethyl thiourea (DMTU;
a hydroxyl radical scavenger) or a-tocopherollascorbic acid (a lipid
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soluble antioxidant). The co-administration of a-tocopherol/ascorbic
acid to PAN-injected rats reduced proteinuria by approximately 90%
over the 18 day period studied. The administration of DMTU or SOD to
PAN-injected rats reduced proteinuria by approximately 40% and 60%
respectively. In a second group of rats, daily urinary protein excretion
was measured and kidneys were processed for qualitative and quanti-
tative transmission electron microscopy 4, 5 and 10 days after injection
of PAN. PAN produced a significant reduction in the number of GEC
filtration slits per 100 m of glomerular basement membrane on days 4,
5 and 10. Electron microscopic morphometric analysis of glomeruli
from PAN-injected rats co-administered antioxidants revealed a re-
markable decrease in GEC cytoplasmic spreading. For example, at day
10, rats injected with PAN alone, PAN and a-tocopherol/ascorbic acid,
PAN and SOD, and PAN and DMTU, contained 75.8 11.2 (mean
SD), 131.6 21.3, 129.9 24.6, and 120.1 6.1 GEC filtration slits per
100 m, respectively. Control glomeruli (saline with or without antiox-
idants) contained 220.0 20.2 slits per 100 m. The protective effects
of these antioxidants on GEC morphology in PAN-injected rats provide
further evidence that ROS are involved in the pathogenesis of PAN
nephrosis.
Deoxyspergualin (DSP) suppresses ICAM-1 expression in experimental
glomerulonephritis (GN). *H Y. Lan, D.J. Nikolic-Paterson, H.C.
Ramm, Hill, M. Zarama, R.C. Atkins, Dept. of Nephrology,
Monash Medical Centre, Clayton, and **Dept. of Anatomy, University
of Melbourne, Parkville, Victoria. We have previously demonstrated
that DSP suppresses progressive renal damage by inhibition of macro-
phage infiltration in a rat model of accelerated anti-GBM GN. We have
now investigated whether this effect of DSP is due to the inhibition of
ICAM-1 expression. Accelerated anti-GBM GN was induced in primed
inbred Sprague-Dawley rats by injection of nephrotoxic serum (day 0).
Groups of 5 animals were treated either with DSP (5 mg/kg body weight)
or saline by daily i.p. injection from day 0 until sacrifice on days 1, 7, 14,
and 21 respectively. ICAM-1 (CD54) and LFA-l/3 expression (CD18)
was assessed by immunoperoxidase staining with monoclonal antibod-
ies, 1A29 and WT3. Giomerular ICAM-1 expression in both treated and
untreated animals was increased from 1 + to 3 + on day 1 and this was
maintained though to day 21, although DSP treatment reduced glomer-
ular macrophage infiltration by 50%. At day 1, both groups of animals
also exhibited a similar but significant ICAM-l expression by tubules
(19 5% DSP and 24 6% untreated vs 9 2% normal, P < 0.05) and
interstitial cells (354 57 cells/mm2 and 298 55 cells/mm2 vs 98 40
cells/mm2 normal, P < 0.05). However, in untreated animals, upregu-
lation of tubular and interstitial cell ICAM-1 expression was apparent
and peaked over days 14—21 (60%—71% of tubules and 571—906/intersti-
tial cells/mm2); most ICAM- I + cellswere localised to the areas of tissue
damage. In contrast to untreated animals, from day 14 onwards, DSP
treatment significantly suppressed ICAM-l expression on both tubules
(50% , P < 0.01) and interstitial cells (45% , P < 0.05), which was
associated with a reduction in interstitial macrophage (80% , P <
0.001) and LFA-1f3 cell (50% , P < 0.05) accumulation and a marked
suppression of renal injury. In conclusion, suppression of ICAM-i
expression within the kidney may be a mechanism by which DSP
treatment inhibits interstitial macrophage infiltration.
Increased tubular EGF production during recovery from acute tubu-
lointerstitial damage in anti-Thy-I nephritis. *D.J. Nikolic-Paterson,
G.H. Tesch, HI'. Lan, K. Nukii, R.C. Atkins, Dept. of Nephrology,
Monash Medical Centre, Clayton, Victoria 3168, Australia. A single
injection of anti-Thy-i antibody into rats causes acute glomerular injury
and tubulointerstitial damage which resolve within I month. It is known
that increased EGF production plays a role in tubular regeneration
following acute ischaemic injury, therefore we analyzed EGF produc-
tion during recovery of acute tubulointerstitial damage in this model.
Inbred Wistar rats (150 g) were injected i.v. with 5 mg/kg body weight
OX-7 (anti-Thy-i) IgG. Groups of animals were killed on days 1, 4, 8,
14, and 28 after injection. Deposition of OX-7 IgG was evident in the
mesangium and on peritubular capillaries in the cortex and medulla.
Glomerular injury (proteinuria) peaked on day 4 (74 20 mg/24 hrs) and
returned to normal range on day 14 (14 4 mg/24 hrs). There was a
significant decrease in renal function at day 8 identified by raised serum
creatinine (j' 20% vs normal, P < 0.05)) and serum urea (C 140%, P <
0.05), and a fall in creatinine clearance ( 35%, P < 0.05). Normal renal
function was recovered by day 14. Histologically, tubular necrosis and
cast formation peaked on day 8 and this recovered to normal tubular
structure by day 28. EGF mRNA production was quantitated by
Northern blot analysis of total cellular RNA extracted from a half
kidney. Relative to a f-actin control, EGF mRNA levels fell to 30—40%
of that of normal kidney on days 1—8, recovered to normal levels on day
14 and was increased to 240% of normal on day 28. Detection of EGF
protein by immunoperoxidase staining of cryostat tissue sections
showed that the distinctive distribution pattern of EGF protein was
unaltered during the disease, but that the intensity of the staining
reaction in proximal tubules was markedly increased on day 28. In
conclusion, increased tubular EGF production may play a role in the
recovery of tubulointerstitial damage during anti-Thy-i nephritis.
Treatment of Heymann's nephritis with monoclonal antibodies to T
cells surface molecules. Austin Spinelli, Cesar G. Quiza, Bruce M.
Hall*, Department of Medicine, Stanford University, Stanford, CA
94205. T cell effectors may contribute to giomerular injury in Heymann
Nephritis (HN), (mt. Immunol., 1992, 4, 423) a rat model akin to
membranous nephropathy in man. Treatment with mAb to T cell
markers CD4, CD8 or TCR can inhibit induction of HN. This study
examined the effect of mAb therapy on established nephrosis by
starting treatment at 6 weeks postimmunization and continuing for 6
weeks and was compared to treatment commenced on the day of
immunization. Biopsies, autoantibodies and proteinuria were assessed
at 4, 8 and 12 weeks. The table summarizes the 24 hour protein in urine
at 8 weeks, and compares to untreated controls 597 199 mg/d and
unimmunized controls 8 1 mg/d.
Early
treatment
Late
treatment
antiCD3 6±2 373±120
antiCD4 5±2 746±121
anti CD8 239 72 547 251
anti CD4 + CD8 NT 448 200
anti TCR 479 14 651 114
cyclosporine 51 21 790 125
The proteinuria results are consistent with antibody and biopsy find-
ings. These studies demonstrate that therapy with anti CD3, anti CD4
prevented induction of disease and both cyclosporine and anti CD8
therapy reduced severity. Reversal of disease was not achieved with
any antibody, however. These studies demonstrate that whilst therapies
directed at T cells were incapable of reversing effector mechanisms of
HN.
Is myocardial ischaemia in dialysis patients "silent" due to autonomic
neuropathy? S.J. Coulshed", D.F. Gray, D.S. Coulshed, PA.
Johnston, A.M. Davison, E.J. Will, St. James's University Hospital,
Beckett Street, Leeds, LS9 7TF, United Kingdom. Silent ischaemia has
been shown to be predictive of subsequent myocardial infarction or
sudden death. Deaths from cardiovascular disease account for 50% of
the mortality on renal replacement therapy, and 12% of these are
sudden (EDTA 1992). We undertook exercise stress testing in 75
dialysis patients, average age 50.5 years (range 13 to 87). All tests were
symptom-limited. Myocardial ischaemia was defined as 1 mm ST
segment depression during exercise. Patients had a high average heart
rate (89.5 14 bpm). They were able to achieve an average maximum
heart rate of only 79.9 12.3% of their predicted value. 25 of the 75
patients developed ischaemic patterns on their ECG's. Only 4 (16%) of
these complained of chest pain. Since silent ischaemia implies impaired
cardiac sensation, cardiac autonomic function was investigated using 24
hour Hölter monitoring to measure heart rate variability (HRV). This
was quantified using the St. George's Index (SGI), a simple, reproduc-
ible, numerical index of beat-to-beat HRV. A reduced SGI (<25) has
been shown to be a poor prognostic factor in patients with heart failure,
or after myocardial infarction. Dysautonomia was common, with a
mean SGI of 21.1 10.5. The difference in HRV between the ischaemic(SGI = 18.6 7.6) and the nonischaemic (22.3 11.2) groups was not
statistically significant (P = 0.15). The two groups were well-matched
for age, diabetes, Hb, urea, creatinine, CaPO4 and medication. Left
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ventricular hypertrophy by ECG criteria occurred in 48% of the
non-ischaemics and in 76% of the ischaemics (NS). There were 6 deaths
during the six-month follow up period. 3 (50%) had shown myocardial
ischaemia compared to 21/68 (31%) alive (NS). SGI was significantly
reduced in those dying (SGI—12.4 11) compared to those surviving(SGI = 22 9.9) (P < 0.03). Both silent ischaemia and dysautonomia
are common in dialysis patients. There is no apparent link between the
two and the prognostic implications need further, prospective study.
Altered haemorheology in the pathogenesis of diabetic nephropathy.
B.I. Shand*, R.R. Bailey, P.J. Graham, K.L. Lynn and R.A. Robson,
Departments of Nephrology & Community Health, Christchurch Hos-
pital, Christchurch. This study aimed to determine whether haemorhe-
ology (blood viscosity) differed in diabetic patients with and without
diabetic nephropathy and to investigate the relationship between
changes in blood viscosity and renal function. Haemorheology, GFR,
blood pressure and glycaemic control were measured 4 times at 6
monthly intervals in diabetics with either normal renal function and no
proteinuria [N = 27], microalbuminuna [N = 13], or nephropathy (overt
proteinuria) [N = 21]. Differences between the groups were assessed by
ANOVA, while the relationships between the variables were investi-
gated by correlation and regression analyses. There were no significant
differences in blood pressure or glycaemic control between the 3 patient
groups. Haemorheology profiles were similar in the diabetics with
normal renal function and microalbuminuria. Despite having signifi-
cantly lower (P < 0.05) haematocrits and therefore blood viscosity,
patients with nephropathy were shown to have marked changes in
qualitative haemorheological properties (ie, decreased red blood cell
deformability [P = 0.008] and raised plasma viscosity [P = 0.001]). No
consistent, significant associations or time relationships were found
between changes in haemorheology, and any of the other clinical
indices within the 3 patient groups. These results indicate that marked
haemorheological abnormalities in diabetes occur secondary to the
development of nephropathy and are not related to any change in
glycaemic control. These changes may negate the protective effect that
relatively low haematocrit levels have on blood viscosity and thereby
contribute to the multifactorial pathogenesis of diabetic vascular dis-
ease.
Preservation of urine for diagnostic microscopy. A. Anpalahan, D.
Birch, G. Becker, Department of Nephrology, Royal Melbourne Hos-
pital, Victoria 3050, Australia. A major difficulty in diagnostic urinary
microscopy is the need to observe a freshly passed urine specimen. We
have therefore studied methods of preserving the urinary sediment,
using common histological fixatives. Initial experiments using venous
red blood cells (RBC) showed that (of glutaraldehyde (GA), formalde-
hyde, methyl alcohol, ethyl alcohol, carbowax and no fixative) GA
0.5% in PBS gave the best morphological fixation, when assessed at 24
hours. In experiments assessing GA 0.5% in fixing midstream urine
specimens and recording the outcome by photomicroscopy the follow-
ing observations have been made: (i) GA 0.5% in whole urine causes a
precipitate to form if there is trace or more proteinuria. This can be
eliminated by centrifugation and resuspension of the sediment 1:20 in
PBS before fixation. (ii) Centrifugation leads to a reduction in RBC
concentration by 30—60%. (iii) Urinary sediment (cells, casts and
crystals) retains similar morphological features for up to 6 weeks at
room temperature if fixed in GA 0.5%. (iv) After 6 weeks cell wall
distortion occurs. We conclude that resuspension of the urinary sedi-
ment in 0.5% GA at room temperature provides a storage medium to
allow transport and diagnostic microscopy up to 6 weeks later. This
should prove useful in situations where the equipment or expertise for
adequate diagnostic microscopy are not locally or immediately avail-
able, and to store urine for teaching purposes.
IgA nephropathy: clinical prediction of outcome. D.K. Packham*,
H.D. Yan, T. Hewitson, P.S. Kincaid-Smith, G.J. Becker, Department
of Nephrology, The Royal Melbourne Hospital. The clinical course of
844 consecutive patients with IgA nephropathy presenting between
1970 and 1991 have been studied. Five hundred and twenty-two patients
were male (62%), 322 were females (38%). The mean interval of
symptoms prior to renal biopsy was 26 months (range 0—552 months)
and the period of followup 52 months (range 0—336 months). Two
hundred and fifteen (29%) of patients presented with the serum creati-
nine of 0. 12 mmolIl. Two hundred and ninety-one patients (34%) were
either hypertensive or on hypertensive medication at the time of
presentation. The mean blood pressure of the hypertensive group was
156/97 compared with 125/78 mm Hg in the normotensive group. Three
hundred and eighteen patients (38%) presented with macroscopic
haematuria and 221 (26%) had loin pain. At the end of followup 145
(17%) had developed either chronic renal failure (CRF) (Cr > 0.2
mmol/l) or kidney death. Progression to renal impairment correlated
strongly with male gender; 22% of males progressing vs 9% of females
(P < 0.0001). Similarly, age at presentation was a strong predicted
factor with 14% of patients <40 y.o. progressing to CRF compared with
25% of patients 40 y.o. (P <0.0001). The presence of hypertension at
presentation correlated with progression (P < 0.0001). Patients present-
ing with macroscopic haematuria or loin pain were no more likely to
develop CRF or kidney death. Of patients who presented with a Cr
0. 12, hypertension and proteinuria, 37% progressed to CRF or kidney
death. Seventeen percent of patients presenting with hypertension and
proteinuria progressed to CRF or kidney death and 18% of patients
presenting with proteinuria progressed to CRF or kidney death.
Accelerated growth in short children with chronic renal failure treated
with both strict dietary therapy and recombinant growth hormone. K.
Jureidini*, M. van Renen, R. Hogg, A. Sweeney, P. Henning, J.
Penfold, Renal Unit, Departments of Nutrition & Dietetics, and
Endocrinology & Diabetes, Adelaide Children's Hospital, Adelaide,
South Australia 5006. Nine boys with severe chronic renal failure aged
between 4.8 and 15.6 years at the onset of the study, who have
previously been reported after one year's treatment, have had a further
12 months' therapy with recombinant human growth hormone
(Genotropin, Kabi, 30 IU/m2/week). They have continued on a strict
low protein, low phosphate diet supplemented with keto and amino
forms of the essential amino acids and histidine and additional energy.
They have been divided into two groups—prepubertal (testicular vol-
ume <8 ml at end of treatment, N = 5) and pubertal (testicular volume
>8 ml, N = 4). Mean height velocity in both groups remained
significantly greater in the second year of treatment compared with at
the onset of the study two years previously, but growth proceeded at a
lesser rate than in the first year. The rate of deterioration of renal
function remained unchanged compared with the first year although five
children entered the dialysis program during this second year as
predicted. Bone age advanced 12 months during the second 12 month
period. There appeared to be no ill effects. Recombinant human growth
hormone appears to be safe and effective in treating children with
chronic renal failure for two years, although the growth rate, while
remaining improved, slows down in the second year of treatment.
Comparison of retinol binding protein, B2 microglobulin and N acetyl
beta glucosaminidase excretion in children with vesico-ureteric reflux. W.
Wong, R.J. Hogg, S. Harris, P. Henning, K.J. Jureidini, Renal Unit,
Adelaide Children's Hospital, North Adelaide, South Australia, 5006.
Urine from children with vesicouretric refiux documented at the time of
voiding cystourethrography was measured for retinol binding protein
(RBP), B2 microglobulin and N acetyl beta glucosaminidase (NAG).
Normal control values for NAG mean 130 + 4.9 SEM nmollmmol
creatinine) were derived from 187 normal children as a part of larger
study involving kindergarten school children. Normal values for RBP
and B2 microglobulin were derived a previous study. Forty-eight
children with refiux were studied with the following distribution: Grade
1 (8), Grade 2 (10), Grade 3 (17), Grade 4 (9) and Grade 5 (4). Mean
NAG excretion was significantly higher in all grades of reflux when
compared with the normal, with progressively higher values with
increasing grade of reflux (P < 0.01) when compared to normal. Only 24
of 48(50%) of patients with reflux had elevated NAG levels with only 14
of 30 (47%) patients with grade 3 refiux or higher had significantly
elevated levels of NAG. RBP showed a progressive rise with increasing
severity of refiux however all values remained within the normal range.
B2 microglobulin levels showed no relationship to the degree of reflux
except with grade 5 reflux where mean values were markedly elevated.
Ten children with documented scars on 99m Technetium-dimercapto-
succinic acid scan (DMSA) had higher levels of NAG excretion
irrespective of the severity of reflux when compared to patients without
scars. NAG identified 70% of patients with documented scars RBP and
B2 microglobulin levels showed no relation to the presence or absence
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of scarring and did not correlate with the degree of reflux. In conclusion
tubular proteinuria using NAG identified different groups of patients
with reflux and appeared to be more sensitive than RBP or B2
microglobulin.
Tubular nephrotoxicity following cardiac surgery. J. Westhuyzenl*,
D.C. McGiffen2, J. McCarthy3, S.J. Fleming4, 'Conjoint Internal
Medicine Laboratory, Departments of Pathology and 4Renal Medicine,
Royal Brisbane Hospital; 2Cardiac Surgical Research and 3lntensive
Care Unit, The Prince Charles Hospital, Brisbane, Australia. Although
cardiac surgery utilising cardiopulmonary bypass (CPB) is now a
relatively safe procedure, the occasional patient may suffer multi-organ
dysfunction including renal failure. The present study examines renal
function in 21 adult patients after cardiac surgery (16 male, 5 female,
mean age 57.4 yrs), utilising sensitive methods for determining proximal
tubular damage. Bypass time averaged 73.6 mm and cross-clamp time
43.0 mm. Patients undergoing thoracic surgery without CPB served as
controls (N = 6). In the cardiac surgical group, postoperative urine
outputs were very high (250—300 mI/hr at 1—2 hrs) but dropped rapidly,
reaching 100 mI/hr by 6 hrs. Creatinine clearances decreased from 102
28 mllmin (mean SD) preoperatively to 78 40 mI/mm at 4 hrs
before increasing to 130 57 mI/mm at 48 hrs, but these changes were
not significant (P = 0.07). There were significant changes in the three
markers of tubular damage studied (P < 0.001). Urinary levels of
/32-microglobulin increased by two orders of magnitude, from a baseline
of 0.28 0.92 mg/L to a postoperative peak of 29.7 16.9 mg/L at 12
hrs. Levels of the brush border antigen adenosine deaminase binding
protein increased 8-fold, from 0.07 0.07 AU to 0.55 0.40 AU at 48
hrs. The lysosomal enzyme N-acetyl-13-D-glucosaminidase increased
nearly 6-fold, from 7.5 5.9 U/L to 39.8 24.9 U/L at 48 hrs. There
were no significant changes in these markers in the control group. Our
results suggest that cardiac surgery employing CPB is associated with
acute tubular injury.
Aboriginal renal failure; more, . . . and more difilcult. David Pugs-
ley*, T.H. Mathew, A.P.S. Disney, G.R. Russ, M. Kirubakaran and V.
Soden, Renal Unit, The Queen Elizabeth Hospital, Woodville, SA,
5011, Alice Springs Hospital NT., Royal Darwin Hospital, NT. The
number of Australian Aborigines (AA) entering end-stage renal failure
programmes (ESRF) has increased dramatically in recent years. In
South Australia (SA) and the Northern Territory (NT) 40% of the total
number of Aborigines who have entered the ESRF programme since
1972 did so within the last three years. The current rate of entry to
programmes is 450 patients/million—around eight times the figure for
the whole of Australia. In earlier years the majority of these patients
were aged between 20 and 50 years, but 60% of the patients who started
such treatment in the last year exceeded 50 years of age. The unad-
justed integrated survival of AA patients in SA and NT with ESRF is
not significantly different from that of other Australians in the same
ESRF programmes. Following renal transplantation, AA patient and
graft survivals in SA and NT are 92% and 83% respectively after twelve
months (N = 46, transplanted since 1983). By the time that three years
have elapsed however, these figures have fallen to 60% and 48%. These
results are significantly worse than for the comparable non-Aboriginal
population (N = 393 over a similar period). Examination of the results
from the group of patients who have undergone living related donor
transplantation showed that they have not fared better. The reasons for
these disappointing results appear to lie in problems of compliance with
anti-rejection treatment over a prolonged period. There is also a marked
rate of serious infection which makes a substantial contribution to the
high patient mortality. It is clear that aspects of the traditional life style
of AA, and the social disadvantages which they endure, provide
barriers to the successful management of chronic renal disease that
advanced medical techniques, of themselves, will not readily be able to
overcome.
Serum and urinary endothelin 1 in mild chronic renal failure. B.
Thatcher, A. Barden, A. St.John, I. Surveyor, K. Warr, L. Beilin, M.
Thomas*, Depts. of Internal Medicine, Nephrology, Biochemistry &
Nuclear Medicine, Royal Perth Hospital, Perth WA 6000. To determine
the effect of the type and degree of renal impairment on the urinary
excretion of endothelin, 24 hour urine samples were collected from 22
patients (l4M:8F, age 25—71) with stable chronic renal failure and
compared with 12 normal subjects (7M:5F, age 36—54) in a cross-
sectional study. Renal impairment was due to GN in 8 (2 with diabetes),
chronic interstitial nephntis in 8, and presumed nephrosclerosis in 6.
Glomerular filtration rate was measured by Tc99M isotopic clearance.
Plasma and urinary endothelin (corrected for creatinine excretion) were
measured by RIA after Amprep C2 column extraction; (7—17% cross-
reactivity of anti-ET1 with ET2/ET3/big ET, sensitivity 2 pg/ml, inter-
assay COV 11%). Results were expressed as mean sD; statistical
comparisons were by t-test, correlations by Pearson's test.
GFR
(mIs/mm)
U Prot
(g/day)
S Endoth
(pg/ml)
U Endoth
(pg/ml)
Normals 102 11 0.17 0.07 6.8 1.2 47.0 29.2
CRF 55 19 0.9 0.9 6.95 3.4 70.5 58.4
Signif. P = 0.000 P = 0.000 P = n.s. P = n.s.
Serum and urinary endothelin 1 levels did not differ between normal and
CRF patients. By univariate and multivariate analysis, urinary endo-
thelin levels showed no independent determinants. These results sug-
gest that endothelin metabolism is not significantly altered in the
presence of mild CRF.
Dysautonomia as a predictor of subsequent mortality in dialysis pa-
tients. S.J. Coulshed*, D.S. Coulshed, D.F. Gray, V. Jassal, AM.
Davison, E.J. Will, Renal Unit, St. James's University Hospital,
Beckett Street, Leeds, LS9 7TF, United Kingdom. Autonomic neurop-
athy is common in patients with chronic renal failure, but has been
difficult to quantify in a simple, reliable and reproducible way. Heart
rate variability (HRV) has been shown to be an accurate measure of
autonomic function and is easily measured by 24 hour Hölter monitor-
ing. We have investigated 150 haemodialysis and 30 CAPD patients
prospectively using 24 hour monitoring to measure HRV. These pa-
tients were chosen at random from our dialysis programme and mean
follow-up was 12 10 months. Patients were monitored with a
Reynolds "Tracker" HOlter monitor and the tapes were processed on a
Reynolds "Professional" analyser. We then calculated the St. George's
Index (SGI), a simple numerical method to quantify HRV. This method
is resistant to the confounding effects of artefactual potentials and
frequent ventricular ectopic beats. The method is non invasive and does
not depend on patient cooperation. We also analysed the recordings for
arrhythmias. In a subset of 40 patients there was a good correlation
between dysautonomia measured by SGI and four clinical tests of
cardiovascular function. We have found the SGI to be reduced in
dialysis patients, mean SGI = 21.5 10.2 (N  25). In those who have
subsequently died SGI 16.6 8.2 which differed significantly with
those still alive the SGI = 23.0 10.4 (P < 0.001). Cardiac arrhythmias,
although frequent, have not been a reliable predictor of mortality
although they have been associated with morbidity and poor dialysis
tolerance. This is no significant relation between arrhythmias and HRV.
We have demonstrated that low HRV is significantly correlated with
subsequent mortality. A relationship between dysautonomia, silent
myocardial ischaemia and dialysis adequacy would explain these find-
ings.
Kindergarten screening programme for detection of renal disorders. K.
Jureidini*, C. Lamb, S. Harris, R. Hogg, N. Wigg, P. Henning, D.
Lawrence, H. Marshall, J. Tonkin, M. van Renen, Renal Unit, Ade-
laide Children's Hospital, Adelaide, South Australia 5006. 7300 kinder-
garten children have been screened for renal disease by measuring
blood pressure, growth percentiles, and frozen first morning urine for
blood, protein, glucose, nitrites and Beta-2 microglobulin (f32M). The
screening abnormality rate was 6.6% (blood pressure >99th percentile
for age 1.1%, elevated /32M 2.4%, proteinuria 0.15%, haematuria 2.3%,
nitrites 0.26%, height significantly reduced 0.3%). Identified children
were followed by clinical investigation, repeat urine assays and renal
ultrasound where indicated. On review, 10.9% of those initially hyper-
tensive had persistent hypertension resulting in the detection of aortic
coarctation (1), Wilm's tumour (1), new vesico-ureteric refiux (VUR)
(2) and old VUR (4). Of those children detected with raised /32M, 2.3%
showed persistently ralsed levels. Abnormalities detected were nephri-
tis (1), idiopathic hypercalciuria (1), renal dysplasia (1) and old VUR
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(1). In those detected with haematuria andlor proteinuria the following
abnormalities were found—biopsy proven significant nephritis (3),
persistent proteinuria and/or haematuria (26), VUR (1) and dominant
polycystic kidneys (1). Of those detected with nitrites, 83% (12) showed
positive urinary tract infections requiring treatment and one had VUR.
The study suggests the screening programme is effective in detecting
renal abnormalities. The use of frozen first morning urine specimens
reduces the false positive rate for proteinuria and haematuria, and
facilitates urine collection while allowing measurement of 132M.
Parathyroid hormone (PTH) suppression by oral calcium in mild
chronic renal failure (CRF). A. St.John, M. Thomas*, I. Surveyor, K.
Warr, B. Ng, R. Prince', Depts. of Biochemistry, Nephrology &
Nuclear Medicine, Royal Perth Hospital; Dept. of Medicine', Sir
Charles Gairdiner Hospital, Perth WA 6000. Since the advent of intact
PTH assays, the dynamic PTH-calcium relationship has been studied in
normal and dialysis patients, (using iv infusion techniques) but not in
mild CRF. To study the effect of mild CRF on the suppressibility of
PTH, serum samples were collected at 0, 30, 60, 120 & 180 minutes
following 2 g elemental calcium (Sandocal 1000) orally. 15 fasting
normal subjects and 21 age-matched patients with mild CRF (GFR 100
12 vs 57 13 mls/min by isotopic clearance, P = 0.000) were studied,
achieving rises in ionised calcium of 0.11 0.03 mmolIl (Normals vs
CRF, P = n.s.). Intact P'f H was measured by immunochemilumino-
metric assay (normal range = 1.0—5.5 pmol/l), and statistical compari-
sons made by Mann-Whitney U-test.
Ca
basal
PTH
basal
PTH
mm
% PTH
fall
Free 1,25
Vit D
Normals 1.22 0.24 2.6 1.0 0.7 0.3 72 10 12.8 4.0
CRF 1.25 0.50 3.7 1.7 1.3 0.7 63 9 8.7 2.8
Signif n.s. <0.03 <0.003 <0.005 <0.003
By univariate analysis, the per cent fall in PTH correlated significantly
with GFR (r = 0.44,P = 0.01), but not baseline PTH, free 1,25 vitamin
D concentration, urinary P04 or serum HCO3. Compared to normal
renal function, mild CRF is associated with decreased free 1,25 vitamin
D, an increase in calcium-independent nonsuppressible intact PTH
concentration and a right-shift in the intact PTH-calcium titration
curve.
Hypertension, ventricular hypertrophy and diastolic dysfunction with
erythropoietin. S.D. Roger*, M. Giles, A.E.G. Raine, Dept. Nephrol-
ogy, St. Bartholomew's Hospital, London, ECIA 7BE, UK. Cardiac
dysfunction accounts for a major proportion of the morbidity and
mortality in dialysis patients. Diastolic function was therefore assessed
by M-mode and Doppler echocardiography in 28 dialysis patients (ages
27—71 years; dialysis duration 6—250 months) receiving either haemodi-
alysis (N = 17)or CAPD (N = 11). They were treated with recombinant
human erythropoietin (r-HuEPO) 50 U/kg 3 times/week for 12.6 1.4
weeks to correct anaemia (Hb: 7.3 0.3 vs 11.0 0.1 gldl, P < 0.0001).
In 13 patients mean blood pressure rose by at least 15 mm Hg during
this period. Compared to baseline, pulsed Doppler echocardiography
showed a fall in Emax (79 6 vs 64 6 cm/s, P <0.001), E/A ratio (1.23
0.14 vs 1.04 0.15, P <0.01) and peak filling rate (5.72 0.65 vs 4.10
0.55 us, P < 0.01) following correction of anaemia in the group that
did not increase their blood pressure. These changes were associated
with a significant fall in cardiac output in that group (4.92 0.35 vs 3.64
0.28 I/mm, P < 0.01) but not in the group that had an increase in blood
pressure (4.50 0.44 vs 3.74 0.28 1/mm, P = NS). Left ventricular
and atrial size were unaltered. There was no change in left ventricular
mass at the time target haemoglobin had been reached (181 14 vs 175
15 g/m2 (N = 22)) however a reduction had occurred after 12 months
of treatment (145 16 g/m2 (N = 12), P < 0.01) in both blood pressure
responders and non-responders. In conclusion, r-HuEPO therapy is
associated with diminished early diastolic filling in patients who main-
tain a stable blood pressure when uraemic anaemia is corrected. This
suggests impaired diastolic relaxation occurring in conjunction with
reduced cardiac output may limit the blood pressure response to
r-HuEPO.
Glycine betaine in human blood and urine. P. Sizeland*, S. Chambers,
M. Lever, L. Bason, R. Robson, Departments of Nephrology, Infec-
tious Diseases and Biochemistry, Christchurch Hospital, New Zealand.
Glycine betaine (GB) is an osmoprotectant in the mammalian kidney.
Most studies suggest that it is accumulated in medullary cells by a
sodium co-transport system. A sensitive assay for GB has been
developed. This study was designed to establish a reference range for
plasma and urine GB, and to compare its renal handling with a closely
related compound, proline betaine (PB). A healthy population was
age-stratified and urine and plasma samples analysed. Results were
(median (95% CI)):
Age N
Plasma GB
(prnolll)
Urine GB
(mmollmol creatinine)
<1 month 18 26.6 (18—41) 416 (195—980)
2 to 5 years 17 — 31(11—162)
6 to 10 years 17 — 9 (4—28)
>10 years 72 34(18—61) 8(3—41)
The fractional clearance for GB was 1.3% (0.5—5.5%) and there was no
relationship evident between plasma and urinary levels. In contrast, the
fractional clearance for PB was 32% (4.0> 100%) and there was a close
correlation between plasma and urine levels (r = 0.81, P < 0.001). We
conclude that: (1) the high urine GB levels in the young probably reflect
the reduced requirement of the kidney for osmoprotectants as a result
of the immature urinary concentrating mechanism, and (2) the low
fractional clearance of GB suggests that accumulation of GB by kidney
cells is at least partially dependent on uptake of GB from the surround-
ing tissues.
Improvement of growth in rats with chronic renal failure following GH
and/or IGF-I treatment. S.f. Hazel', C.M. Gillespie, L.C. Read, A.A.
Martin, Child Health Research Institute and Co-operative Research
Centre for Tissue Growth and Repair, 72 King William Rd, North
Adelaide, SA, 5006. Growth hormone (GH) is currently used to improve
growth in children with chronic renal failure. However, as chronic renal
failure appears to be a GH resistant state, insulin-like growth factor-I
(IGF-I), which mediates some of the growth effects of GH, may offer
more promise in promoting growth either alone or in combination with
GH. The aim of this study was to compare the efficacy of GH and/or
IGF-I, in promoting growth using a rat model of chronic renal failure
and growth retardation. Female SD rats of 60—100 g body weight
underwent a two stage operation with 2/3 resection of the right kidney
followed by removal of the left kidney 2 days later. Seven weeks after
surgery treatment commenced for 7 days using 420 g/d of IGF-I
infused by subcutaneous osmotic minipump, 500 ,ild of GH by daily
subcutaneous injection, a combination of IGF-I and GH as above, and
vehicle treatment, with eight rats per group. Treatment with IGF-I, GH
and IGF-I + GH significantly improved weight gain over 7 days
compared to vehicle (23.4 1.6, 28.7 1.9, 39 1.7, and 4.2 1.7 g
respectively; mean SEM P < 0.001) with IGF-I + GH treated rats
increasing in weight more than the GH or IGF-I groups (P < 0.001) and
GH causing more effect than IGF-I (P < 0.05). Snout to tail length was
significantly increased in the IGF-I and combination treatment groups
compared to the vehicle treated group (P < 0.05). GH treatment caused
a significant increase in food consumption compared to the vehicle,
IGF-I and IGF-I + GH groups (6.5 0.1 vs 6.1 0.2, 6.0 0.1 and 6.0
0.1 g/100 g bw/d respectively, P < 0.05). The efficiency of food
utilization was significantly improved in the IGF-I, GH and IGF-I + GH
compared to the vehicle group (24.83 1.24, 27.50 1.57, 39.63 1.59
and 0.06 0.03% respectively) with the IGF-I + GH group being
significantly greater than the IGF-I or GH groups (P < 0.05), and no
significant difference between the IGF-I and GH groups. Glomerular
filtration was not affected by treatment since creatinine clearance did
not change over the treatment period in any group, and no significant
difference in the remnant kidney weight was found between groups. In
summary, both GH and IGF-I have significant growth effects in this
model of chronic renal failure and growth retardation.
Differential regulation of Vi and V2 vasopressin receptors in diabetes
mellitus. PA. Phillips*, D. Trinder, J. Stephenson, J. Risvanis, M.
Cooper, and CI. Johnston, Department of Medicine, University of
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Melbourne, Austin Hospital, Heidelberg 3084, Victoria. Diabetes mel-
litus causes hyperglycaemia, hypertonicity, polydipsia and polyuria. As
downregulation of AVP V2 receptors might contribute to the polyuria
through diminished V2 receptor mediated free water retention, we
investigated the effect of raised plasma [AVP] on VI and V2 AVP
receptors and their respective second messengers. Female Sprague-
Dawley rats (150—200 g) received 55 mg/kg i.p. streptozotocin or saline.
Over the next two weeks half the diabetic rats received 4 U ultralite
insulin s.c. daily. After sacrifice, plasma [AVP] and [glucose] were
measured. Selective VI and V2 antagonist radioligands were used to
determine liver VI and renal V 1 and V2 receptor numbers (Bmax) and
affinities (Kd) by Scatchard analysis. Vi and V2 receptor second
messenger activity were determined by AVP stimulated total inositol
phosphate production and renal cAMP generation respectively. Diabe-
tes significantly increased plasma [AVP], osmolality and [glucose] (P <
0.001). Insulin partially lowered these. Renal and hepatic VI receptor
Bmax and total inositol phosphate production were downregulated (P <
0.05) with diabetes and insulin treated diabetes without change in Kd.
Renal V2 receptors and cAMP generation were not changed.
Control Diabetes Insulin
AVP 4.6 0.5 8.9 0.6 6.7 0.5 pg/ml
Liver Vi Bmax 98 15 24 2 30 4 fmollmg
Renal Vl
Renal V2
Bmax
Bmax
49 6
99 19
30 4
94 13
32 4
97 1
fmol/mg
fmol/mg
These results demonstrate differential regulation of AVP receptors and
suggest that downregulation of renal V2 receptors does not contribute
to the polyuna of diabetes.
Abnormalities of the glomerular angiotensin II receptor in experimen-
tal diabetic nephropathy. M. Makarious*, K. Duggan, J. Charlesworth,
G.J. Macdonald, Department of Nephrology, Prince Henry Hospital,
Little Bay, NSW 2036. The development of nephropathy in human and
experimental diabetes has been linked to glomerular hyperfiltration and
previous studies suggest that the renin-angiotensin system plays a role
in the pathogenesis of this abnormality. This work examined the
effect(s) of blood glucose control and pre-existing hypertension on the
relationship between plasma angiotensin II (All) and its glomerular
receptor in an experimental model of diabetes. Diabetes was induced in
spontaneously hypertensive rats (SHR) and their normotensive control
strain, Wistar Kyoto rats (WKY) and animals maintained with either
poor or strict blood glucose control. They were sacrificed at 1, 7 or 30
days, plasma All measured by RIA and glomerular All receptors
analysed by Scatchard using the iterative program, LIGAND. Prior to
diabetes both groups of rats showed an inverse relationship between
plasma All and receptor number (AII-R), although AII-R and creatinine
clearance were higher in the SHR. Plasma All and AII-R remained
normal in WKYs 7 days' post-diabetes irrespective of blood glucose
control. However, plasma All levels were lower in the well-controlled
SHR compared to poorly-controlled animals (P = 0.0002). Also,
diabetic WKYs maintained a significant inverse correlation between
All & AII-R (P < 0.05)) while this was lost in the SHR. Poorly-
controlled SHRs had a reduced creatinine clearance compared to their
sham (P = 0.02), although normal levels were restored with adequate
diabetes control. At 30 days, both groups showed a reduction in plasma
All and All-R, irrespective of blood glucose control, and with mainte-
nance of the AII/AII-R relationship in the WKY group. Creatinine
clearance was higher in the well controlled SHR (P = 0.006) than in
poorly controlled animals, while no difference was observed in the
WKY rats irrespective of diabetes control. We conclude that induction
of diabetes is followed by loss of the AII/AII-R relationship in the SHR.
This lack of appropriate receptor response to varying ligand concentra-
tion may contribute to the development of nephropathy in these
animals.
Response to acute saline loading in cirrhosis. M.A. Lonergan*, S.
Aglibut and M.J. Field, Department of Medicine, University of Sydney,
Concord Hospital, NSW 2139, Australia. To facilitate studies of the
pathogenesis of sodium and water retention in cirrhosis, we have
devised a protocol for evaluating the response to acute saline loading in
two rat models of cirrhosis. Sprague-Dawley rats were used for both
models, namely carbon tetrachloride-induced cirrhosis (CC14) and
common bile duct ligation (CBDL). CCI4 rats received pretreatment
with phenobarbitone, then twice weekly CC14 by intramuscular injec-
tion. The dose of CC14 was adjusted for individual rats based on daily
weight changes. The rats were treated for 15 weeks and then studied at
a minimum of one week following the last dose of CC14. The control
group consisted of phenobarbitone-treated rats. CBDL rats had a
laparotomy under Nembutal anaesthesia, followed by ligation of the
upper and lower ends of the bile duct with resection of the intervening
segment. Rats were studied 5 weeks following the surgery. The control
group consisted of sham operated animals. To examine the response to
saline loading, animals were studied under mactin anaesthesia. Ringer's
solution was infused at 1% body weight/h following a priming injection
of 1%. After an equilibrium period, two baseline clearances (20 mm
each) were performed, following which the rate of Ringer's infusion was
increased to 4% body weight/h. After four clearance periods, the
Ringer's solution was reduced back to 1% of body weight/h for two
further periods. Tritiated inulin was included in the infused fluids to
permit calculation of GFR and fractional electrolyte excretion rates.
Significant sodium retention occurred during the acute saline load in
both models. In CC14 rats the increase in fractional excretion of sodium
(AFENa) was 0.27 0.2 vs 4.12 0.8 (percent of filtered load) in
control (P < 0.01), and absolute Na excretion followed a similar
pattern. Urine flow rate increased by 3.42 2.5 d1min/l00 g in CC14
versus 56.06 5.7 in control (P < 0.001). In CBDL, AFENa was 1.77
0.6 vs 4.29 0.2% in control (P < 0.01), while A flow was 24.28
5.9 vs 60.0 3.5 (P < 0.001). GFR was not significantly different
between groups in both models. This protocol clearly defines the
impairment in salt and water excretion in cirrhosis, and allows evalua-
tion of interventions to identify potential mediators of this phenome-
non.
The acute effects of ouabain in healthy volunteers. G.B. Pidgeon*,
A.M. Richards, M.G. Nicholls, E.A. Espiner, T.G. Yandle, Depart-
ments of Nephrology, Cardiology and Endocrinology, Christchurch
Hospital, Christchurch. To assess the acute effects of plant derived
ouabain, 7 normal male subjects were given a single intravenous dose of
ouabain 0.5 mg, in a single-blind, randomised, placebo controlled,
cross-over study. Inulin and PAH infusions were administered to
determine glomerular filtration rate (GFR), and renal blood flow (RBF).
Holter monitoring and manual 15 minute blood pressures and heart
rates were recorded. Hourly urine volumes, and sodium and potassium
excretion were measured. Vasoactive hormones were measured at
hourly intervals. There was a reduction in diastolic blood pressure
during the first 20 minutes after injection (66 2.1 vs 74 4.9mm Hg,P = 0.02), with a trend to increased systolic and pulse pressures.
Minimum and average hourly heart rates fell significantly (P 0.02 and
0.001 respectively). There was no change in GFR, RBF, urine volume,
sodium or potassium excretion. Angiotensin II levels declined signifi-
cantly during the first three hours post injection (6.7 0.6 v 10.9 1.7
pmolll, P = 0.005). Plasma renin activity was reduced. Plasma epineph-
tine and norepmnephrine remained unchanged. Aldosterone was ele-
vated in the first hour post dose (200 41 v 158 33 pmolIl, P 0.08),
without similar change in cortisol. Both plasma atrial natriuretic peptide
(P = 0.01) and plasma brain natriuretic peptide (P = 0.05) were elevated
post-dose, but probably not to a biologically significant extent. Plasma
and urinary levels of cyclic GMP were not significantly altered. Al-
though not confirming ouabain as an acute pressor or natriuretic
substance, this study confirms significant effects on vasoactive hor-
mones. Ouabain may have important modulating effects under patho-
physiologic conditions such as volume overload, congestive heart
failure and hypertension.
Epidermal growth factor (EGF) is diuretic and natriuretic. C.B. Gow
and PA. Phillips*, School of Agriculture, LaTrobe University, Bun-
doora, and *Department of Medicine, University of Melbourne, Austin
Hospital, Heidelberg 3084, Victoria. Epidermal Growth Factor (EGF)
activates Na7H exchange in fibroblasts, depolarizes renal cortical
collecting ducts (CCT) and inhibits arginine vasopressin (AVP)- and
cAMP-stimulated water permeability in isolated CCT in vitro. There-
fore the aim of this study was to determine the effects of EGF infusion
on fluid balance, electrolyte and hormone profiles in vivo. Trial 1. 23
Abstracts 1277
ewes were infused i.v. with saline for 8 days (days 1—8) followed by 0
(controls, N = 6), 2 (low dose, N = 6), 10 (medium dose, N = 6) or 20
(high dose, N = 5) g EGF/hour for 4 days (days 9—12). All ewes then
received a saline infusion for 8 days (days 13—20). During EGF
treatment water intake and urine volume increased in a dose-related
fashion (both P < 0.001). There was no effect of EGF on overall
creatinine clearance, water balance nor plasma Na concentration but
there was a dose-related natriuresis (P < 0.001). PRA and aldosterone
concentrations were increased during infusion of the two higher doses
of EGF (both P < 0.001), but there was no effect of EGF on plasma
AVP or ANP concentrations. Trial II. During a similar experiment ewes
(N = 12) had the amount of water offered during days 9—12 fixed to the
mean drunk over days 1—8. During the period when water intake was
fixed, EGF infusion (10 sg/hr) caused an increase in urine volume (P <
0.05), natriuresis (P < 0.05) and sustained increases in plasma Na (P <
0.01) and AVP (P < 0.001) concentrations. After EGF infusion ad
libitum water intake was increased (P < 0.001) and plasma Na and AVP
levels fell. Trial I demonstrates that in vivo EGF causes concurrent and
sustained polydipsia, polyuria and natriuresis. Results from trial II
suggest that EGF acts as a diuretic, possibly as an antagonist to the
AVP V2 receptor.
Streptomycin-induced alterations in free calcium transients in LLC-
PK1 cells. S.D. Bird*, M.J. Hubbard, R.J. Walker, Division of Health
Sciences, University of Otago, Dunedin, NZ. The effect of conven-
tional antibiotic (penicillin-streptomycin) additives on LLC-PK1 renal
epithelial cells in culture was investigated by measuring growth and
intracellular free calcium (Ca1). Aminoglycosides (streptomycin) can
produce alterations in phospholipid metabolism which may then alter
intracellular calcium. Parallel cultures (3—7 weeks) plus or minus
antibiotics demonstrated no change in Ca1 (measured by fura 2 fluores-
cence) at rest or when challenged with up to 14 mM external calcium.
AVP (10—6 M) produced a significantly higher Ca, (nM) transient in plus
cells compared to minus cells. A similar difference was elicited with
calcium ionophore.
Ca, minus Ca, plus
rest 66.6 6.5 58.0 6.3
AVP 219.0 14.4 279.3 14.8*
ionophore 203.9 10.7 285.8 3.8**
* P < 0.025, **P < 0.001 (N = 5 mean 5EM)
In prolonged culture (>20 weeks) minus cells had slower growth rates
despite no obvious morphological changes. Reverse experiments
changing the antibiotic status in the media produced similar results.
Penicillin-streptomycin reversibly alters some properties of LLC-PK1
cells by altering intracellular calcium homeostasis. This finding has
important implications for cell culture studies of agonist and drug
effects where these additives are in the culture media.
Effects of IGF.I and LR3-IGF-I on kidney function and body growth in
rats with acute renal failure (ARF). A.A. Martin*I, G.M. Gillespie', F.J.
Ballard2 and L.C. Read', Cooperative Research Centre for Tissue
Growth and Repair, at the 'Child Health Research Institute and
2CSIRO Division of Human Nutrition, S.A. Insulin-like growth factor-I
(IGF-I) increases glomerular filtration rate (GFR) in normal humans and
rats, improves the growth rate of sub-totally nephrectomized rats and
may also play a role in the regeneration of renal tubule cells after
transient ischaemia of the kidney. In this study we investigated the
hypothesis that IGF-I administration would increase the rate of recov-
ery of renal function in ARF while, at the same time, improving body
weight gain. Since the LR3 variant form of IGF-I has been shown to be
more potent than IGF-I in vivo, we tested its effects on recovery, in
comparison with IGF-I itself. ARF was produced in male Sprague-
Dawley rats (200—250 g bw) by clamping both renal arteries for 45 mm.
Treatment was commenced at the time of renal artery occlusion with
either vehicle (control group), IGF-I (2.0 mg/kg/d) or LR3-IGF-I (1.5
mg/kg/d) by s.c. osmotic pump for up to 7 d, with rats being held in
metabolism cages. GFR was estimated by the use of 51Cr-EDTA
clearance, with the 51Cr-EDTA being administered by s.c. osmotic
pump. Three days after renal ischaemia GFR was reduced by 75% of
normal in the vehicle-treated group, by 60% in the IGF-I group and by
75% in the LR3-IGF-I group. After 7 d, GFR had recovered back
towards normal levels. Average urine output rose by 42% in controls
over the 7 d of ARF, but rose by only 13.5% and 17.1% in the IGF-I and
LR3-IGF-I groups respectively. At the same time urine osmolality
decreased, particularly in rats treated with LR3-IGF-I, in which frac-
tional excretion of sodium was increased. Body weight gain was
significantly improved from —8 10 g/d in controls to 26 3 g/d with
IGF-I, and to 14 17 g/d with LR3-IGF-I treatment for 7 d. At the same
time nitrogen retention was significantly enhanced over control levels
by 277% with IGF-I treatment and 223% with LR3-IGF-I. This improve-
ment in retention was due to reduced nitrogen excretion rather than
improved intake. We conclude that while IGF-I and LR3-IGF-I increase
body weight gain and nitrogen retention in ARF, there is no improve-
ment in renal function.
Desferrioxamine (DFO) reduces tubular damage in rat remnant kidney
(RK). B.J. Nankivell*, J. Chen, Y.C. Tay, D.C.H. Harris, Dept. of
Renal Medicine, Westmead Hospital, Sydney. Iron accumulates within
proximal tubular lysosomes in the rat and in humans with chronic renal
failure and is associated with tubular damage. Dietary iron restriction
does not prevent tubular iron accumulation or damage in RK due to an
intrinsic deleterious effect of iron deficiency. Therefore, this study
compared the effect of DFO (30 mg/kg/day, via intraperitoneal osmotic
minipump) and DFO chelated to equimolar FeCl3 (DFO-Fe) on tubular
lysosomal iron accumulation, histological damage and renal function in
RK (N = 18) and sham-operated (SO, N = 6 rats). There were no
differences in blood pressure, creatinine clearance, protein excretion or
serum urea, creatinine and iron concentrations in RK or SO rats at 4
weeks. However, in RK the number of iron-containing lysosomes (0.59
0.28 vs 3.13 0.94, mean SEM, P < 0.05) and the mean lysosomal
concentration of iron (12.7 5.0 mg% Fe vs 189.9 32.4, P < 0.001)
was reduced by DFO compared to DFO-Fe, respectively. Furthermore,
tubular damage, assessed semiquantitatively in RK was reduced by
DFO (0.39 0.07 vs 0.94 0.10, P < 0.001). Damage correlated with
the number of iron-containing lysosomes (r = 0.52) and the mean
lysosomal iron-concentration (r = 0.56). In summary, the iron-chelator
DFO reduces proximal tubular uptake of iron and limits tubular damage
in RK, independently of protein excretion and renal function. Further
long-term studies of DFO in RK are required to determine its efficacy in
chronic progressive renal disease.
Short term response of the osmoprotectants to fluid deprivation. P.
Sizeland*, S. Chambers, M. Lever, L. Bason, R. Robson, Departments
of Nephrology, Infectious Diseases and Biochemistry, Christchurch
Hospital, New Zealand. Studies using cell-culture and animal models
have suggested that the osmoprotectants do not subserve a significant
role in the short term adaptation of renal medullary cells to hyperto-
nicity. In contrast, we have shown that in humans the urinary excretion
of the osmoprotectants glycine betaine (GB) and sorbitol (S) rapidly
increase in response to a water load, presumably as a result of efflux of
the osmoprotectants from medullary cells to surrounding tissues. This
current study was designed to measure the short-term response of the
osmoprotectant system to a hypertonic stimulus, as indicated by
changes in the plasma concentration and urinary excretion of GB and S.
Healthy males (N = 6) were administered intra-nasal dDAVP (30 g)
and fluid restricted for 6 hours. Urine minute volume fell (<1 mI/mm)
and osmolality increased (>700 mmol/kg) in all subjects. There were no
significant changes, however, in the urinary excretion of GB and S, or
the plasma concentration of GB during the study period. We conclude
that the osmoprotectants GB and S are not physiologically significant in
the short term response of the medullary cells to high tissue NaC1 and
urea levels. It is probable that the acute response of medullary cells to
hypertonicity involves an increase in inorganic ions, followed by a
slower accumulation of the osmoprotectants.
Renal dysfunction in pre-eclampsia: impaired natriuresis and renin
release following frusemide. MA. Brown*, L. Reiter, M.X. Wang, V.C.
Zammit, M.A. Carlton, G.M. Cario, A. Rodger, J.A. Whitworth,
Departments of Renal Medicine, Medicine and Obstetrics, St. George
Hospital & University of NSW, Kogarah, Sydney NSW 2217. Sodium
retention and reduced plasma active renin concentration (PRC) and
renal prostacyclmn (PgI2) production are characteristic of pre-eclampsia
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(PE). We tested the hypothesis that the reduced PRC of PE was due to
impaired Pg12 release or activity by examining the PRC response to
intravenous (IV) frusemide (F) [a prostacyclin-dependent stimulant of
renin secretioni in 10 normal pregnant women (NP), 9 women with PE
and 10 normal non-pregnant women (N). Six N and five NP women
acted as controls, receiving 2 ml. IV normal saline instead of F. PRC,
aldosterone (aldo) and urinary sodium excretion (UNa) were measured
before, 15, 30 and 60 minutes after IV F. Baseline PRC (but not UNa or
aldo) was reduced in PE compared with NP women [4 (0.6—10.2) vs 6.7
(3.5—15.4) pniol Al/mi/hr. P < 0.05; median, range]. UNa and plasma
aldo rose significantly following F in all groups but did not change in
control subjects. PRC rose significantly only in N and NP women. The
median maximum rises in PRC, aldo and UNa were significantly lower
in PE than NP women. PRC and natriuretic responses to frusemide are
blunted significantly in pre-eclamptic women. This supports the hypoth-
esis that renal prostacyclin deficiency impairs renin release in pre-
eclampsia although other mechanisms may also contribute to these
changes.
Production of vasoactive substances by human late pregnancy decidual
capillary endothelial cells. E.D.M. Gallery*, A. Fry, J. Rowe, C.
Jackson, L. Schrieber, T. Magoulas, R. Penny, Royal North Shore
Hospital and Centre for Immunology at St. Vincent's Hospital, NSW.
Normal pregnancy involves invasion of maternal decidual blood vessels
by cytotrophoblast, not seen in women who develop pre-eclampsia.
The involved maternal vascular tissue may be intrinsically abnormal,
responding to an abnormal stimulus by a circulating factor/s, or to a
feto-placental derived abnormality. We have developed a technique for
isolation and culture of pure human decidual microvascular endothelial
cells (Amer J O&G 165:191—6, 1991), and are currently examining their
production of vasoactive substances. Incubations (4 and 24 h) are
performed in multiwell plates, at passage 2, and results (pg/b6 cells)
compared with those for HUVEC's. Results: The replication of
HUVEC's is significantly faster than decidual capillary endothelial
cells, and not affected by serum from pre-eclamptic women. Both cell
types secrete endothelin 1 and prostacyclin, although the amounts
secreted and time courses are different for the two cell types.
Day 2 (non-confluent) Day 7 (confluent)
NT serum HT serum NT serum HT serum
(a) Endothelin I
HUVE (4 h) 105 29 119 33 41 15 41 10
N dec (4 h) 22 22 23 21 23 12 28 12
HUVE(24h) 196±39 165±37 147±46 148±38
Ndec(24h) 238±42 250±79 228±36 228±49
(b) Prostacyclin
(measured as
6keto PGF1)
HUVE (4 h) 335 66 362 61 — —
N dec (4 h) 126 145* 77 82***
HUVE (24 h) 548 133 478 91 191 31 240 54
Ndec(24h) 547±181 765±214 209±63 244±72
Conclusions: We have developed a technique which is useful for
assessment of decidual capillary endothelial cell function in vitro. There
are both similarities to and differences from the control endothelial cell
population examined. These must be considered in use of cell culture
experiments to gain information about specific disease states.
Clusterin depletion of perfused plasma enhances immune glomerular
injury in the isolated perfused kidney. J.R. Saunders*, A. Aminian#,
J.L. McRae*, K.A. O'Farrell*, W. Adam#, B.F. Murphy*, *Depart
ment of Medicine, St. Vincent's Hospital, #Renal Unit, General
Repatriation Hospital, Heidelberg. Clusterin is a component of SC5b-9
terminal complement complexes and has been detected in glomerular
immune deposits co-localizing with SC5b-9. It has been shown to inhibit
complement mediated haemolysis. We sought to examine, using an
isolated perfused kidney (IPK) model of C5b-9 dependent passive
Heymann nephritis, whether depletion of clusterin in the perfused
human plasma enhanced C5b-9 induced glomerular injury and conse-
quently proteinuria. Each experimental set included two paired perfu-
sions, using human plasma from the one donor. Half of the plasma was
depleted of clusterin by monoclonal antibody affinity chromatography.
As a control, the other half of the plasma was depleted of plasma
fibronectin using a monoclonal antibody column. Three days prior to
perfusion, a nephritic dose of 2 non complement fixing sheep anti-Fx1A
was administered. Each kidney was initially perfused with a standard
IPK perfusate, replaced after ten minutes with human plasma depleted
of either clusterin or control plasma depleted of fibronectin. After a
further ten minutes guinea pig anti-sheep IgG (heat inactivated) was
added initiating the formation of glomerular immune complexes. Urine
and perfusate samples were collected every twenty minutes. Protein-
uria, UFA, GFA, Na reabsorption and renal vascular resistance were
measured. Ten technically successful sets of perfusions were per-
formed, eight of these having adequate depletion of clusterin. There is
significantly greater proteinuria in the experiments using clusterin
depleted plasma (P < 0.01, repeated measures ANOVA). In the two
other experiments when the affinity column, following multiple use,
failed to significantly deplete clusterin, the proteinuria was similar in
both groups. The increased proteinuria seen in kidneys perfused with
clusterin depleted plasma suggest that clusterin may function as an
inhibitor of the terminal complement complex in vivo. It is likely that
clusterin depletion permits increased C5b-9 mediated damage to gb-
merular epithelial cells and hence increased proteinuria.
Pathology of implantation graft biopsies. J.P. Dowling', P. Allan, D.
Francis2, R. Miller2, R. Walker2 and G. Becker', Departments of
Anatomical Pathology', Surgery2 and Nephrology2, Royal Melbourne
Hospital. The use of the "immediate" transplant biopsy as a guide to
the status of the graft has been debated. The pathology detected in 59
cadavenc and 9 living-related and 1 living unrelated kidneys was
examined using multiple sections and a peroxidase anti-peroxidase
(PAP) immunoperoxidase method to detect IgG, IgA, 1gM, C3, Clq and
fibrinogen with negative control. Findings were as follows: l0(4)*_
non-specific glomerular changes; 39(1)—evidence of ischaemic tubular
change (acute tubular necrosis); 10(1)—variably developed nephroscle-
rosis with arterial and arteriolar sclerosis and/or hyalinosis; 7(0)—IgA
deposition in the mesangium with 1(0) showing mesangial proliferation;
8(2)—focal and diffuse mesangial proliferation with 5(1) associated with
1gM mesangial staining; 1(1)—isolated crescents; 4(0)—glomerular cap-
illary loop thrombi; 2(0)—segmental sclerotic lesions; 4(2)—patchy
interstitial fibrosis and 5(0)—positive vascular immunohistochemistry
of 1gM and/or Clq staining. The findings suggest that immediate
biopsies provide useful background data for assessment of graft pathol-
ogy. 0*_number of living-related biopsies.
